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Abstract
This thesis describes investigations into mechanisms responsible for cancer cell motility in 
vivo. Chapters 1 and 2 provide a review o f current literature in this field and also describe the 
techniques used to generate the following the results. Chapter 3 describes a candidate-based 
approach to investigate whether ROCK1 might be regulated by phosphorylation. 
Mutagenesis o f ROCK1 was carried out at 3 chosen sites (T233 T380 T398) in the activation 
loop and the hydrophobic domain and the phenotypes o f the mutants were analysed. 
Chapter 4 describes a parallel approach finding phosphorylation sites in ROCK1 by mass 
spectrometry. From these results T518 was chosen for further investigation and its possible 
function is investigated.
Chapter 5 describes an siRNA screen designed to identify novel regulators o f the cortical 
acto-myosin cytoskeleton. The read-out for this was based on the disruption o f  rounded 
blebbing morphology o f A375 cells cultured on 3D gel matrices. The rounded morphology is 
similar to that observed in amoeboid cancer cell motility in vivo, therefore we hypothesised 
that genes required for contracted, rounded morphology might also be required for motility. 
Results identified PDK1 amongst other genes as a potential regulator o f contractile forces in 
A375 cells and the role o f PDK1 was investigated further. It was found that PDK1 was 
required both in vitro and in vivo for amoeboid cell motility. Chapters 6,7 and 8 detail the 
investigations into the mechanism o f how PDK1 regulates the cytoskeleton and amoeboid 
cell motility. It was shown that PDK1 was responsible for the localisation o f ROCK1 but 
not ROCK2 at the plasma membrane. This regulation was achieved by the direct binding of 
ROCK1 to PDK1. It was further found that PDK1 was able to compete with and prevent 
RhoE, a negative regulator o f ROCK1, from binding.
Chapter 9 investigates the relationship between cell morphology, motility and pigment 
production. It was found that it was possible to image melanin containing vesicles using 
multiphoton excitation, and using this technique, the motile behaviour o f pigmented 
melanoma cells was observed in vivo. It was found that motile invasive cells tended to 
contain less melanin than non-motile cells suggesting that they were less well differentiated. 
This chapter details investigations into what differences in signalling could be responsible for 
a switch to a de-differentiated, more invasive/metastatic phenotype. The final chapter 
discusses the findings contained within this thesis and the possible implications.
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Supplementary Movies
Figure 5.3 -  Actin Cytoskeleton
A375 cells transfected with either control non-targedng siRNA or PD K I targeting siRNA 
were plated on deformable collagen/matrigel gels, then fixed and stained with TRITC 
phalloidin. The two movies shown are rotating 3D reconstructions o f the acting 
cytoskeleton.
A- Control actin
B- PD KI siRNA actin
Figure 5.7 A375 GFP CAAX
A375 cells expressing GFP-CAAX were plated on deformable collagen/matrigel gels and
imaged using confocal microscopy at a rate o f 1 frame every 3 seconds. 4 Movies are shown.
A. Control CAAX — cells treated with control non-targeting siRNA
B. PD K I siRNA CAAX — cells transfected with PD K I targeting oligos
C. Blebbistatin CAAX- cells treated with 2.5 pM Blebbistatin during imaging
D. Cytochalasin D  CAAX — cells treated with 2 pM  Cytochalasin D  during imaging 
Figure 6.2 A375 cell motility in vivo
Movies from in vivo intravital imaging o f A375 GFP CAAX xenograft tumours. 4 movies 
are shown.
A- Whole tumour area and matrix — shows 3D reconstruction o f  tumour area imaged 
including the surrounding collagen fibres (in red)
B- Whole tumour area GFP only — Shows only the tumour cells in tumour area imaged. 
Note amoeboid movement at tumour margin, and elongated cell movement further 
away from the tumour margin.
C- Amoeboid crop — Shows time-lapse o f the amoeboid movement shown in figure 6.2 
top two panels
D- Elongated crop -  Shows time-lapse o f the elongated movement shown in figure 6.2 
lower 2 panels.
Figure 6.10 A375 cell motility in vivo continued
Movies from in vivo intravital imaging o f A375 GFP CAAX xenograft tumours. 2 movies 
are shown.
A- PD K I knockdown -  Shows protrusive type o f  cell motility that constitutes the 
majority o f cell movement events in the PD K I knockdown tumours
B- Chaotic blebbing switching to amoeboid -  Shows an example o f the plasticity in cell 
motility. The cell shown switches from blebbing chaotically in one position (similar 
to what is seen in vitro) to rapid directional amoeboid movement.
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Figure 7.8 GFP ROCK tim e-lapse
A375 cells were transfected with either control non-targeting siRNA or PD K I targeting 
siRNA oligos and also GFP-ROCK1 were plated on collagen/matrigel matrix and imaged at 
a rate o f 1 frame every 3 seconds. 4 movies are shown.
A- Control GFP ROCK1 — shows the localisation o f ROCK1 during blebbing cell 
movement
B- Control kymograph — movie o f  the control cell slice used for the kymograph in figure 
7.8 panel ii.
C- PD K I siRNA GFP ROCK1 a — shows the cytoplasmic localisation o f ROCK1 in 
cells depleted o f PD K I
D- PD K I siRNA GFP ROCK1 b — Shows that even when ROCK1 is asymmetrically 
distributed in cells lacking PD K I, ROCK1 is unable to drive cell motility as in the 
control cells.
Figure 8.11 D ouble knockdown restored cell motility
MTLn3E cells transfected with control non-targeting siRNA, PD K I targeting siRNA or 
both PD K I and RhoE targeting siRNA were plated on deformable collagen/matrigel matrix 
and imaged by phase contrast at a rate o f 1 frame every 5 minutes. 1 movie is shown that 
sequentially shows the motile behaviour o f cells from each transfection
A- MTLn3E phase time-lapse — this movie first shows control cells, then elongated 
PD K I depleted cells and finally the rescued cell motility when PD K I and RhoE are 
knocked down together.
Figure 9.9 B16 cell m otility in vivo
B16 F2 cells stably expressing G FP CAAX were injected subcutaneously into the flank o f 
nude mice. Intravital multiphoton time-lapse imaging is shown.
A- Whole tumour area — Shows the whole imaged area. Tum our cells are in green, 
collagen fibres are in blue, and pigment containing speckles are shown in pink.
B- Crop collective and single cell — cropped area o f the above movie showing and 
example o f both single cell movement and also a group o f cells moving collectively.
Figure 9.20 TGF01 and TG F02 increase cell motility o f B16F2 cells in vitro.
B16F2 cells were plated on deformable collagen/matrigel matrix and treated with either 
MSFI, T G F p i or TGFP2 for 24 hours before imaging. Cells were then imaged by phase 
contrast for 16 hours.
A- untreated B16F2 cells
B- B16F2 cells treated with TGFP2
B16F2 cells treated with TG FP2 have less dendritic morphology and move much more 
rapidly.
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1 Chapter 1 -  Introduction
This thesis reports investigations into mechanisms o f cancer cell motility with particular 
focus on the behaviour o f cells in vivo, and in complex 3-dimensional in vitro environments. 
This introduction will cover current knowledge o f cell motility and focus particularly on 
metastasis and modes o f cancer cell motility. The main cell type that has been used as a 
model system for the experiments carried out is melanoma, so particular attention will be 
paid to the origins o f melanoma and its invasive behaviour. The signalling pathways that 
have been found to play a role in the types o f cell motility investigated here are focussed 
around the generation o f contractile forces, so current knowledge o f Rho and ROCK 
signalling is reviewed in detail. It was also found that PD K I was required for regulation o f 
ROCK, so the role o f PD K  signalling and phospholipids in cell motility is discussed. Finally 
it was found that pigment production and invasive potential o f melanoma cells was 
influenced by TGF-(3 signalling.
This introduction will cover a wide range o f signalling pathways, which reflects the 
complexity o f cell motility mechanisms in vivo. This thesis only begins to uncover some o f 
the details as to how cancer cells really move and invade in vivo; more work is required to 
investigate this issue in detail.
1.1 Melanoma
The majority o f the experiments in this thesis have utilised melanoma cell lines as a model 
system. Melanoma is a type o f skin cancer arising from the aberrant proliferation o f 
melanocytes. It is relatively easy to treat provided metastasis has not occurred, however 
metastatic melanoma is particularly aggressive and prognosis is very poor \  The highly 
invasive nature o f this cancer type made it an interesting model in which to study cell 
motility.
1.1.1 Functions of melanocytes
Melanocytes reside in the lower levels o f the epidermis and exist at an approximate ratio o f 
1:10 with keratinocytes. The melanocyte stretches out long dendritic process and the melanin
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that the melanocyte produces is exported along the dendrites and is taken up by the 
keratinocytes (Figure l . l ) 2. This is the process that gives skin its colour. Pigment production 
is largely determined by the expression o f melanocortin-1 receptor (MC1R) which is a G- 
protein coupled receptor positively linked to adenylate cyclase by the G-protein subunit G as. 
MC1R is stimulated by agonists a-Melanocyte stimulating hormone (a-MSH) and 
adrenocorticotropic hormone (ACTH)2. Stimulation by both a-M SH and ACTH can up 
regulate the expression o f MCI R forming a positive feed back loop. Agouti signalling protein 
(ASP) is an antagonist for MC1R 2.
MC1R driven increases in cAMP activate cAMP-dependent kinase (PKA), which in turn 
activate the cAMP response element-binding transcription factor (CREB). Activity o f CREB 
leads to the transcription o f microphthalmia-associated transcription factor (MITF). MITF 
has many target genes but among them are genes encoding the enzymes critical for melanin 
production, such as tyrosinase. In addition to regulating MITF, cAMP levels down-regulate 
PD K  activity as well as stimulate Rac activity and inhibit Rho activity which leads to the 
dendritic cell morphology 3’4. In fact it has even been reported that inhibition o f RhoA is 
additionally required for melanogenesis as well as dendrite formation 5.
UV radiation is harmful to cells as it produces free radicals able to cause DN A damage. In 
response to UV light, melanocytes are stimulated to rapidly oxidise and polymerise existing 
melanin that is rapidly exported to keratinocytes migrating upwards, and skin gets darker in 
colour. The increase in pigment in the upper layers o f the skin is thought to help protect the 
stem cells and melanocytes in the lower levels o f the skin from D N A  damage 6. The 
expression o f microphthalmia-associated transcription factor (MITF) is also up regulated 
rapidly following UV exposure. The up regulation o f MITF is thought to be required for 
production o f pigment and also play a role in effective repair o f D N A  damage.
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a Dermal Fibroblast Keratinocyte 
Melanocyte 
Basem ent membrane
Figure 1.1 Schematic diagram showing the position of 
melanocytes in the skin. Melanocytes reside in the basal 
area of the epidermis. Melanin is produced and transported 
along dendrites then exported and taken up by surrounding 
keratinocytes. The keratinocytes migrate upwards to form the 
protective cornified layer of the epidermis that is in contact 
with the outside environment.
1.1.2 Melanin
Melanin is a pigment found in both plants and animals. In humans melanin is found in the 
skin, hair, iris and also in certain pigment containing neurones in the substantia nigra 2. The 
chemical properties o f melanin means that it acts to protect cells from harmful radiation. 
Melanin molecules absorb UV-light and convert the energy to heat. This keeps the 
production o f free radicals at a minimum and reduces DNA damage 1. There are several 
different forms o f melanin. Eumelanin and Pheomelanin are found in human skin, 
Neuromelanin is present in specific neurones in the substantia nigra. Eumelanin is found in 
two forms, black and brown, and they are more abundant in people with dark skin. Blonde 
individuals tend to have less black eumelanin and a small amount o f brown eumelanin. 
Pheomelanin is red in colour and is responsible for the colouring o f red hair. The function o f 
neuromelanin in the brain is as yet unclear, but loss o f these pigmented neurones is 
correlated with degenerative diseases such as Parkinson’s disease 8.
Melanin molecules are synthesised from tyrosine and the first and rate-limiting step o f 
melanin production is the conversion o f tyrosine to dopaquinone by the enzyme tyrosinase “. 
Individuals with dark skin contain similar numbers o f melanocytes in their skin as fair­
skinned individuals however the tyrosinase activity and the pigment production in black skin 
is much higher 2. Melanocytes synthesise melanin molecules in melanosomes that are 
transported to the cell periphery using the microtubule network, which is dependent on 
kinesin. At the cell periphery, a Rab27A complex is required to allow melanosomes to be 
recruited onto the actin network. The melanosomes are then anchored to the plasma 
membrane through an interaction o f Slp2, Rab27A and phosphatidyl serine in the 
membrane. The melanin can then be released from the melanocyte and taken up by the 
surrounding keratinocytes. Rab27A is transcriptionally up regulated by increases in cAMP 
levels and this can promote the interaction o f melanosomes with cortical actin at the cell 
periphery, increasing the rate o f expo rt9.
1.1.3 The origin and differentiation of melanocytes
Melanocytes are generally a very stable population in the lower level o f the epidermis (Figure 
1.1) or at the base o f hair follicles and proliferate very slowly in contrast to the transit 
amplifying population o f keratinocytes that proliferate relatively rapidly. Melanoblasts 
originate from the neural crest, a population o f cells that develops from the neural tube. The
17
neural crest cells migrate and differentiate to form diverse tissues ranging from cranio-facial 
structures, neurones and melanocytes 10. They must develop and migrate to the appropriate 
sites then survive and differentiate depending on signals for the local environment 10. MITF 
plays a critical role in promoting the differentiation o f melanocytes u. The mutation o f MITF 
in mouse models results in reduced numbers o f melanocyte precursor cells, whereas 
constitutive MITF expression in vitro is able to convert murine fibroblasts to melanocyte­
like cells 11. It is thought that M ITF controls differentiation o f melanocytes but is also 
required for the survival o f cells in the neural crest lineage. A potential mechanism for this 
has been described by McGill et al, who found that MITF was able to transcriptionally 
regulate Bcl2 to protect cells from apoptosis 12.
1.1.4 Melanoma
Exposure to UV light is the major risk factor for developing melanoma. The initiation o f 
melanoma is the aberrant proliferation o f melanocytes which gives rise to nevi within the 
epidermis. The majority o f these nevi do not progress to malignant disease, but it was 
thought a small sub-set can progress and begin to invade into the dermis (vertical growth 
phase) before becoming metastatic and spreading to distant sites. This has recently been 
challenged and it has been proposed that metastatic melanoma originates from new nevi 
which rapidly progress to malignant disease \  To understand malignant melanoma it is 
important to determine the genetic changes occurring between benign nevi and melanoma 
invading the dermis '.
One major advance in the understanding o f melanoma was the discovery that the serine 
threonine kinase B-RAF was mutated in 66 % o f all malignant melanoma, and that V599E 
accounted for 80% o f all B-RAF mutations and significantly increased B-RAF kinase activity 
13. B-RAF signals through the MAPK pathways to increase levels o f phosphorylated ERK. 
ERK has many substrates, both nuclear and cytoplasmic, which can increase cell 
proliferation, apoptosis and survival 14. Activating mutations in N-RAS, which is upstream of 
B-RAF are able to account for the majority o f the melanomas that do not express mutant B- 
RAF. Mutation o f both N-RAS and B-RAF is rare and these oncogenic mutations are 
generally exclusive o f one another H. However the role o f B-RAF in melanoma progression 
remains unclear, as many benign nevi also express mutant B-RAF, so expression o f over 
active B-RAF is not necessarily sufficient for the progression to metastatic disease. Another
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commonly mutated gene found in melanoma is phosphatase and tensin-homologue (PTEN) 
l5, l6. Similarly to B-RAF, mutation o f PTE.N is generally found mutually exclusively o f N- 
RAS mutations. However simultaneous mutadon o f both B-RAF and PTEN in the same 
tumour does occur 16. PTEN is a phosphatase that converts PI(3,4,5)P3 to PI(4,5)P2. 
Mutadons in PTEN result in elevated PI(3,4,5)P3 and therefore increased Akt/PKB 
signalling, leading to increased proliferation and reduced cell death.
1.1.5 Invasive behaviour of melanoma
Developing melanoblasts are a non-pigmented, modle cell populadon. However 
differentiated melanocytes are fixed in their position in the skin and produce pigment. The 
idea that the motile behaviour o f developing melanoblasts might predispose melanoma to 
being highly aggressive has been tested. Gupta et al. found that when cell lines o f different 
origins were transformed with the same set o f oncogenes, only melanocytes became 
metastatic whereas other cell lines could form tumours but were not invasive 17. It was 
discovered that non-transformed melanocytes still expressed Slug, a transcription factor 
governing neural crest migration, and that expression o f Slug co-operated with the oncogenic 
mutations to give rise to intrinsically invasive tumours 17. This information has led 
researchers to hypothesise that the invasive behaviour o f melanoma arises due to a failure of 
melanoma cells to differentiate, meaning that the mechanisms for cell motility which should 
have been shut down are still potentially active. For example, RhoA, which is inhibited 
during differentiation and needs to be active at only low levels to allow the formation o f 
dendrites. In this case the failure to differentiate might allow high levels o f Rho activity that 
could be responsible for increased cell motility. The role o f RhoA in cell motility is discussed 
later.
There is some interesting evidence to support the hypothesis that invasive behaviour 
correlates with poorly differentiated tumours. MITF, the transcription factor critical for 
melanocyte differentiation and survival has been linked to invasive behaviour o f melanoma. 
Firstly it has been found that M ITF is able to regulate the gene DIAPH1 encoding Dial 18. 
Low levels o f M ITF led to down-regulation o f Dial which in turn resulted in higher levels o f 
ROCK signalling which is linked to amoeboid cell invasion (see 1.8.2). MITF also plays a 
role in cell proliferation, and low levels o f MITF can cause cell cycle arrest; but complete loss 
o f MITF is detrimental to the survival o f melanoma cells as they are unable to proliferate l8.
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Put together, these results might suggest that motile melanoma cells are also less 
proliferative. Another study has shown that over-expression o f MITF in melanoma cell lines 
rendered the cells less invasive. MITF over-expression caused the up regulation o f 
melanocyte differentiation markers and xenograft tumours from these cells were smaller in 
size and failed to metastasise 19. Both o f these studies strongly suggest that less well- 
differentiated melanoma cells are also more invasive and have greater metastatic potential. 
There are also cases o f amelanotic malignant melanomas 20. Patients with these tumours have 
a particularly poor prognosis, which may suggest that the lack o f pigmentation and 
presumably less well-differentiated status o f these nevi mean that they are inherently more 
aggressive. However because o f the lack o f pigment production, it is also true that 
amelanotic melanoma is usually harder to diagnose and is usually identified at a later stage 
than pigmented lesions which could also explain why the prognosis is very poor 20.
It has been suggested that the microenvironment is also important for the aggressive 
phenotype o f melanoma. Normal differentiated melanocytes can be transiently converted to 
an aggressive melanoma-type cell by placing them in contact with melanoma cells. However 
the converse is not true and the normal melanocyte microenvironment is not able to convert 
aggressive melanoma cells to less invasive differentiated cells 21. However, an embryonic 
environment is able to re-programme metastatic melanoma cells. Firstly it has been shown 
that metastatic melanoma cells injected into a chick embryo would migrate and follow the 
path o f normal neural crest cells rather than forming tumours 22. It has also been found that 
metastatic melanoma cells express nodal, a member o f the Transforming growth factor-(3 
(TGF-P) super-family, which is normally expressed during embryonic development. Over­
expression o f nodal in melanoma inhibits differentiation 23, 24. These findings suggest that 
invasive melanoma is less differentiated and that aggressive cells could be controlled with the 
correct cues from the microenvironment. If  it would be possible to treat aggressive 
melanoma by mimicking signalling from an embryonic environment it may be possible to 
induce the melanoma cells to differentiate causing them to stop invading and proliferating. 
The aggressive cells o f a melanoma tumour could be less differentiated because they have 
lost the differentiation signalling required, but another hypothesis is that the aggressive cells 
were never properly differentiated and are a type o f cancer stem cell. Highly aggressive 
melanoma cell subsets have been reported to have a molecular signature similar to 
pluripotent stem cells 25. This hypothesis is as yet unproven but several markers such as
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ABCB5 have been found and can be used to isolate populations o f cells that contain a higher 
proportion o f stem cells as measured by tumourigenic potential 26. The relationship between 
pigment production, invasive behaviour and cell morphology is investigated in chapter 9.
1.2 TGF-/5 signalling
Transforming-growth factor p ligands are a family o f cytokines and in humans there are 42 
isoforms which are split between 2 sub-families; TG FP/A ctivin/N odal family and the bone 
morphogenetic protein (BMP)/growth and differentiation factor (GDF) family. T G F ligands 
interact with membrane serine/threonine kinase receptors27 (Figure 1.2). Ligands are thought 
to exist as dimers and interact with hetero-tetrameric receptors made up o f 2 type II 
receptors and 2 type I receptors. Upon ligand binding the type II receptor phosphorylates 
and activates the type I receptor. The activated type I receptor then phosphorylates the 
receptor SMADs (Small Mothers Against Decapentaplegic) (Figure 1.2). In the case o f the 
canonical TGFJ3 signalling, the receptor SMADs are SMAD2 or SMAD3. Once 
phosphorylated, SMAD2 or SMAD3 interact with SMAD4 to form a complex, and 
translocate to the nucleus. In the nucleus, the SMAD complex combines with other 
transcription factors to regulate gene transcription (Figure 1.2)28. Different cell types express 
different combinations o f SMAD co-factors so the transcriptional profile is cell type 
dependent. SMAD7 is an inhibitory SMAD and acts to inhibit the activation o f receptor 
SMADs and compete for binding to SMAD4. SMAD7 can also disrupt receptor SMAD 
complexes from binding to DNA 29.
TGF|3 signalling controls many aspects o f cell behaviour. TGFP has been characterised as a 
growth inhibitory chemokine but it has also become clear that the growth inhibitory effects 
o f TG FP are dependent on the cell type and also the differentiation status o f the stimulated 
cell, and that in some contexts TG FP can have the opposite effect. During embryogenesis, 
TG FP signalling does not act as a growth inhibitor, but as cells mature they gain the ability to 
respond to TG FP in a different way and either stop growing or undergo apoptosis. TG FP in 
cancer is a much-discussed topic, as tumour cells can also overcome the growth arrest signals 
downstream o f TG FP and instead TG FP can stimulate cells to become more invasive and 
increase their metastatic potential.
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In tumour cells increased TGFP production is correlated with increased severity and higher 
tumour grades 3U. TG FP signalling can inhibit the growth and proliferation o f leukocytes 
such as T-lymphocytes, and this can increase the ability o f tumour cells to evade detection by 
the immune system 31. TGFP can also signal to other cells in the tumour microenvironment, 
such as endothelial cells, to stimulate angiogenesis through the induction o f V EG F 32. TGFP 
can also act on the stromal fibroblasts causing them to up regulate proteases such as MMP9 
and changing their behaviour, making them more invasive and more prone to promote 
tumour cell invasion 33. When TGFP acts on the tumour cells themselves, it can stimulate an 
epithelial to mesenchymal transition (EMT) as discussed above. TGFP induces transcription 
o f SNAIL, which can repress transcription o f E-cadherin, causing cells to become less 
epithelial 34,35. For cells to invade, they must also acquire motile behaviour, which requires re­
organisation o f the actin cytoskeleton. The role o f TG FP in melanoma may be at least in part 
SMAD-independent as it has been reported that there is significant cross talk between TGFP 
and ERK signalling. It has been shown that TG FP is able to signal through RhoA and RhoB 
to induce stress fibre formation and actin polymerisation 36. It is still unclear how TGFP is 
able to signal to Rho, but it has been seen that the activation o f Rho is extremely rapid 
following TG FP stimulation 36. A recent paper has gone further and suggested that TGFP 
signalling over long periods o f time not only induces EMT but switches the profile o f cancer 
cells to cells with more stem cell-like properties 37.
The skin is one organ that is very sensitive to TG FP signalling. If  TG FP is expressed in 
differentiated suprabasal layers o f the epidermis then this causes an increase in the rate o f cell 
division 38,39, whereas expression o f TG FP in the proliferating cells in the basal level caused 
growth arrest 40. TG FP has also been reported to play a role in melanoma progression. 
Increased expression o f TGFP isoforms in melanoma has been reported 41. TGFP2 and 
TGFP3 are not expressed in normal melanocytes but are up regulated in melanoma and seem 







Figure 1.2 Schematic diagram of TGF-(3 signalling. TGFP 
ligand binds to heteromeric transmembrane serine/threonine 
kinase receptors. Activation and transphosphorylation of the 
receptors leads to the phosphorylation of receptor SMAD, 
SMAD2 or SMAD3 (R-SMAD). Receptor SMADs can then 
form a complex with the Co SMAD, SMAD4, and these 
complexes translocate to the nucleus. In the nucleus the 
SMAD complex binds to DNA and initiates gene transcription.
1.3 Rho GTPase family
Rho GTPases belong to the Ras super family o f small G-proteins that are highly conserved 
among all eukaryotes. 20 genes have been identified that encode different Rho family 
members but to date most research has been carried out on 3 sub-families; Rho (RhoA, 
RhoB, RhoC), Rac (Racl Rac2 Rac3) and Cdc42 (Cdc42, RhoJ, RhoQ) (Figure 1.3). Atypical 
Rho family members will be discussed below. Rho, Rac and Cdc42 are able to act as 
molecular switches to regulate many cellular responses, most notably, control o f the 
cytoskeleton. The acdvity o f Rho GTPases is controlled through the binding o f either the 
nucleoddes GTP or GDP, GTP-bound being the active state, and GDP-bound being the 
inactive state. Despite being referred to as GTPases, family members actually elicit little 
GTPase activity 43 and require interaction with Guanine nucleotide exchange factors (GEF) 
or GTPase activating proteins (GAP) to cycle between active and inactive conformations 44. 
There are over 100 known Rho GEFs and GAPs in the mammalian genome, which allow for 
complex and specific regulation o f Rho family GTPases 44. Rho GTPases can also be 
regulated by G D P dissociation inhibitors (GDI), which act to sequester GTPases in the 
cytoplasm and prevent interaction with GEFs. The significance o f the activity o f RhoGDI 
was shown in a mouse model over-expressing RhoGDIa, which significantly reduced the 
activity o f Rho, Rac and Cdc42. Over-expressed RhoGDI caused embryonic lethality at early 
stages, showing the vital role o f these GTPases in many cellular functions 45.
Rho GTPases are also regulated by their sub cellular localisation. Most GTPases require 
interaction with cellular membranes to carry out their functions. This is controlled by 
modification o f a C-terminal CAAX sequence (A= aliphatic residue). Firstly the CAAX 
cysteine is modified and linked to either farnesyl or geranylgeranyl lipid by either farnesyl 
transferases or geranylgeranyltransferases (GGTs). Substrate specificity is determined by the 
amino acid in the *X’ position, although most Rho family members are geranylgeranylated. 
The C-terminus is then cleaved to remove ‘AAX’. The final step to the modification is the 
methylation o f the exposed cysteine residue 46. The result o f the modifications is to leave a 
hydrophobic C-terminal domain when the rest o f the molecule is relatively hydrophilic. This 
hydrophobic domain, in conjunction with basic amino acids immediately upstream then 
allows the GTPase to be inserted in the plasma membrane 46. Immediately upstream o f the 
CAAX m otif is a hypervariable region that is also implicated in the regulation and 
localisation o f Rho family members. Racl and RhoA both contain polybasic residues in their
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hypervariable region similar to K-Ras and are required in some cases (K-Ras, Racl) for 
plasma membrane localisation 47.
Over a decade ago it was found that RhoA regulated the formation o f actin stress fibres, Rac 
induced actin polymerisation for lamellipodia and membrane ruffling, and Cdc42 promoted 
actin assembly into filopodia 48, 49. Since this initial finding it has been shown in many 
different systems that these Rho GTPases act as master regulators to control the actin 
cytoskeleton in many different cell contexts. Control o f the actin cytoskeleton can also lead 
to regulation o f gene transcription. Serum response factor (SRF) is a transcription factor that 
controls transcription o f many genes activated by mitogenic stimuli such as serum addition. 
SRF is activated downstream o f a mechanism which is able to sense the levels o f 
unpolymerised G-actin in the cytoplasm. This regulatory mechanism is able to sense the 
depletion o f the G-actin pool and up regulate mRNA production. The activity o f Rho, Rac 
and Cdc42 can stimulate the polymerisation o f actin and therefore indirectly activate SRF, 
altering the transcriptional profile o f the cells 50. Rac and Cdc42 can also alter transcription 
by activating JN K  and p38 MAPK pathways though this is thought to be independent o f 
their activities affecting the cytoskeleton 51,52. The activity o f the transcription factor N FkB 
can also be regulated by PAK1, which is an effector o f Racl and Cdc42 53.
Rho, Rac and Cdc42 are also able to control cell cycle progression 54. This was first observed 
when cells were treated with Clostridium botulinum C3 transferase54 55, or microinjected with 
dominant negative forms o f Rac and Cdc42, which caused a Gl-S-phase cell cycle arrest. 
RhoA is able to inhibit the transcription o f p21, a potent cyclin-dependent kinase (CDK) 
inhibitor 5<s. Additionally, over-expression o f Racl or Cdc42 that are deficient in GTPase 
activity has been found to be sufficient to induce cyclin-Dl expression57. Although it has 
been seen that Rho, Rac and Cdc42 families o f GTPases have distinct effects on the 
cytoskeleton, it is also true that these pathways are intimately linked and over-lapping, as 
downstream effector proteins are able to interact with more than one Rho GTPase. For 
example p21-activated kinase (PAK) family members interact with Racl, Rac2, Rac3, Cdc42, 
as well as some other less well studied family members 58.
1.3.1 RhoA sub-family
Rho stands for Ras homologue gene family. RhoA, RhoB, and RhoC are highly homologous 
in sequence (~85% identity based amino acid sequence) (Figure 1.3) but seem to have
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distinct non-redundant functions despite all three isoforms being ubiquitously expressed in 
all tested tissues59. The C-terminal CAAX sequence o f the 3 Rho proteins is the most 
variable and could dictate their specificity by controlling their different sub-cellular 
localisation. RhoB localises mainly to late endosomes, whereas activated RhoA and RhoC are 
found at the plasma membrane or in the cytoplasm59.
Rho isoforms interact with their regulator GEFs and GAPs and also to their downstream 
effectors through regions named switchl and switch2. The switchl region clamps GTP or 
G D P between itself and the rest o f the molecule, and interaction with a magnesium ion is 
essential for binding to G D P 60. This magnesium ion is removed by interaction with GEFs 
and promotes nucleotide release.
The control o f filamentous actin is achieved by the binding o f active Rho GTPases to their 
effectors. RhoA is able to directly stimulate actin polymerisation through activation o f 
diaphanous-related formins (Dia proteins)61 62. The activation o f ROCK by RhoA can also 
contribute to an increase in actin filaments through the phosphorylation and inhibition o f 
cofilin. ROCK and mDia are also able to work together in the generation o f stress fibres. 
Rho proteins are also implicated in the regulation o f cell adhesions. The turnover o f 
adhesions is required for effective cell motility, and Rho has been shown to be required for 
the release o f cell adhesions in the rear 63. RhoA and RhoC are also able to regulate adherens 
junctions and tight junctions through the activation o f ROCK. Regulation o f ROCK is the 
focus o f chapters 3 and 4 so will be discussed in greater detail below.
RhoA and RhoB are able to promote transformation o f cultured fibroblasts and RhoA has 
been shown to be over-expressed in several cancer cell lines. The transformation induced by 
RhoA requires the activity o f ROCK effectors 64. In contrast, RhoC does not seem to be able 
to induce transformation but RhoC has been found to be up regulated in tumours that have 
increased metastatic potential 65,66. RhoC has also been reported to interact more strongly 
with the effectors ROCK1 and ROCK2 than RhoA, so RhoC could be up regulated in 


















Figure 1.3 Rho family of GTPases. The 23 members of 
the Rho family of GTPases are shown grouped together by 
their homology to each other. Highlighted are the RhoA 
sub-family, the Rac family, the Cdc42 family and also the 
Rnd family of atypical Rho family GTPases.
Rho activity has also been implicated in differentiation in numerous systems 6?. As 
mentioned above, inhibition o f Rho activity seems to be required for differentiation o f 
melanocytes and formation o f dendrites, but adjusting Rho activity has also been shown to 
alter the differentiation programme o f adipocytes and myocytes 68. Mice lacking 
pl90RhoG A P have excessive Rho activity; this causes a down-modulation o f insulin/IG F 
signalling. This impairs the ability o f cells to undergo conversion to adipocytes, instead cells 
lacking pl90RhoG A P tended to undergo myogenic differentiation68.
RhoA can also be regulated by phosphorylation. Phosphorylation o f RhoA in the C-terminus 
by PKA, when levels o f cAMP are elevated, acts to reduce the membrane localisation o f 
RhoA 69. This could potentially be involved in the down-regulation o f Rho activity in 
melanocytes as they differentiate and become dendritic in morphology as discussed earlier.
RhoB appears to play a role mostly in endocytic pathways and is localised to intracellular 
membranes and not the plasma membrane like RhoA and RhoC 59. RhoB is thought to 
interact with a variety o f proteins and is required for their trafficking between the membrane 
and endocytic compartments 70.
1.3.2 Rac family
Racl, Rac2 and Rac3 are members o f the Rac subfamily o f Rho GTPases. Rac2 is specifically 
expressed in haematopoietic cell lineages. Racl controls actin polymerisation to drive 
lamellipodia formation and cell migration by activating WAVE, which is discussed later. Rac3 
is not required for lamellipodium formation but depletion o f Rac3 still strongly inhibited cell 
invasion through 3D matrix, even though cell migration in 2D was not affected. 71,72.
Rac and Rho have been shown to be antagonistic in a variety o f contexts, and this exclusivity 
in signalling would act to spatially separate Rho and Rac activity in cell. One way in which 
Rac is able to antagonise Rho activity is through pl90RhoGAP. Rac activity is able to induce 
the translocation o f pl90RhoGAP to adherens junctions where it locally inhibits Rho activity' 
73. There is also an opposite mechanism by which Rho activity leads to the activation o f a Rac 
GAP, FilGAP to inactivate Rac 74.
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1.3.3 Cdc42 family
Cdc42 and related family members RhoJ and RhoQ are able to activate actin polymerisation 
75 77. When GTP-bound Cdc42 binds to PI(4,5)P2 in the cell membrane, this recruits Wiskott 
Aldrich syndrome protein (WASP) and changes conformation that allows the activation o f 
N-WASP76. The subsequent recruitment o f the ARP2/3 complex then drives actin 
polymerisation at the cell periphery78. MRCK is another effector o f Cdc42, able to co­
ordinate the actin cytoskeleton. Signalling through this pathway has been shown to be 
required for the collective migration o f squamous carcinoma cells in 3D environments 79. 
Another group o f Cdc42 effectors are the p21-activated kinases (PAKs). Activity o f PAKs 
can lead to the dissolution o f actin stress fibres, and also the activation o f the MAPK 
pathway activating JN K 80. Cdc42 is also involved in a cell polarity complex through binding 
to Par3, Par6 and atypical PKCs81, and can act to control apical/basolateral polarity and the 
maintenance o f cell junctions81.
1.3.4 Atypical Rho family GTPases
The atypical Rho GTPases include R nd l/R hoE , Rnd2, Rnd3, RhoBTBl, RhoBTB2, RhoH, 
R hoTl, RhoT2, RhoU, and RhoV (Figure 1.3). These Rho family members are not regulated 
in the same way as the family members described above. Although they contain a GTPase 
domain, this domain is frequently different in sequence form the classical Rho GTPases in 
residues critical for hydrolysis o f the bound nucleotide, meaning that they are GTPase 
defective. Therefore instead o f their activity being regulated by G E Fs/G A Ps and the 
exchange o f GTP for GDP, regulation is generally via their expression level, their 
degradation or their protein-protein interactions 82.
R n d l, Rnd2, and Rnd3 (RhoE) are one branch o f the atypical Rho family. Rnd proteins bind 
only very weakly to G D P and have very low GTPase activity, so they exist predominantly in 
GTP-bound state 82. RhoE is interesting, as many of RhoE’s functions appear to be the 
opposite to the functions o f RhoA 83. Over-expression o f RhoE leads to a loss o f  actin stress 
fibres and the induction o f many branching protrusions. RhoE is able to bind to 
pl90RhoGA P causing increased GAP activity towards RhoA and causing a reduction in the 
levels o f active GTP-bound RhoA 83 84. RhoE can also inhibit Rho activity by directly binding 
to the Rho effector ROCK1. Although RhoE and RhoA have relatively similar structures 
they bind to different parts o f the ROCK1 sequence 85. It is also interesting that RhoE
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specifically interacts with ROCK1 and not the closely related ROCK2. RhoE binds to 
ROCK1 around the kinase domain, and requires the amino acid sequences 375-420, and also 
a region in the extreme N-terminus.
RhoE is phosphorylated by ROCK1 at several residues, this phosphorylation causes RhoE to 
localise to the cytoplasm in a similar way to the phosphorylation o f RhoA by PKA 69. In 
addition to altering RhoE localisation, phosphorylation o f RhoE by ROCK1 also increases 
the protein stability o f RhoE 86. The phosphorylation o f RhoE by ROCK does not affect the 
binding o f ROCK1 to RhoE so it is possible that ROCK1 and RhoE interact at cell 
membranes, then move into the cytoplasm together, meaning that ROCK1 could inhibit its 
own activity by phosphorylating RhoE to increase RhoE stability causing ROCK1 to be 
sequestered and inhibited in the cytosol.
RhoE has been shown to be regulated by p53. p53 is able to induce RhoE expression in 
response to D N A  damage, and the increased levels o f RhoE act to inhibit ROCK1 -mediated 
apoptosis 87,88. A recent paper has also implicated p53 in cell motility driven by Rho and 
ROCK. It is possible that the role o f p53 in this context is also through the up regulation o f 
RhoE and the subsequent inhibition o f ROCK1 signalling 89.
1.4 Activity and function of Rho-kinases
RO CK l and ROCK2 are effectors o f RhoA-GTP RhoB-GTP and RhoC-GTP. They are 
also termed RO K 0 and RO Ka/Rho-kinase, respectively. The term ‘RO CK’ is used to mean 
ROCKl and ROCK2 collectively. ROCKl and ROCK2 are members o f the AGC family o f 
serine threonine kinases based on sequence homology o f their catalytic subunits (Figure 1.4). 
Both RO CK l and ROCK2 contain an N-terminal kinase domain, a coiled coil region and a 
Rho-binding domain, and a PH domain in the C-terminus (Figure 1.5). They are largely 
similar in sequence so it was assumed that they would carry out similar functions and act 
largely redundantly. This has since been shown not to be the case. The differences in their 
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Figure 1.4 Diagram showing members of the AGC 
family of protein kinases. This diagram is adapted from
http://www.cellsianal.com/reference/kinase/aac.htm l. 
Family members are grouped together based on 
homology to one another.
Although the focus o f the experiments in this thesis is to investigate the regulation o f ROCK 
(used to mean RO CK l and ROCK2 generically) in the organisation o f the cytoskeleton for 
cell motility in vivo, the activities o f ROCKl and ROCK2 are far more wide ranging. In a 
cell context ROCK activity is required for contractility o f F-actin filaments which is required 
to maintain cell shape and is also required for cell motility. As described above, ROCK 
activity is also implicated in the establishment and maintenance o f cell adhesions. Too much 
ROCK activity is able to disrupt tight junctions in some contexts, and increases permeability 
o f cellular barriers, but ROCK activity is required for the integrity o f cell-cell adhesions in 
other cell types 90,91. ROCK kinases are also involved in transformation. It had been known 
that activated RhoA strongly enhanced transformation induced by Raf and it has been shown 
that this effect is carried out through the effectors RO CK l and ROCK2 64. Rho-ROCK 
signalling is involved in cell division and also cell-death. ROCKs are also responsible for the 
membrane blebbing observed when a cell undergoes apoptosis. The blebbing arises from 
increases in cell contraction similar to what is required for blebbing during amoeboid cell 
motility. Rho-ROCK signalling is also locally required during mitosis. Contraction through 
this pathway is required to contract the cleavage furrow between new daughter cells to 
complete cytokinesis 92. It has also been shown that ROCK is found bound to the centriole 
during mitosis and plays a role in positioning o f the centrosomes 93.
In a more general context, the activity o f ROCKs is required for the contraction o f whole 
tissues. For example, the tone o f smooth muscle o f blood vessels can be controlled by 
ROCK activity, and ROCK inhibitors are currently under investigation as drugs for various 
cardiovascular diseases 94. ROCKl has also been shown to be required for the closure o f 
eyelids in developing mouse embryos, by controlling the contractile ring o f actin through the 
whole epithelial sheet o f cells 95. Interestingly ROCK2 knockout mice showed a similar 
phenotype suggesting that both ROCKl and ROCK2 are cooperating in this context %.
1.4.1 ROCK substrates
The consensus site for phosphorylation by ROCKs is generally agreed to be R /K X S /T  or 
R /K X X S/T  97. ROCKs can also be autophosphorylated although these sites have not yet 
been identified to know if and how they affect ROCK function 98. The kinase domains o f 
ROCKl and ROCK2 are 92 % similar in sequence so it is likely that both kinases would be 
able to phosphorylate the same substrates at least in vitro. Potential substrates have not
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always been tested against both ROCKl and ROCK2 but it is difficult to determine whether 
what is tested in vitro is truly physiological. As discussed below, it is possible that RO CK l 
and ROCK2 have different functions due to different localisation. Localisation would also 
impact the substrates that each kinase is in contact with.
ROCKs phosphorylate myosin-light chain (MLC) in vitro on SI 9. This is the same residue 
that is phosphorylated by myosin-light chain kinase (MLCK). MLCK usually requires the 
presence o f Ca2+, but it appears that ROCK may not " . ROCK also increases levels o f 
phosphorylated MLC by phosphorylating and inhibiting myosin-light-chain phosphatase 
(MLCP) (also known as MYPT1) 97. It is difficult to measure in vivo whether the increase in 
pMLC following ROCK activity is directly due to phosphorylation o f MLC by ROCK or 
mosdy through the inhibition o f MLCP, so it is still questionable whether MLC is a genuine 
ROCK substrate in vivo. ROCK is also able to phosphorylate zipper-interacting protein 
(ZIPK) kinase. Z IP  kinase is able to phosphorylate MLC direcdy and also inhibit MLCP in a 
similar way to ROCK. One other recently described target o f ROCK is the Rac GAP 
FilGAP (FilaminA-binding Rho GTPase activating protein). ROCK activity downstream of 
RhoA is able to activate the activity if FilGAP and therefore inactivate Rac.
Other targets o f ROCK are the LIM kinases. Phosphorylation activates LIMK and leads to 
the phosphorylation o f the LIMK target cofilin, which inactivates cofilin. Cofilin normally 
functions to bind actin filaments and causes depolymerisation and together with ARP2/3 
causes more branching 10°. Therefore ROCK activity promotes the generation o f thick F- 
actin filaments and inhibits branching. ROCK activity can also affect the cross linking o f 
actin to the plasma membrane by the phosphorylation o f Ezrin/radixin/m eosin (ERM) 
family members 101. Phosphorylation by ROCK interferes with their intramolecular 
interactions that are required for their cross linking functions and promotes their interaction 
with the plasma membrane 101.
The major role o f R O CK l and ROCK2 is to coordinate contraction o f actin filaments but it 
is also becoming clear that these kinases are involved in many processes governing the 










Figure 1.5 Diagram of the domain structure of ROCK1. ROCK 1 
and ROCK2 are highly homologous members of the AGC family of 
kinases. The kinase domain is located in the N-terminus. The central 
part of the sequence encodes a coiled coil structure implicated in the 
dimerisation of ROCK molecules and also contains a Rho-binding 
domain. In the C-terminus there is a pleckstrin homology (PH) domain 
which is split by a cysteine rich sequence, numbering indicates ROCK1 
aminio acid sequence.
1.4.2 Mechanism of activation
ROCKl and ROCK2 (collectively termed ROCK) are thought to exist in an auto-inhibited 
conformation with the C-terminus binding to the N-terminus and obscuring the kinase 
domain. The mechanism for activation has been thought to be that RhoA-GTP or RhoC- 
GTP binds to the Rho-binding domain in the C-terminus (Figure 1.5). This interaction then 
relieves the auto inhibition and allows the kinase domain to interact with its substrates 103. 
However it is also true that this increase in kinase activity upon binding to Rho-GTP is 
relatively modest and there are potentially more regulatory mechanisms in place 104,105. It has 
also been shown that ROCK2 can be activated independently o f Rho by some lipids, for 
example arachadonic acid 106.
Analysis o f crystal structures have further revealed that the coiled coil domain o f  ROCK is 
likely to exist in a parallel dimer even when not bound to RhoGTP, it is also likely that 
dimers could interact to form tetramers 1<)3. This is in contrast to a similar kinase PKN that 
also interacts with RhoA, but does so as an anti-parallel coiled coil dimer 107. ROCK binds to 
Rho-GTP through contacts with between 10/13 residues in the extreme C-terminal end o f 
the parallel-coiled coil region 108. The hypothesis that Rho-binding activates ROCK activity 
has been supported by experiments using region specific antibodies, and it was found that an 
antibody targeting the Rho-Binding domain o f ROCK2 was able activate kinase activity 
independently o f Rho 103. ROCK l and ROCK2 can also be activated independently o f Rho 
during apoptosis; in this context RO CK l is activated by caspase 3 cleaving off the inhibitory 
C-terminus, ROCK2 is cleaved by a different mechanism by granzyme B, resulting in similar 
consequences as caspase cleavage o f R O C K l.
The Rho-binding domain (RBD) in the C-terminus has been well characterised but there 
have also been other regions o f the ROCK molecule implicated in Rho-binding. Firstly 
another Rho-interacting domain (RID) directly adjacent to the Rho-binding domain has been 
identified and appears to co-operate with the RBD to bind Rho in a GTP-dependent manner 
109. Secondly an HRl-like domain was identified in the coiled coil region between 420-550 
a.a. which had structural similarity to the equivalent domain in PKN that is involved in Rho- 
binding. However the binding o f this HR1 domain to Rho appeared to be independent o f 
GTP-loading o f Rho. The HR1 domain may bind to RhoA at sites outside the switch regions 
and perhaps contributes to conformational changes required for kinase activity 109.
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As discussed above, Rho GTPases are able to localise to cell membranes through the 
modification o f their C-terminus. The binding o f Rho to ROCK could also permit the 
localisation o f ROCK at the plasma membrane. This could mean that Rho-binding activates 
ROCK in two ways; conformational change to activate kinase activity, and membrane 
localisation to bring ROCK to interact with substrates.
Other members o f the AGC family o f kinases are regulated by phosphorylation in either the 
activation loop or the hydrophobic extension o f the kinase domain no’11 \  To this point this 
has not been shown to be true for ROCKl or ROCK2 and investigation into whether 
ROCK is also regulated by phosphorylation is carried out by mutational analysis and by mass 
spectrometry and is described in chapters 3 and 4.
The pleckstrin homology (PH) domains o f ROCKl and ROCK2 have not been extensively 
studied. The PH domains o f ROCKl and ROCK2 share only 65-70 % sequence identity 
suggesting that this region could be responsible for functional differences between the two 
kinases 112. The PH domain is unusual in that the PH domain is split by a cysteine rich 
sequence (Figure 1.5)108. This may impact the role o f the PH domain in the regulation o f 
ROCK. Investigation into the PH domain o f ROCK2 found that antibodies against the PH 
domain inhibited stress fibre formation and caused ROCK2 to mislocalise suggesting a 
functional for for the PH domain 103. Analysis o f the importance o f the C-terminus has also 
been carried out in R O C K l. Ishizaki and colleagues cloned sequential truncations o f 
ROCKl and examined the phenotypes induced. It was found that A1 mutant (lacking PH 
domain) and A2 mutant (lacking PH domain and also Rho-binding domain) were both able 
to induce stress fibres to the same degree, meaning that neither the PH domain or Rho was 
required for this phenotype, however the pattern o f stress fibres was altered, and were in a 
star-like pattern rather than parallel. Cells expressing A5 mutant (1-375) were not able to 
induce the changes in actin morphology and this mutant had reduced kinase activity in vitro 
98. It has since been shown that the hydrophobic m otif o f ROCKl is required for 
dimerisation o f the kinase, which is able to explain the lack o f activity in this m u tan t113. The 
different sensitivity o f RO CK l and ROCK2 to phospholipids has been shown to result in 
ROCKl and ROCK2 regulating different cellular pools o f myosin 114, it may also explain the 
different roles o f RO CK l and ROCK2 in the regulation o f fibronectin matrix assembly 11S.
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1.4.3 Negative regulators of ROCK activity
The best characterised inhibitor o f ROCK signalling is RhoE 85. RhoE binds specifically to 
ROCKl and not to ROCK2 to inhibit stress fibre formation. O ther small GTPases from the 
Ras super family have also been shown to inhibit ROCK activity. Gem was discovered 
through a yeast 2-hybrid screen to interact with RO CK l in a region adjacent to the Rho- 
binding domain (RBD), and over-expression o f Gem was able to inhibit ROCK activity 
cause cells to lose actin stress fibres and become dendritic or collapsed 116. Interestingly Gem 
only caused a decrease in MLC phosphorylation and not cofilin phosphorylation potentially 
implicating this interaction in the substrate specificity o f R O C K l. The region bound by Gem 
overlaps with a less well characterised Rho-interacting domain o f ROCKl that is discussed 
below. It could be hypothesised that Gem competes with Rho for binding to this region o f 
ROCKl.
1.4.4 Distinct functions of R0CK1 and ROCK2
The different mechanisms o f regulation o f ROCK l and ROCK2 are discussed above. 
ROCKl and ROCK2 have also been shown to play non-redundant roles in a variety o f 
cellular processes. Firsdy selective knockdown o f  either RO CK l or ROCK2 by siRNA 
results in alterations to the actin cytoskeleton, suggesting they are not able to compensate for 
one another 114. Furthermore double knockdown o f both RO CK l and ROCK2 has a more 
striking phenotype than either depleted alone (this is confirmed in the siRNA screen in 
chapter 5). ROCK2 has been genetically deleted in mice and it was found to cause embryonic 
lethality at around E l 3.5, probably due to placental dysfunction. This is further evidence that 
ROCKl is not able to compensate for loss o f ROCK2 117. The two ROCK proteins also 
interact with different binding partners; for example, RhoE binds and inhibited only 
R O C K l, whereas Rafl only binds to ROCK2 85, m .
Both ROCKl and ROCK2 are able to regulate the actin cytoskeleton, yet even in this role 
they appear to control different aspects. It was found that RO CK l was largely responsible 
for the generation o f stress fibres and that ROCK2 was required for phagocytosis and was 
sensitive to the presence o f PI(3,4,5)P3 whereas RO CK l was not 114. This sensitivity to 
membrane lipids meant that ROCK2 was mosdy located to ruffling membranes, presumably 
where PI3K activity is high, whereas ROCKl was seen to have a more general membrane 
distribution 114. It has also been shown that RO CK l and ROCK2 might have different
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substrates, for example myosin light chain phosphorylation on S I9 was sensitive to ROCKl 
levels but not ROCK2 114.
1.5 PDK1 functions
PD K l is a 63kDa serine/threonine kinase that is ubiquitously expressed in human tissues. 
PD K1, like ROCKl and ROCK2 also belongs to the AGC family o f protein kinases (Figure
1.4). PD K l has been termed a ‘master kinase’ due to the fact that it is responsible for 
interacting with and activating so many downstream signalling pathways (Figure 1.6). One 
major signalling pathway downstream o f PD K l is Akt/PKB. A kt/PK B  in turn signals to 
many different downstream targets. PKB signalling promotes cell survival, through inhibition 
o f caspase 9 activity, and inhibition o f Bcl-2 family member Bad to give cells a resistance to 
apoptosis 119. A kt/PK B is also required for insulin signalling pathways and can signal through 
proteins such as GSK3 and m TOR to stimulate cell growth and increase cell metabolism. 
Independendy o f A kt/PK B, PD K l can also signal to S6K, a ribosomal protein that is also a 
regulator o f cell metabolism and cell size through the regulation o f translation 119. PD K l has 
also been implicated in cell motility. It has been shown that PD K l is required for endothelial 
cell migration 12°, and also that PD K l is able to regulate the organisation o f cortical actin 
through interaction with the Rho effector PKN m .
PD K l contains a C-terminal PH domain that binds to PI(3,4,5)P3 and PI(3,4)P2 in the 
plasma membrane (Figure 1.6). Both o f these lipids are products o f PI3K activity, and when 
PI3K activity is high, PD K l is localised to plasma membranes through its PH domain. When 
PI(3,4,5)P3 levels are low P D K l is mostly cytoplasmic 122. P D K l is likely to have just as 
important a role in the cytoplasm, as at the cell membrane, because in organisms such as 
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Figure 1.6 Schematic diagram of PI3K signalling and 
PDK1 activity. PI3K activity can be stimulated by receptor 
tyrosine kinases such as PDGF receptor. PI3K phosphorylates 
inositol lipids in the plasma membrane. PDK1 interacts with 
PI(3,4)P2 and PI(3,4,5)P3 via its PH domain. PDK1 interacts 
with other AGC kinases such as PKB and can activate their 
activity by phosphorylating their activation loop (1) and/or their 
hydrophobic motif (2).
PD K l stands for phosphoinositide-dependent protein kinase, but despite this name, most 
PD K l substrates are phosphorylated efficiendy in vitro without the requirement for 
interaction with lipid 119; the exception to this is Akt/PKB. Signalling through PI3K is 
required to generate PI(3,4,5)P3 in the plasma membrane. The PH domains o f PKB and 
PD K l then interact with this lipid to co-localise and allow the phosphorylation o f PKB on 
Threonine 308 by PD K l ,23.
PKB is further phosphorylated on Serine 473 and it has been unclear whether this site was 
also phosphorylated by PD K l as in vitro studies had shown that recombinant PD K l would 
only phosphorylate Threonine 308. A second enzyme, PDK2 was thought to carry out the 
second phosphorylation. However in cell contexts is now believed that PD K l does actually 
sequentially phosphorylate both sites in PKB but that in order to phosphorylate the second 
site it must undergo a conformational change, and it is thought that this conformation 
change is brought about by the interaction o f PD K  with a different substrate such as PRK; 
meaning that PD K l is in fact also PDK2 124.
With substrates other than PKB, PD K l normally interacts with sequences in the 
hydrophobic m otif in the C-terminus of the catalytic domain. The conserved sequence in 
AGC kinases ‘FXXF’ seems to be required for interaction with PD K l in . Some AGC 
substrates o f PD K l contain a serine/threonine phosphorylation site in the hydrophobic 
motif; FXXFS/TY and phosphorylation o f this site is thought to be required for interaction 
with PD K l (Figure 1.6). This is the case for substrates such as S6K and RSK 125. However, 
other PD K l substrates interact with PD K l in the absence o f phosphorylation in the 
hydrophobic motif, such as PKC isoforms. PKC’s interact with PD K l and are 
phosphorylated in the activation loop. This first phosphorylation then allows PKC to 
autophosphorylate itself at other sites including the hydrophobic m otif that confers its full 
active conformation no’126. The phosphorylated hydrophobic m otif is sometimes known to 
form an intramolecular interaction with phosphate binding pocket, and it is this interaction 
and conformational change that is thought to stabilise the proteins m .
PD K l itself, despite being an AGC family kinase does not contain a hydrophobic m otif at 
the C-terminus o f its kinase domain. However PD K l does still contain the hydrophobic 
pocket capable o f interacting with a hydrophobic motif o f other AGC kinases. This pocket 
has been termed the PDKl-interacting fragment (PIF) p o ck e t127. The PIF pocket is essential
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for interaction o f PD K l with hydrophobic motifs o f AGC kinases such as S6K and RSK but 
not for interaction with Akt/PKB. This has been elegantly shown in a genetic mouse model 
where both copies o f PD K l were replaced with a ‘knock in’ gene that had full catalytic 
activity but had a disrupted PIF pocket 128. This model was able to prove conclusively that 
PD K l has two distinct ways o f interacting and activating its downstream targets; one 
involving the PIF pocket and one that does not. Targeting the PIF pocket o f PD K l may 
potentially allow the generation o f drugs that specifically block only part o f PD K l function 
and do not block signalling through Akt/PKB.
1.6 Cell motility
Cell motility is a vital process in organisms ranging from single celled amoebae to complex 
mammals. Although the aim o f the experiments in this thesis have focused on aberrant 
acquisition o f cell motility in tumour cells, it is important to highlight the numerous normal 
and essential functions that require cell motility. On the simplest level, cell motility allows 
single celled organisms to change location and search for nutrients and suitable conditions to 
survive in. Even microbes such as vaccinia and shigella are able to hijack cell motility 
machinery o f the cells they infect in order to spread and infect neighbouring cells 12913°.
There are many different ways in which cells can move within an organism. They move in 
collective cohorts and also as single cells. During development, cells must migrate in order to 
organise themselves into tissues, for example during the formation o f human facial 
structures. The layers o f mesoderm must migrate towards each other and fuse, if migration is 
insufficient a cleft palette can result 131. Collective migration is common in multicellular 
organisms during development as organs and other structures being to form. However 
collective migration is not restricted to development. For example, groups o f endothelial 
cells are able to migrate together to sprout new blood vessels, a process that allows the 
vasculature to remodel itself. This process can also be stimulated by tumour cells and initiates 
the formation o f new blood vessels to provide oxygen and nutrients to a growing tumour 132. 
Collective cell migration is also continuously occurring in the tissues that require high rates 
o f turnover, such as the skin and the lining o f the gut. Cells in these tissues undergo a large 
amount o f stress and are physically sloughed off the surface regularly. To replace these old 
cells, new cells are produced by proliferating stem cells in the lower parts o f the tissue. In the 
case o f the gut, the new cells must collectively migrate up from the base o f the crypts
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continuously to keep the gut lining functional 133. Collective migration is also required during 
wound healing in order to close a wound as quickly as possible to limit the chance o f 
infection 134.
Single cell migration is also vital. Perhaps the best example o f this is the migration o f 
immune cells. Populations o f immune cells continuously survey the tissues o f the body 
searching for foreign antigens, prepared to initiate an immune response if necessary 135. 
During their trafficking, leukocytes are able to move into and out o f lymph nodes 
responding to cues that guide them in the correct direction 135. Recent research has also 
suggested that there are specific populations o f immune cells primed to survey specific 
tissues 136. This is potentially very significant as is could mean that to treat autoimmune 
diseases, it may not be necessary to inhibit the whole immune system, but instead target a 
specific population o f leukocytes leaving the remaining surveillance system intact. In the case 
o f infection or injury immune cells, such as neutrophils are able to respond and infiltrate the 
affected tissue extremely quickly 137. The speed o f the response implies that they are able to 
traverse endothelial barriers extremely easily; the question o f whether tumour cells are able to 
mimic this in order to metastasise will be addressed later.
1.7 Mechanisms of cell motility
In order for a cell or a group o f cells to be able to move they can organise polarity so as to 
have a defined front and back, then make a protrusion in the right direction. Having done 
this, the cell must then make contacts with the surrounding matrix and /o r other cells to 
tether itself to its new position. Finally contractile forces are also required to maintain cell 
integrity, to pull the rear o f the cell along with the front (Figure 1.7). Optimal migration and 
cell speed requires a delicate balance between adhesion and contraction138. The timing and 
coordination o f these processes is critical, as in many cases these process are occurring 
simultaneously but in different areas o f the cell. Cell adhesion is very important, but too 
much adhesion and a cell could tether itself too tightly to the substrate to move. Cell 
contraction is able to detach weaker adhesions at the back o f the cell which is important to 
move forwards, but uncontrolled cell contraction could overcome too many of the cell 
adhesions and can also be detrimental..
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Most investigation into cell motility has been carried out by studying the behaviour o f cells, 
such as fibroblasts, migrating across rigid surfaces. By culturing cells in a collagen matrix, it is 
now possible to monitor cell motility in vitro in deformable 3D-environments that more 
closely mimic the environment that cells might encounter in vivo. It is clear that cells behave 
differendy in these two different in vitro environments and it is now important to bridge the 
gap and discover how current knowledge o f cell motility applies to cell moving in 3D and in 
vivo.
I.7.1 Cell protrusions
The first step to initiate cell motility is usually to generate a cell protrusion. Many different 
types o f cell protrusions have been identified, such as lamellipodia, filopodia, podosomes and 
membrane blebs. Most cell protrusions require actin polymerisation to provide the 
propulsion to drive the cell membrane forwards 139. Monomeric globular actin (G-actin) 
molecules assemble asymmetrically; the plus-end or barbed end is the site at which new actin 
monomers are added and the minus-end or pointed end is less dynamic. The structure o f 
actin filaments is controlled by proteins that direcdy bind to actin and control processes such 
as: nucleating, capping, severing, depolymerising, cross linking and bundling o f filaments 139.
The activation o f Rho family GTPases Cdc42 and Rac can stimulate actin polymerisation by 
initiating the nucleation o f new actin filaments. Cdc42 bound to G TP interacts with Wiskott- 
Aldrich syndrome protein (WASP), relieving WASP auto-inhibition and promoting the 
interaction o f WASP with actin filaments and also with the ARP2/3 complex 11' 14°. WASP 
was initially identified as the protein involved in the immunosuppressive condition Wiskott- 
Aldrich Syndrome, and its expression is restricted to haematopoietic cell lineages. It is N- 
WASP that is found in most other cell types, and performs an analogous function to WASP
II. The interaction o f N-WASP and ARP2/3 with actin filaments causes branching the 
existing filament at a 70° angle. It is thought that this occurs because the ARP2/3 complex 
mimics the shape o f an actin dimer allowing new actin monomers to bind 141. Another 
nucleation promoting factor is WAVE (WASP-family verprolin-homologous protein-1). The 
binding o f GTP-bound Rac can activate WAVE; the interaction with Rac recruits WAVE 
and ARP2/3 to the membrane causing localised actin polymerisation 141. Actin filaments can 
also be lengthened by the activity o f formins. Formins bind to the barbed ends o f actin
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filaments and promote the lengthening but not the branching o f filaments. Unlike ARP2/3, 
formins remain at the tips o f the actin filaments as they lengthen.
Actin polymerisation is also a self-organising process and can be reconstituted in vitro with 
the right combination o f proteins; actin depolymerising factor (ADF)/cofilin, profilin, 
capping proteins, and nucleating factor ARP2/3 142. Newly synthesised filaments are initially 
weakly coupled to the rest o f the actin cytoskeleton but subsequently the actin 
polymerisation is coupled with new cell adhesions and can then anchor the cell as contractile 
forces are applied 143.
Filopodia are long, thin, unipolar, actin-driven cell projections that can act as scouts for the 
cell, sensing the nearby environment 144. Developing blood vessels include a leading tip cell 
that is able to sense direction o f VEGF gradients 145. The tip cell o f the endothelial sprout 
produces multiple filopodia to sense direction and also to make contacts with other new 
vessels to make branches. Filopodia can be driven by the activity o f the small GTPase Cdc42 
driving actin bundling at the leading edge 44. The straight actin filaments are thought to be 
induced mostly through the activity o f formins, or through the activity o f Ena/VASP 
proteins which attach to the barbed ends to drive the formation o f long unbranched actin 
filaments 144. Filopodia do not appear to require the activity o f N-WASP, as they are still 
present in N-WASP deficient cells 146. Lamellipodia are broad protrusions at the front o f cells 
migrating across 2D substrates. Lamellipodia are typically driven by actin polymerisation 
downstream o f Rac activation 48. Lamellipodia require the nucleation activity o f A R P2/3 to 
promote the progression o f a broad, branching actin network.
Another cell protrusion, thought to be used by cells to invade matrices is the podosome. 
These are actin-rich structures associated with protease activity and driven by activation o f 
the tyrosine kinase Src. Podosomes force their way into underlying matrix and are able to 
induce proteolytic degradation o f matrix in their path through the localised activity o f 
secreted matrix-metallo-proteases 147. Podosomes have been observed in monocyte-derived 
cells, fibroblasts and also some carcinoma cells, where they are termed invadopodia 148. 
Podosomes are one possible mechanism to explain how invasive cancer cells are able to 
cross basement membranes.
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Another type o f cell protrusion that is not directly driven by acdn polymerisation is 
membrane blebbing. Blebs are thought to be generated by contractile forces squeezing the 
cell contents and increases in hydrostatic pressure forcing parts o f the membrane to detach 
from the under lying actin cytoskeleton and protrude as a bleb 149. Contractile forces driven 
by alterations on acto-myosin downstream o f Rho-ROCK signalling are described below. 
The membrane bleb is formed at weaker points in the actin cortex, and as expansion o f the 
bleb ceases, the actin cortex reassembles 15°. Blebbing has been observed in Dictyostelium in 
response to the chemoattractant cAMP 1S1. Bleb-like protrusions have also been observed in 
primordial germ cells in zebrafish 152. Blebbing in this context is driven by contraction of 
myosin, stimulated in regions o f the cell with higher intracellular calcium levels 152. This 
mechanism o f cell protrusion is not well studied at present but it is becoming clear that 
blebbing can be utilised by cancer cells moving in an amoeboid manner and may be very 
relevant to the motility o f invasive tumour cells in vivo 153~155. Membrane blebbing can also be 
associated with apoptosis. However in this type o f blebbing ROCK is activated by caspase 
cleavage, so the activation o f Rho is not required 156.
1.7.2 Cell adhesions
A new protrusion must form attachments to the surrounding matrix to tether the moving 
cell to its new position. Contractile forces applied to the new adhesions will then be able to 
cause the translocation o f the cell body. Cell adhesions also generate intracellular signals to 
control cell behaviour. For example, if a cell loses attachment to the matrix or to surrounding 
cells apoptosis can be induced, and is termed anoikis 157. Interestingly it is also true that 
transformed cancer cells are less reliant on signals from cell adhesions and a common 
measure o f transformation is to suspend cells in soft agar. In this assay transformed cells are 
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Figure 1.7 Schematic diagram of cell motility mechanisms in
2D and in 3D systems. A) diagram showing cell motility across 2D 
substrates, cells are spread with broad lamelipodia and F-actin 
stress fibres. B) diagram showing mechanisms of amoeboid cell 
motility in 3D environments. Cells are contracted and show 
membrane blebs. F-actin is organised around the cell cortex. In 
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Our current understanding o f cell-matrix adhesions is mosdy based on studying focal 
adhesions in 2D in vitro cell culture, commonly using fibroblasts. Integrins are often utilised 
by migrating cells, and form an essential component o f focal adhesions. Focal adhesions 
mediate strong attachment o f the cell to the matrix and considerable forces can be applied to 
these attachments, in fact mechanical force applied to focal adhesions is able to signal to 
increase the strength o f the complex 158, 159. Focal adhesions characteristically contain 
integrins linked proteins such as to paxillin, talin and vinculin, which tether the adhesion to 
the actin cytoskeleton. Integrins contain an alpha and a beta subunit, each combination 
having specific matrix substrates that they are able to bind to, such as fibronectin, collagen, 
and laminins. The signalling downstream o f the integrins also provides specificity, for 
example a 2 p i integrin binding to collagen is reported to activate RhoA, whereas a3f3l 
integrin binding to laminin activates PAK1 and inhibits RhoA 160. The engagement of 
different integrins will therefore regulate cell motility differently, perhaps providing the 
correct balance o f protrusions and contractility that are suitable for the type o f matrix 
encountered by the cell.
Focal adhesion kinase (FAK) is recruited to sites o f integrin clustering and associates with 
proteins such as talin and vinculin. This complex formation stimulates the auto­
phosphorylation o f FAK on Y397 creating a docking site for SH2 domain containing Src 
family kinases. The integrin-mediated activation o f FAK and Src influences many aspects o f 
cell behaviour including the turn-over o f focal adhesions, cell motility and invasion 161,162
Flowever, the types o f cell-matrix adhesion studies in fibroblasts in vitro do not always 
accurately replicate the types o f cell adhesions used by motile cells in vivo. Analysis o f cell 
adhesions in 3D matrices and in vivo has shown that size and organisation o f focal adhesions 
depends largely on the rigidity o f the substrate 163. In vivo cells do not encounter a surface as 
rigid as glass or plastic, and therefore the adhesions are different both in their morphology 
and their composition. For example the phosphorylation o f FAK, commonly observed in 
2D focal adhesions is significantly reduced in 3D 163.
It has recently been reported that immune cells are able to migrate in vivo without the 
requirement for integrins 164. This work showed that dendritic cells were able to migrate 
between peripheral tissues and draining lymph nodes even when all expressed integrins had 
been genetically deleted. They conclude that 2D and not 3D cell migration is dependent on
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integrin-type adhesions. Instead it is hypothesised that the dendritic cells are motile due to 
‘squeezing’, which is dependent on myosin II 164. It is possible that cancer cells moving in an 
amoeboid manner use similar integrin-independent mechanisms, and we have observed that 
carcinoma cells are motile in vivo when integrin p i is depleted (Sahai lab-unpublished data). 
It is thought that some cancer cells moving in an amoeboid manner use an alternative type of 
adhesion complex, but the molecules that could be used have not yet been identified.
1.7.3 Generating contractile force
The component o f cell motility required move the cell body and to detach adhesions is the 
generation o f contractile force. Without contraction the front o f the cell would move 
forwards but the result would be only stretching o f the cell unless the back o f the cell was 
retracted. Cell moving across 2D surfaces often exhibit actin stress fibres. A stress fibre 
contains between 10-30 actin filaments that are held together by cross linking proteins such 
as a-actinin, or fascin which interact with the actin bundles at specific points periodically 
spaced along the fibre 165. Myosin is also combined with actin, and contraction is able to 
occur when the phosphorylated light chain o f myosin binds to the actin filament allowing an 
increase in the myosin ATPase activity; the binding o f myosin to the actin fibres is controlled 
by another class o f actin interactor, tropomyosin 166. Myosin light chain (MLC) can be 
phosphorylated on two residues, T18 and S I9, and the regulation o f the levels o f 
phosphorylated myosin light chain is critical to the regulation o f contractile forces within a 
cell 167. Cell motility requires both the assembly o f filamentous actin and also generation o f 
contractile forces. Inhibition o f either actin polymerisation (e.g. cytochalasinD treatment) or 
myosin ATPase activity (e.g. Blebbistatin treatment) impedes cell motility.
Stress fibres were found to be regulated by the activity o f RhoA through its effectors 
ROCK l and ROCK2 (collectively termed ROCK). ROCKl and ROCK2 are serine 
threonine kinases that are able to increase the availability if phosphorylated myosin-light- 
chain in several ways. Firsdy by phosphorylating and inhibited myosin-light-chain 
phosphatase, secondly by phosphorylating zipper-interacting protein kinase (ZIPK) which in 
turn phosphorylates MLC on both T18 and S I9 168, and finally perhaps by phosphorylating 
MLC direcdy at SI 9 165.
Another RhoA effector mDia is also required for the correct organisation o f stress fibres. 
ROCK activation alone tends to typically form a star-like pattern o f stress fibres in the centre
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of the cell. mDia acts to extend the polymerisation o f actin filaments from cell membranes. 
It is thought that to produce thick parallel stress fibres downstream o f RhoA, mDia is 
required. However activation o f mDia alone does not induce thickly bundled actin filaments. 
The activities o f both ROCK and mDia are required in concert for the proper organisation 
o f actin 169.
Stress fibres are the predominant form o f contractile actin structure seen in 2D cell culture. 
In 3-dimensional culture and in vivo actin can still be bundled and it is likely that the 
mechanisms controlling contractility are similar. However the actin bundles tend to be 
located around the cell periphery creating a thick actin cortex and are not always seen as 
stress fibres 154. Contractility in 3-dimensions can help to keep cells rounded, and as 
discussed above, is able to generate hydrostatic pressure to force out bleb-like protrusions.
Myosin light chain phosphorylation can also be regulated by MRCK down stream o f Cdc42 
1?0. It has been found that Rho-ROCK signalling drives rounded amoeboid cell motility, but 
in the absence o f ROCK signalling, cells are still able to invade in an elongated/mesenchymal 
manner. Elongated cell invasion still required contractility as it is inhibited by blebbistatin, 
but this was regulated by Cdc42 and MRCK instead o f Rho and ROCK 17°. Additionally 
signalling through Cdc42 and MRCK has been shown to control contractility in groups o f 
cells moving collectively, and acts to maintain cohesion within the groups o f cells by 
regulating bundles o f contractile myosin that are continuous around the edges o f the group 
rather than within each individual cell79.
It is clear that contractility is required for different types o f cell motility, whether this is in 2- 
dimensions or in vivo, in single cells or collective groups. The organisation o f contractile 
machinery however varies between different modes o f motility. Depending on the 
mechanism o f cell motility used, cells are able to activate different signalling pathways in 
different spatial locations, enabling cell migration.
1.7.4 Cell polarity during motility
Polarity is required for the normal functioning o f many cells in healthy tissues. Polarity 
allows the cell to maintain its correct position between other cells and allows cells to function 
together as a tissue. Apical basolateral polarity is essential for the functioning o f epithelial cell 
layers. The polarisation leads to the transport o f specific proteins to the surface at which they
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are required, and cell-cell junctions function to maintain the separation o f the apical and 
basolateral surfaces. The loss o f cell polarity in epithelial layers is associated with disruption 
o f epithelial barrier function. Loss o f polarity also occurs in carcinomas undergoing and 
epithelial to mesenchymal transition and is associated with higher invasive poten tialxlx.
Cell polarity can also occur within single cells to define the front and the back during cell 
migration. This is very clearly seen when adherent cells such as fibroblasts migrate across a 
2D substrate. The front o f the cell is normally characterised by the presence o f a cell 
protrusion such as a lamellipodia driven by actin polymerisation. Actin polymerisation does 
not occur at the rear o f the cell, instead thick filamentous actin cables are contracted to pull 
the ‘tail’ forwards as the front pushes forwards. RhoA activity, which controls contractility o f 
cells is high at the back and is involved in retraction o f the rear. Levels o f RhoA were 
thought to be reduced at the front o f the cell and instead active Rac and Cdc42 are recruited 
drive actin polymerisation 172. One mechanism that restricts RhoA activation at the front is 
the degradation o f RhoA following ubiquitination by the HECT domain E3 ubiquitin ligase 
Smurf 1 m ' 174. However, in cells moving in 3-dimensional environments, it has also been 
shown that Rho signalling and contractility o f myosin is also required at the front o f cells 154,
175, 176
Sub-cellular organelles are also re-positioned within cells as polarity is established. This 
organisation has been extensively studied utilising confluent layers o f adherent cells and 
scratching a ‘wound’ across the cells. Cells will then polarise and start to migrate into the 
space created. It has been shown that structures such as the MTOC and Golgi apparatus will 
be organised to the front o f the nucleus as a cell polarises 172. The positioning o f the MTOC 
requires micro tubule dynamics and the positioning o f the Golgi is actin-dependent177.
The polarisation o f motile cells can help to maintain direction to migration. In cells moving 
across a 2D substrate it is clear to see that polarisation is stably maintained and signalling 
events at the front and back o f the cells can be easily monitored, as there is a reasonable 
degree o f spatial separation. When cells move in a 3-dimensional environment polarisation is 
less clear. Immune cells and some tumour cells moving in an amoeboid manner are rounded 
and contracted meaning there is less spatial separation between the front and the back. Cells
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are also able to change direction very quickly, so it would seem that cell polarity can also be 
less stable and more transient, but still functional to allow cells to sense direction.
1.7.5 Directional migration
In many cells the direction o f motility is influenced by local environmental cues. Chemotaxis 
is the ability o f cells to organise their movements based on the direction o f a specific 
molecule present in their environment. Chemotaxis is required for sperm to find and fertilise 
an egg, it is also required for the migration o f neurons as the brain develops. Cells can 
respond to gradients o f a variety o f molecules and migrate towards them. For example 
Dictyostelium will migrate towards higher concentrations o f cAMP and arachadonic acid 178. 
These chemoattractants cause release o f intracellular calcium that is required for motile 
behaviour 179. Cells are also able to follow gradients o f adhesion molecules and matrix such 
as fibronectin; this directional motility is termed haptotaxis, and is important for migrating 
cells in developing embryos but is also used by some cancer cells during the metastatic 
process 180,181. One important question is how cells polarise and move directionally across 
very shallow gradients over large distances in vivo. For example, immune cells homing to 
lymph nodes from peripheral tissues. This would require an amplification o f signalling to 
reinforce and exaggerate the differences in the gradient from front to back.
Signalling pathways such as PI3K signalling have been documented to be specifically 
activated at the front o f migrating cells in response to chemotactic stimuli. This signalling is 
able to promote actin polymerisation in the direction o f the stimulus. It has been seen that 
PI(3,4,5)P3 is selectively accumulated at the front o f migrating cells 182, 183 and is removed 
from the sides and rear o f the cell by the localised action o f phosphatase and tensin 
homologue (PTEN) 184. However this model that PI3K is activated by higher concentrations 
o f chemoattractant at the front o f cells to drive protrusions has been challenged by a new 
theory suggesting that protrusive activity generates cell extensions at random, and that 
direction is determined by selecting the protrusion which is in the most accurate direction 185. 
This suggests that PI3K activity controls the generation o f protrusions but does not control 
their directionality.
Neutrophils respond to gradients o f chemokines such as IL-8 but also to bacterial peptides 
such as fMLP. Interestingly, the requirement for PI3K signalling to sense these two gradients
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is different and it is suggested that neutrophils responding to fMLP do not require PI3K 
signalling 186. There is also evidence that metastasising tumour cells are able to respond to 
chemokines and that this directional migration leads to the presence o f secondary tumours in 
particular target organs; this is addressed in more detail in a later section 187. Chemokines 
bind to specific G-protein coupled receptors in the cell membranes to trigger signalling 
events to control immune cells activation in addition to cell migration. Much research is 
underway to determine whether specifically blocking chemokine signalling could be 
beneficial to patients suffering autoimmune diseases, inflammation and also cancer 187 188.
In vitro, chemotaxis is modelled using soluble chemoattractants presented to cells either by 
separation o f two chambers, between which the migrating cells may preferentially migrate 
towards a chemokine, for example the Dunn Chamber, or the chemoattractant is contained 
within a pipette which can be moved and the cells follow 189. This has been useful to show 
the principles o f chemotaxis. How chemotaxis occurs in vivo is now being investigated. 
Firstly gradients in vivo are set up over very large distances between tissues; furthermore the 
gradient must remain stable for long periods o f time. The presence o f matrix components 
may act as a hindrance to diffusing chemoattractant molecules, or conversely the 
chemoattractant molecules could be bound to matrix components and presented to passing 
cells. One recent paper has suggested that interstitial flow within tissues can act to guide 
cells. It was found that chemokine secreted by the migrating cell was drawn in the direction 
of interstitial flow, meaning that the cell can provide their own chemotaxis gradient and may 
explain how tumour cells are able to migrate to draining lymph nodes 19°. It is also possible 
that migrating cells do not require the chemokine to be presented as a gradient. Work into 
how the lateral-line primordium migrates during zebrafish development has shown that cells 
at the leading edge o f the cohort require the presence o f SDF-1 191. However, if the SDF-1 is 
absent at any point along their route, the cohort o f cells is able to turn around and follow the 
SDF-1, still present from the direction they have just traveled from, in the opposite direction, 
meaning that the SDF-1 is unlikely to be presented as a gradient192.
1.8 Metastasis
Metastasis is the process by which malignant cancer cells are able to leave the primary 
tumour and arrive in secondary sites to form secondary tumours (Figure 1.8). I f  a primary 
tumour is identified early and surgery to remove it is successful then the outcome for the
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patient is generally good, however if cancer cells are found to have spread the prognosis for 
the patient is much worsened. Most o f cancer deaths are due to the onset o f metastatic 
disease, which makes this an important area o f cancer research with potentially huge benefits 
to patients.
Until recently, the process o f metastatic spread o f tumours has been difficult to study in 
detail. Most studies relied on the development o f macroscopic secondary tumours as a 
measure o f the metastatic capability o f tumour cells. Clinically, metastatic disease is studied 
through the use o f tissue sections taken from patients by biopsy. This approach has been 
useful to determine the organisation o f secondary tumours and to analyse protein expression, 
but it lacks the dynamic information to explain what happens to cells between leaving the 
primary tumour and arriving and proliferating and forming the secondary tumour. Important 
studies conducted in the 1950’s and 60’s, directly observed cancer dissemination by 
implanting tumours into rabbit ears 193. These studies pre-dated our genetic understanding o f 
cancer, and the discovery o f fluorescent proteins, so used very simple imaging technologies. 
The development o f intravital confocal microscopy technology has allowed researchers to 
visualise the motile behaviour o f tumour cells in the primary tumour with high resolution, 
and start to put together a picture o f how cancer cells move in vivo.
Our estimates indicate that between 1-5% o f cells in the primary tumour are motile 
(Giampieri et al. — unpublished data). This suggests that even though metastatic disease is 
associated with higher-grade tumours and is thought to be a late stage o f tumour 
progression, tumour cells are able to invade, at least locally, from a much earlier stage than 
originally thought 194. Despite large numbers o f cells acquiring motile behaviour and leaving 
the primary tumour, the number o f metastatic secondary tumours is relatively low. This 
implies that the whole process o f metastasis is inefficient and that only a minority o f cells 
manage to complete every step required.
For a cancer cell to metastasise, it must first release itself from the rest o f the primary tumour 
cells. In carcinomas, cell-cell contacts are generally maintained and can be seen by the 
presence o f E-cadherin at cell junctions 195. Loss o f E-cadherin is thought to correlate with 
increased invasive potential, and is sometimes indicative o f epithelial to mesenchymal 
transition (EMT), which is discussed later 171195.
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O f these motile cells, some may invade blood vessels to enter the blood stream, and others 
may migrate to draining lymph nodes (Figure 1.8). It has been shown that tumour cells are 
able to orientate themselves towards blood vessels meaning that there may be some 
chemotactic response to an unknown factor produced by the blood vessels 1%. It has also 
been shown that macrophages infiltrating the tumour are able to aid cancer cells entering the 
circulation 197. Entering blood and the lymphatic circulations are the ways in which cancer 
cell are able to travel large distances from the primary site and arrive in new organs, but it is 
still unclear whether movement through the lymphatic vessels or the blood is the primary 
mode o f transit from the primary tumour 198.
The method used by tumour cells to enter blood vessels is also unclear. It is thought that 
tumour cells would need to use proteases to degrade basement membrane surrounding the 
endothelial cells before entering the vessels (Figure 1.8). However this may not always be the 
case as recent research has shown that tumour cells are able to up regulate endothelial 
specific genes and incorporate themselves into the walls o f blood vessels 199 20°. This process 
has been termed vascular mimicry and potentially explains how tumour cells would be able 
to enter the vasculature without requiring proteases. Another potential mechanism o f entry 
to the vasculature is for the cancer cell to mimic the transendothelial migration mechanisms 
o f leukocytes such as neutrophils. Neutrophils are able to cross endothelial barriers in 
matters o f minutes and recent research has shown that this is due to the generation o f high 
levels o f mechanical force that disrupts endothelial cell junctions 201.
Once in the blood stream, tumour cells must be able to survive transit in the circulation. The 
shear forces exerted are considerable and the majority o f cells entering the blood are likely to 
undergo apoptosis even if they reach a secondary site. It has been shown that metastatic and 
non-metastatic cells are able to interact with blood vessels in primary tumours but that the 
metastatic cells are better able to survive the sheer stresses 202. It also seems that rounded, 
contractile cell morphology is more suitable for entry into the blood vessels and survival in 
the blood stream 173. Perhaps contractile forces enable cells to maintain greater cortical 
rigidity, which protect the cancer cell from damage and enable cells to withstand greater 
mechanical stresses.
If  an invasive cancer cell survives transit in the blood stream, it will probably come to rest in 
a capillary bed where it will slow down and get lodged, for example in the lungs (Figure 1.8).
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It has been shown that tumour cells can lodge in small vessels in association with platelets in 
a small clot 203. Following arrest in a blood vessel, the clot is dissolved and the tumour cells 
interact with the endothelium by attaching and spreading 203. This process may be important 
for subsequent extravasation. It is also possible that tumour cells do not need to extravasate, 
but proliferate within the capillary and invade into the lung tissue subsequently when the 
metastatic secondary tumour reaches a larger volume.
The final location o f tumour cells travelling in the blood can be determined by the next 
capillary bed they reach and get lodged in. However there are also specific examples o f 
certain tumour types preferentially metastasising to certain sites. For example breast cancer 
cells often metastasize to bones 204. This tissue specificity could either be due to the cancer 
cells specifically migrating to these organs, but it could also be because the cancer cells are 
only able to survive and proliferate in certain locations. This question was first addressed 
over 100 years ago, when Paget hypothesised that sites o f metastasis were defined by both 
the cancer cell (the seed) and also the microenvironment o f the secondary site (soil)205. This 
hypothesis still holds true and research has shown many examples o f tumour cells expressing 
receptors to enable them to home to tissues specifically expressing certain cytokines 206. For 
example the expression o f CXCR4 is highly up regulated in some breast tumours and may be 
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Figure 1.8 The metastatic process. For tumour cells to spread 
to distant site and form secondary tumours, they must escape 
from the primary tumour and invade the surrounding matrix. 
Having done this some cells will enter the blood or lymphatic 
vessels and be carried to other organs. On reaching a capillary 
bed they may become lodged. To form a secondary tumour the 
cells must also extravasate and be able to survive and proliferate 
in their new environment.
Metastasis is a complex and inefficient process, but one essential factor is the acquisition o f 
motile behaviour. I f  cell motility in the primary tumour could be successfully inhibited, and 
the numbers o f cells entering the blood and lymph could be significandy reduced, then the 
occurrence o f metastatic secondary tumours should also be substantially reduced. The 
experiments in this thesis aim to gain more insight in the mechanisms o f cancer cell motility 
in vivo.
1.8.1 Experimental approaches to study cell motility in vivo
Numerous approaches are now available to researchers to investigate the behaviour o f cancer 
cells in vivo. The method utilised in this thesis is intravital multiphoton microscopy. In order 
to study the behaviour o f cancer cells in vivo, cells are stably transfected in vitro to express 
fluorescent markers and are then injected either subcutaneously or into the mammary fat pad 
o f immune-compromised mice. Tumours develop within 2-4 weeks and are imaged between 
4-6 mm in diameter. These tumours are then imaged using a combination o f single and 
multi-photon confocal microscopy. Multi-photon microscopy uses almost simultaneous 
delivery o f multiple photons o f longer wavelengths to excite fluorophores. Longer 
wavelengths (between 600 and 1000 nm) are able to penetrate deeper into tissues and this 
allows researchers to visualise what is happening more than 100 microns inside a tumour 
whilst causing less photo-damage to the surrounding tissue outside the focal point. Also as 
excitation requires more than just one photon, excitation only occurs at the focal point 
allowing good optical sectioning and 3D resolution 207. Recently developed high N.A. lenses 
that efficiently transmit infra-red light allow the subcellular localisation o f a variety o f 
cytoskeletal proteins to be visualised. However this approach requires either invasive surgery 
at the time o f imaging, and so is not possible to image a tumour more than once, or window 
chambers can be implanted which allow multiple imaging sessions o f one site but have the 
disadvantage o f creating a rather artificial environment. O ther non-invasive imaging 
techniques have lower resolution but nonetheless have many applications and are a useful 
adjunct to multi-photon microscopy.
Much of the tissue architecture can be seen using reflectance imaging, including some 
circulating immune cells. The collagen fibres, by virtue o f their protein structure can also be 
seen using second harmonic signals (a complex physical process which generates light exactly 
half the wavelength that they are illuminated with) 208. Blood vessels can be seen either as
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areas containing less dense matrix when imaged by reflectance, or a fluorescently labelled 
marker can be injected intravenously. The fluorescently labelled cell lines can then be imaged 
against the background o f the tissue microenvironment. Fluorescent proteins can be used to 
observe the localisation o f cell structures including the plasma membrane, the nucleus or 
proteins o f interest during cell movement events 198.
To model the tumour environment and amoeboid motility in vitro 3D matrices comprising 
mostly collagen (2-4 mg/ml) can be used 209. This creates an environment with similar elastic 
properties to tumour tissue 21°. Cells mixed within this matrix, or plated on top behave 
similarly to what we observe in vivo. Cells displaying amoeboid motility in vivo appear 
rounded when plated on a 3D matrix and have prominent cortical actin.
1.8.2 Cancer cell motility in vivo
Cancer cells are able to move and invade in a variety o f ways. It is also possible for tumour 
cells to switch modes o f motility when one mechanism is inhibited 21 \  This plasticity in 
cancer cell motility presents a huge challenge when designing potential future treatments and 
it is likely that successful anti-metastatic treatments will need to block different modes o f cell 
motility simultaneously.
In vivo, cancer cells are able to move with a range o f morphologies. Cells can invade as 
individual cells in either an amoeboid or an elongated manner, and they are also able to move 
as collective cohorts 212. These categories o f cell motility are not completely distinct, and 
tumour cells are often able to switch between modes, this is discussed below. The 
mesenchymal type o f cell motility is characterised by elongated fibroblast-like cell 
morphology. Elongated cells utilise integrin-based adhesions and up-regulate cell surface 
pro teases to degrade extracellular matrix in their path 213. This type o f cell migration requires 
active Rac and Cdc42 but is less dependent on Rho signalling 153, 170’ 214. Due to the time 
required to degrade the matrix and to turnover integrin adhesions, this type o f cell motility is 
relatively slow.
Epithelial to mesenchymal transition (EMT) is a well-documented phenomenon that occurs 
during morphogenesis during embryonic development 171. EMT in adult tissues contributes 
to the pathology o f fibrotic conditions for example in the kidney. EM T in this context 
prevents the proper functioning o f the epithelial tissue215. EMT is also thought to occur in
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carcinomas as they begin to become invasive, in cases where tumours o f epithelial origin are 
observed to move in an elongated manner. EMT is characterised by the loss o f epithelial 
markers such as E-cadherin, and the simultaneous up regulation o f mesenchymal markers 
such as vimentin. EM T can be induced and maintained by TGF-(3 signalling which was 
discussed earlier. Prolonged TGF-J3 signalling causes changes in the transcriptional profile o f 
cells through the activation o f transcription factors such as twist, slug and snail216,2X7. These 
changes in protein expression cause cells to lose cell-cell adhesion and start to become 
motile. Analysis o f tumour tissue has shown that cells at the tumour periphery are less 
epithelial in morphology, and in some cases, look more similar to fibroblasts, and have 
started to express mesenchymal markers 218. The cells that are more mesenchymal in nature 
are thought to be able to lead cell invasion by degrading and deforming surrounding matrix.
It has also been shown that EMT is not always required for cell invasion. For example 
squamous cell carcinoma cells (SCC) are able to collectively invade whilst retaining epithelial 
characteristics. Their invasion is possible because the stromal fibroblasts are able to lead the 
invading strands o f SCCs. The mesenchymal properties o f the fibroblasts allow them to 
remodel the matrix and lay down components such as fibronectin. They also deform the 
matrix, leaving holes for SCCs to move through and thick tracks o f collagen to guide them 79. 
This is an example o f epithelial-like cells hijacking the mesenchymal properties o f resident 
host cells to invade, and shows clearly that although remodelling o f the matrix is required, it 
is not necessary for the carcinoma cells to carry out this function themselves by undergoing 
EMT.
Recent advances in microscopy techniques has allowed the visualisation o f the behaviour o f 
live tumour cells, and it has been seen that tumour cells o f different origins (carcinoma, and 
melanoma) commonly move very rapidly in an amoeboid manner. In contrast to 
mesenchymal migration, amoeboid cell migration is extremely rapid (up to 15 microns/min). 
Amoeboid cell migration o f tumour cells resembles the dynamic movement o f the amoeba 
Dictyostelium 219. Amoeboid cell migration is driven by dynamic changes in cell shape 
downstream o f strong contractile forces. Amoeboid cell motility requires signalling through 
RhoA and ROCK but does not require integrins or stable focal adhesions with the matrix 220. 
The dynamic changes in cell shape are sufficient to physically deform the matrix and /o r 
allow cells to squeeze through small spaces without requiring degradation o f the matrix by 
proteases 154. This type o f cell motility is also used by migrating leukocytes 164. Amoeboid
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cells are generally rounded in morphology and can exhibit membrane blebs due to high 
contractile forces driven by Rho and ROCK signalling (see above). Perhaps a full conversion 
from epithelial to mesenchymal characteristics is not always occurring, as it seems clear that 
cancer cells are able to be individually modle in vivo without the need to activate 
mesenchymal gene expression 221.
The ability o f cancer cells to switch between mesenchymal and amoeboid motility has also 
been documented 222. Blockade o f protease function inhibited mesenchymal cell motility but 
amoeboid blebbing motility still allowed cells to invade. Blocking Rho-ROCK signalling 
inhibited amoeboid cell invasion but cells were still able to invade in a mesenchymal manner. 
A combined blockade o f both mechanisms was required to completely inhibit cell invasion 
153. These results can help to explain why clinical trials o f Matrix-metallo-proteases have been 
relatively unsuccessful 223 224’225.
Switching between modes o f invasion may also be required by cancer cells to complete the 
metastatic process, as both mesenchymal and amoeboid cell motility have distinct 
characteristics. Amoeboid cell motility is fast and it is also likely that rounded contractile 
morphology is advantageous when travelling through the blood and colonising a secondary 
site. However when a cell is faced with a very dense matrix that does not permit amoeboid 
cells to squeeze through, protease activity might be required. Protease activity may also be 
required for cells to degrade and pass through a basement membrane to enter blood vessels. 
It will be interesting to find out whether the inter-conversion o f cell motility mechanisms 
occurs in vivo.
One very interesting observation from the in vivo studies o f cancer cell motility was that 
some areas o f tumour show no cell motility whilst other areas o f the same tumour contain 
many motile cells (Figure 6.1). Although the ability o f a cell to become motile may be in part 
determined by intrinsic factors, it seems that the microenvironment also plays an important 
role. As discussed above it has been shown that host stromal fibroblasts are able to induce 
the collective invasion o f SCC. Other examples o f host cell/tumour cell interactions have 
also been documented. For example, it has been reported that tumour associated 
macrophages produce Epidermal growth factor (EGF) which stimulates motility in 
mammary carcinoma cells. In turn the carcinoma cells produce CSF-1, which stimulates the
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macrophages to produce more EG F 226. This paracrine loop is likely to be just one o f many 
signalling interactions between tumour cells and host cells.
In conclusion, the study o f cancer cell motility in vivo is still at an early stage. Despite the 
range o f modes o f motility so far observed, it is also clear that tumours show a huge degree 
o f heterogeneity, which has not been modelled previously in 2D assays. The signalling 
pathways that determine why one cell or group o f cells should be motile and its neighbours 
not are likely to be complex and will require much more investigation. Also the mechanisms 
allowing cells to switch between collective and single cell invasion, and also between 
elongated/mesenchymal and amoeboid motility are still poorly understood. The interplay 
between tumour cells and surrounding host cells will also be important to explore further. 
The work documented in this thesis aims to uncover some o f the mechanisms controlling 
cancer cell motility in vivo with particular focus on amoeboid cell motility.
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2 Materials and Methods
2.1 Reagents and chemicals
Below is a list o f commonly used reagents; other reagents will be specified in the section for 
the assay in which it was used.
Sodium Chloride (NaCl), Potassium Chloride (KCl), TRIZMA base, TRIZMA HCl, 
Potassium phosphate (KH2P 0 4), Sodium phosphate (Na2H P 0 4), ethylene diamine tetraacetic 
acid (EDTA), glycine, Dithiothreitol (DTT), P-mercaptoethanol, Sodium Pyrophosphate, 
Sodium Orthovanadate (N aV 04), Sodium deoxycholate, Tetramethylethylenediamine 
(TEMED), Ethanol (EtOH), aprotinin, leupeptin, hydrochloric acid (HCl), Dimethyl 
sulphoxide (DMSO), TW EEN-20, TRITO N X I00, nonyl phenoxylpolyethoxylethanol, (NP- 
40), Brij35, bromophenol blue, Brilliant blue, ponceau S, Bovine serum albumin (BSA), 
Adenosine triphosphate (ATP), Feotal Calf Serum (FCS), were all purchased from SIGMA. 
Methanol (MeOH), acetic acid, glycerol, Boric acid, sodium dodecylsulphate (SDS), 
magnesium chloride (MgCy were purchased from Fisher Scientific.
Matrigel and Rat-tail collagen type I were purchased from BD biosciences, a-M EM  was 
purchased from GIBCO.
2.1.1 Enzymes
Restriction enzymes were purchased from NEB and were supplied with the appropriate 
buffers. PCR reactions were carried out using Phusion also from NEB, and was supplied 
with two different reaction buffers, H F buffer was used in all cases for site directed 
mutagenesis. Ligation reactions were carried out using T4 DN A ligase also from NEB. 
Details o f reaction conditions are given in later sections.
2.1.2 Buffers and solutions
Some o f the buffers and solutions used repeatedly throughout these experiments are listed 
below. Alterations to these are specified in the sections below in the appropriate places.
Phosphate buffered saline (PBS):
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1.5 mM K H 2P 0 4, 8 mM Na2H P 0 4, 2.7 mM KC1,137 mM NaCl, pH 7.4
Tris buffered saline (TBS1
137 mM NaCl, 2.7 mM KC1, 20 mM TRIZMA HCl, pH 7.4 
TE  Buffer
lOmM Tris HCl pH 7.5, ImM EDTA
IPX Protein Buffer
1.92M glycine, 0.25M Tris base
SDS running buffer
100 ml 10X protein buffer, 890 ml dH 20 ,  10 ml 10% SDS 
Transfer Buffer 1 litre
200 ml Methanol, 100 ml 10X protein buffer, 1ml 10% SDS 
IPX TBE Buffer
108 g Tris base, 55 g Boric acid, 9.3 g Na4EDTA, dH20  to 1 Litre
(pH is 8.3 and does not need to be adjusted use 0.5X for running agarose gels)
2x SDS gel loading buffer
lOOmM Tris HCl pH 6.8, 4% SDS, 20% glycerol, 200mM P-mercaptoethanol, 0.2 % 
bromophenol blue
Lysis buffer
50 mM Tris pH 7.5, 1 % triton xlOO, 10 mM MgCl2, 150 mM NaCl, 1 mM DTT, 40 mM Na 
pyrophosphate, 1 mM N aV 0 4, 2 mM PMSF, 50 ng/ul, 0.025 % N P 40, 0.05 % 
deoxycholate, 10 pg/m l aprotinin, 10 pg /m l leupeptin, dH20
Kinase assay buffer
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50 mM Tris pH 7.5, 1 mM EDTA pH8.0, 10 mM MgCl2, 50 mM NaCl, 0.03% Brij35, 1 mM 
DTT, 40 mM Na pyrophosphate, 1 mM N aV 0 4, 2 mM PMSF, 50 ng/ul, 0.025 % N P 40, 
0.05 % deoxycholate, 10 ixg/ml aprotinin, 10 ^ig/ml leupeptin, 10 JJM ATP, dH 20
2.2 Mammalian Cell culture manipulations
2.2.1 Cell lines
A375 cells are amelanotic human melanoma cells. A375 cells were cultured in DMEM + 
10% FCS in 10% C 0 2. Polyclonal cell lines stably expressing GFP-MLC and monoclonal cell 
lines with stable knockdown of PD K -lw ere also cultured in these conditions after they had 
been selected in antibiotic containing media (see later). Two types o f A375 cells are used in 
these experiments, A375P and A375M2. A375P are used as a model system for looking for 
increases in ROCK activity, A375M2 cells are used as a model to look for the disruption o f 
rounded cell morphology e.g. the siRNA screen and the in vivo experiments. MTLn3E cells 
were originally isolated from a rat mammary carcinoma. MTLn3E cells were cultured in a -  
MEM + 5% FCS in 5% C 0 2. B16 F2 cells are a mouse, pigment-producing melanoma cell 
line. B16 F2 cells were cultured in DMEM + 10% FCS in 10% COz
DMEM was made to the following protocol in house by media production services.
2.2.2 Cell culture
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a-M EM  was purchased in powdered form from GIBCO (11900-073) and was made up with 
sodium bicarbonate according to the manufacturer’s instructions.
Cells were removed from cell culture dishes with 0.1% trypsin and 0.02% versene after 
washing the cells with PBS. Trypsin was neutralised by adding 10 ml media containing 10% 
FCS.
2.2.3 Generation of 3D collagen/matrigel matrix
The gel-mix used throughout the 3D in vitro assays are previously described 209. The 
components are as follows.
20% Matrigel (BD biosciences)
3.2 m g/m l Collagen type 1 (BD biosciences),
10% FCS
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Collagen type 1 was mixed with 5X aM EM  with sodium bicarbonate to neutralise the acidic 
pH. Matrigel and FCS were added to the concentrations above. The volume was made up 
with IX  media +10% FCS that was suitable for the cell line used in the subsequent assay.
The gel mix was then spread into glass-bottomed cell culture dishes from MatTek using the 
tip o f a sealed glass pipette. 45 fil was used to cover a coverslip 1.3 mm in diameter. The gels 
were left for 15 min at 37 °C to set before they were covered with media and cells.
2.2.4 Transient DNA transfections
Cells were plated in 6 well plates 24 hours before transfection. A375 cells and MTLn3E cells 
were transfected with effectene (Qiagen). 1 pg DNA was mixed with 100 pi EC buffer + 3 
pi enhancer solution. After 20 minutes, 10 pi o f effectene was added to the mix. After a 
further 20 minutes, 900 pi o f complete media was added and the total mix (1 ml) was added 
to the cells. The cells were washed with PBS after 2 Vi hours and left in the appropriate 
media + 10 % FCS to recover over-night before any further manipulation. In cases where 
cells are co-transfected with more than one DN A construct, the two plasmids were mixed in 
equal concentrations in the transfection mix, using a total o f 1.5 pg DNA.
On occasions where cells where subsequently analysed by immune fluorescence, cells were 
trypsinised 24 hours after transfection and plated on glass-bottomed MatTek dishes or 
collagen/matrigel gels for imaging. Cells could also be treated with inhibitors after 
transfection before fixation.
2.2.5 Transfection of siRNA oligos
siRNA oligos were ordered from Dharmacon and stock concentrations made up at 20 pM. 
For the siRNA screen, Dharmacon provided a 96 well plate, each well containing a smart 
pool o f 4 siRNA oligos for each gene. The oligos in the plate was also made up at 20 pM. 
siRNA oligos were used in the transfections at a final concentration o f 100 nM. The 
transfection reagent used was oligofectamine (Invitrogen).
Transfection mix:
Per well for a 48 well plate
1) 1 pi siRNA oligo (stock concentration 20 pM) mixed with 11.5 pi opti-MEM
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2) 1 pi oligofectamine reagent + 11.5 pi opti-MEM
After 5 minutes mix both 1) and 2) together and incubate for a further 20 minutes for 
complexes to form. Wash cells and add 175 pi opti-MEM to each well. Add the 25 pi o f 
siRNA and oligofectamine reagent mix and leave on cells for 8 hours. Transfection is 
stopped by adding opti-MEM containing 30 % FCS, so that the final concentration o f FCS 
was 10 %.
For the siRNA screen, 20,000 A375 cells were plated into each well o f 2 x 48 well plates and 
allowed to adhere over-night. 200 pi o f transfection mix (see above) was added to each well 
for 8 hours. After this time 100 pi o f opti-MEM + 30 % FCS was added to each well. 24 
hours later the cells were washed and media replaced with DMEM + 10 % FCS.
For transfection o f siRNA oligos for use in other assays the siRNA oligos were used at a 
final concentration o f 100 nM. The transfections were scaled up to 6 well plates containing 
150,000 A375 cells according to the instructions supplied with the oligofectamine reagent. 
Briefly, for a 6 well plate: 1) 5 pi siRNA oligo (stock concentration 20 pM)
Mixed with 75 pi opti-MEM
2) 5 pi oligofectamine reagent + 15 pi opti-MEM
After 10 minutes mix 1) and 2) and leave for 20 minutes. Then add 900 pi opti-MEM and ass 
the total mix (1 ml) to the 6 well plate.
2.2.6 siRNA oligos used in transient knockdown experiments
Target Oligo name Dharmacon number Seauence
RhoA RHOA#2 D-003860-02 GAACUAU GU GGC AGAU AU CUU
PDK1 PDK1#1 D-003017-05 CAAG AGACCU CGU GGAGAAUU
PDK1 PDK1#2 D-003017-06 GACCAGAGGCCAAGAAUUUUU
RHOE RH O E#l D-007794-02 GAACGUGAAAUGCAAGAUAUU
RHOE RHOE#2 D-007794-03 GAAAUUAUCCAGCAAAUCUUU
In cases when cells were transfected with siRNA oligos and also DNA constructs, the siRNA 
transfection was carried out first, as above, and 24 hours later, after the cells had been
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recovered in DM EM  + 10 % FCS, the DNA transfection was carried out as detailed above. 
Two separate transfections was the preferred method to obtain optimal knockdown and also 
optimal expression o f the DNA construct. In cases when cells were depleted o f both PDK1 
and RhoE, siRNA oligos were mixed in equal concentration in the reaction mix and the total 
final concentration o f oligo was 150 nM.
2.2.7 siRNA screening in A375 cells
As detailed above, a 96-well plate containing smart-pools o f 4 siRNA oligos targeted against 
each gene was acquired from Dharmacon. The genes included had been selected in 
collaboration with other group leaders at the LRI and included genes known to be involved 
in cell motility, cell adhesion, actin dynamics and also some other major signalling pathways. 
The gene symbols and Dharmacon catalogue numbers are listed below. The plate also 
contained several non-targeting siRNA controls and also empty wells also as controls.
CTTN M-010508-00, RHOBTB3 M-020480-01,
WASL M-006444-01, RHOT1 M-010365-00,
PXN M-005163-00, RHOT2 M-008340-00,
VCL M-009288-00, DIAPH1 M-010347-01,
TLN1 M-012949-00, DIAPH2 M-012029-00,,
RAC1 M-003560-02, WASF1 M-011557-00,
RAC2 M-007741-00, WASF2 M-012141-00,
RAC3 M-008836-01, CFL1 M-012707-00,
CDC42 M-005057-00, PTK2B M-003165-03,
RHOA M-003860-00, ITGA1 M-008516-00,
RHOB M-008395-01, ITGA2 M-004566-01,
RHOC M-008555-00, ITGA3 M-004571 -01,
RHOD M-008940-00, ITGAV M-004565-03,
ARHE M-007794-01, ITGA5 M-00803-01,
RND1 M-008929-00, ITGA6 M-007214-00,
ARHN M-009727-00, ITGB1 M-004506-00,
RHOF M-008316-00, ITGB3, M-004124-02,
RHOG M-008995-00, ITGB4 M-008011 -01,
RHOH M-008804-00, CIT M-004613-01,
RHOJ M-010367-00, AKT1 M-003000-02,
RHOQ M-009943-00, AKT2 M-003001 -01,
RHOU M-009882-00, AKT3.M-003002-02.
RHOV M-006374-00, PDK1 D-003017-05
RHOBTB1 M-009389-00,
RHOBTB2 M-009252-00,
For ROCK1, ROCK2, M RCKa MRCK(3 specific sequences were used as previously 
published170 114. A375 cells transfected with the siRNA oligos as detailed above. 36 hours 
after transfection, the cells were trypsinised and plated onto collagen/matrigel gels in glass- 
bottomed 8-well chambers (Lab-Tek) in a total volume o f 250 pi (see above for details o f gel 
mix). Cells were allowed to adhere for 24 hours and then were fixed with 4 % PFA for 10
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minutes. Cells were then permiabilised with 0.25 % TRITON X I00 in PBS for 10 minutes 
before blocking in 3 % BSA in PBS for 1 hour. Cells were then stained with TRITC 
phalloidin and propidium iodide, (see immune fluorescence section for more details). Each 
well was then imaged using confocal microscopy. 7 z-sections taken at 2-micron intervals 
were captured for each field, and subsequendy these images were projected onto a single 
plain to allow a more 3D representadon o f each field to be compared. These pictures were 
taken by both Erik Sahai and myself.
2.2.8 Screen of small molecule inhibitors in A375 cells
In a parallel analysis to the siRNA screening, A375 cells were also treated with a range o f 
small molecule inhibitors to see what affect they had on cell morphology. A375 cells were 
plated onto collagen/matrigel gels in glass-bottomed 8-well chambers similarly to above and 
allowed to adhere over-night. The cells were then treated for 18 hours with the inhibitors 
below at the concentradons listed. Following this the cells were fixed and stained with 
TRITC phalloidin and propidium iodide as above. The inhibitors and their targets are listed 
below:
DMSO 0.05%,
Blebbistatin 5 pM (non-muscle myosin),
TAT-C3 500 nM 55 (Rho),
Y2763210 pM (ROCK),
HA1077 10 pM (ROCK,PKA),
HI 152 5 pM (ROCK),
U0126 10 pM (M EK1/2),
SB203580 10 pM (p38 MAPK’s),
SP600125 10 pM (JNK’s),
2.2.9 Generation of stably transfected cell lines
A375 cells stably expressing GFP-MLC were generated by transiendy transfecting cells with 
eGFP-MLC. Cells were then cultured in selection media, DMEM + 10 % FCS + 1 m g/m l 
G418 for 2 weeks. Subsequent sorting o f the cells for GFP expression by FACS then 
ensured high expression.
A375 cells stably depleted o f PDK1 were generated by infecting the cells with retrovirus and 
subsequent selection o f infected cells with puromycin (2.5 mg/ml). Retrovirus was made by
AG1478 10 pM (EGFR’s),
SB431542 10 pM (TGFbetaRI, Alk4,5,7), 
LY294002 20 pM (PI-3K’s),
BIM 0.5 pM (PKC’s),
ML-7 25 pM (MLCK),
PP2 10 pM (Src family kinases),
Go6983 10 pM (PKC’s).
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transfecting the amphotropic cell line phoenix-AMPHO with effectene with the DNA 
construct pSuperRetro manipulated include shRNA sequences targeted against PDK1 (see 
below for details). The media from the phoenix-AMPHO cells was removed and mixed with 
polybrene (SIGMA) (0.4 m g/m l final concentration), and incubated for 15 minutes, before it 
was added to A375 cells, which had been plated in 6-well cell culture plates. 48 hours after 
infection the A375 cells were washed with fresh media and trypsinised before plating them at 
low density in 15 cm cell culture dishes. They were then selected in media containing 2.5 
m g/m l puromycin (SIGMA). Individual clones were selected and tested for their expression 
o f PDK1 by western blotting.
B16 F2 cells were infected with retrovirus to stably express either mRFP CAAX, or GFP 
CAAX. As above, phoenix-AMPHO cells were transfected with Effectene with the pBABE 
puro vector modified to include sequences encoding mRFP CAAX, or GFP CAAX (see 
below for details). As above the media containing the virus was used to infect B16 F2 cells 
plated in 6-well cell culture plates. The B16F2 cells stably expressing the constructs were 
selected with puromycin. The B16F2 GFP CAAX and B16F2 mRFP CAAX were cultured as 
polyclonal cell lines.
2.2.10 FACS analysis and cell sorting
Fluorescent stably labelled cells lines were sorted by flow cytometry to ensure a high 
proportion o f brightly labelled cells were used for injections for the generation o f xenograft 
tumours. To prepare cells for FACS analysis, cells were trypsinised, then centrifuged at 1200 
rpm for 5 min. The cell pellet was then washed with sterile PBS and centrifuged again at 
1200 rpm. Then the cell pellet was resuspended in PBS and filtered through a 70 micron 
sterile cell filter (BD Falcon). The filtered cells were then transferred to a polypropylene 
FACS tube (BD Falcon). Sorted cells were collected in the same type o f tube containing 
media + 10 % FCS. After sorting cells were re-plated and cultured as normal.
Tumour cells isolated from B16F2 GFP-CAAX xenograft tumours were also analysed by 
FACS. Mice were culled when tumours reached 1 cm in diameter. The tumours were 
dissected and cut into small pieces. The tumour pieces were incubated in collagenase/dispase 
(Roche) in PBS (1 mg/ml) for 2 hours at 37 °C, at which point the majority o f cells had 
dissociated and were in solution. The cell suspension was filtered 2-3 times through 70 
micron filters. The cells were then centrifuged at 1200 rpm for 5 min and the cell pellet was
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resuspended in PBS. The tumours cells were identified by their emission in the range o f 500- 
530 nm (GFP). The tumour cells were then sorted into high and low melanin expression by 
their emission in the violet range. As a control a B16F2 tumour that did not express GFP 
was analysed along side. The two populations o f B16F2 cells expressing either high or low 
melanin levels were then collected and RNA was extracted for analysis by microarray.
2.2.11 Extraction of RNA from FACS sorted B16F2 tumour cells
The cell populations expressing either high or low levels o f melanin separated by FACS 
sorting were centrifuged at 1200 rpm for 10 minutes. Typically around 100,000 cells could be 
collected in each gate from 3 dissected tumours. RNA was then extracted using the RNeasy 
kit (Qiagen). Briefly, the pelleted cells were resuspended in 350 |il RLT buffer and disrupted 
by passing the lysate through a 20-guage needle 20 times. 350 (il 70 % E tO H  was added and 
the sample was loaded onto a spin column and centrifuged for 15 s at 10,000 rpm. DN A 
digestion was carried out on the column and then the column was washed with RW1 buffer. 
500 pi RPE buffer was then washed through the column and when the column was 
completely dry, the RNA was eluted in 20 pi RNAase free water.
The quality o f the RNA samples was checked by running 1 pi o f each on a Aglient 
Bioanalyser using an RNA pico chip. Profiles obtained from the chip are shown in chapter 9. 
Microarray analysis was carried out in collaboration with the Paterson institute. Affymetrix 
chips (MOE430 2.0) were used which included probes o f the whole mouse genome.
2.3 Nucleic acid manipulations
2.3.1 Preparation of DNA
E.coli transformed with the DNA construct o f interest were grown in 100 ml LB broth over­
night with the appropriate antibiotic included (ampicillin 50 pg/m l, kanamycin 50 pg/ml). 
DNA was then extracted from the E.coli using the Qiagen midi kit according to the 
manufacturers instructions. Briefly: Spin down culture at 4,000 rpm, remove all broth. 
Resupsend pellet in lOmls buffer PI containing RNAase. Add 10 ml buffer P2 -  mixture 
turns viscous. Incubate at room temp for 5 min. Add 10 ml chilled P3 — mix gently white 
precipitate forms containing all cell debris. Incubate on ice for 15-20 mins. Centrifuge on full 
speed at 4C for 30 mins. Collect supernatant and spin again to remove all precipitate.
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Equilibrate column with QBT buffer, add cleared supernatant to column. Wash x2 with 30 
mis buffer QC. Elute DN A in 5mls buffer QF. Precipitate by adding 3.5mls propan-2-ol to 
5ml eluted DNA. Centrifuge mix at 10,000 rpm at 4 °C and wash pellet in 70 % EtO H . Dry 
pellet and resuspend in TE  buffer.
An in house research service laboratory carried out Minipreps, using a robot for high 
through put.
2.3.2 Nucleic acid quantification
The concentration o f nucleic acid from minipreps or maxi preps was determined using 
‘nanodrop’ equipment (Thermo Scientific) that reads the absorbance o f 1 pi sample at a 
wavelength of 230 nm.
2.3.3 PCR mutagenesis
Mutagenesis was carried out by PCR in 2 steps. Firstly studying the nucleotide sequence and 
choosing appropriate restriction sites determined a fragment o f DNA that was easily cloned 
in and out o f the vector/gene o f interest. In the case o f myc-ROCKl pCAGGS, this 
fragment was cut using Xba-I sites, one site that was within the gene another which was in 
the vector prior to the myc-tag. Mutagenesis primers were then designed to change the 
nucleotides so as to cause a different amino acid to be coded at the position o f interest.
The first step o f the PCR was to amplify the front half o f the fragment using a forward 
primer including the restriction site (e.g. Xba-I) and the reverse mutagenesis primer. The 
same was done for the 2nd half o f the fragment (using a reverse primer including the 
restriction site and the forward mutagenesis primer). These two PCR products were purified 
to be used in the second step o f the PCR. The second step used the two mutant PCR 
products and the two primers, forward and reverse, that contain the restriction sites in order 
to clone the PCR product back into the vector. The two PCR products from the first step 
will bind to each other and prime each other, as the area covered by the mutagenesis primers 
is over-lapping and complementary. The product from the 2nd round o f PCR is purified and 
then digested with the appropriate restriction enzymes e.g. Xba-I. The vector undergoes the 
same digest and is also treated with calf intestinal phophatase (CIP). Ligations were then 
carried out as below.
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The mutation in the Rho binding domain was carried out using Xho-1 sites, T518A mutation 
was made using a fragment cut with Nsi-1 and Sph-1. Mutations o f PDK1 were made using 
the whole gene cut from the vector with EcoRI.
PCR reactions 
1 pi DNA template (10 ng)
10 pi 5X HF buffer (supplied with Phusion polymerase)
1 pi forward primer (10 pmol)
1 pi reverse primer (10 pmol)
2 pi dNTPs (1 mM)
1 pi Phusion polymerase 
1 pi DMSO 
dH20  to 50 pi
Temperature cycles
95 °C 5 min
96 °C 1 min - denaturing
52 °C 1 min - annealing
72 °C 1 -3 min - extension return to denaturing x 18 - 25 cycles 
4 °C hold
2.3.4 DNA sequencing
All cloning o f DNA constructs was checked by sequencing the maxiprep before they were 
used in a cell-based assay. Big Dye terminator (BDT) kit (Applied Biosystems) was used 
according to manufacturers instructions. Each sequencing reaction contained:
8 pi BDT reaction mix 
1 pi DNA (100 ng)
1 pi primer (3.2 pmol)
10 pi dH20
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The temperature cycles were as follows:
95 °C 1 min
96 °C 10 sec - denaturing 
61 °C 5 sec - annealing
60 °C 4 min - extension return to denaturing x 25 cycles
4 °C hold
Annealing temperature was calculated for each primer. Approximately 5 °C below melting 
temperature was routinely used.
Sequencing reactions were precipitated by adding 2 pi of 125 mM EDTA, and 2 pi o f 3M 
sodium acetate (pH 5.2). after mixing, 50 pi 100 % EtO H  was added and the mixes were left 
at room temperature for 10-15 min. Mixes were then centrifuged at 2000 rpm for 30 min. the 
supernatant was removed and the pellets washed with 100 pi 70 % EtOH. Tubes were 
centrifuged again at 3000 rpm for 30 mins. The supernatant was removed and pellets allowed 
to dry at room temperature. The purified DNA was then analysed by an in house research 
services laboratory.
2.3.5 Purification of DNA fragments from agarose gels
DNA bands cut from agarose gels were purified using an Illustra™ DNA and gel band 
purification kit (GE Healthcare) according to the manufacturers instructions. Briefly, the 
agarose band containing D N A  is dissolved in 300 pi extraction buffer heated to 65 °C for 5- 
10 min. The dissolved band is then added to a column and centrifuged at 13,000 rpm for 1 
min. The column is then washed with 500 pi wash buffer. When column is dry, the D N A  is 
eluted with 20-50 pi dH 20 .
2.3.6 Ligation of DNA fragments
A small amount o f both the vector and insert fragments were run out on an agarose gel to 
determine ratios. Ligation reactions were set up using a range o f ratios (vectorrinsert) 
between 1:1 to 1:5. Each 20 pi ligation reaction contained: 2 pi T4 ligase buffer, 1 ul ATP (10 
pM stock concentration), 1 pi vector DNA, 1-3 pi insert fragment DNA, 1 pi T4 ligase,
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dH 20. The reaction was left at room temperature for at least 4 hours. The ligation reaction 
was then used to transform competent E.coli.
2.4 Plasmids and oligonucleotides
2.4.1 Mammalian expression constructs
Mvc-ROCKl constructs:
The full-length wild-type ROCK1 used throughout these experiments was previously 
described 98. The cDNA sequence matches that o f the human gene (NM_005406). ROCK1 
is cloned into the pCAGGS vector with an N-terminal myc-tag under the control o f a CMV 
promoter.
Truncated mvc-ROCKl
The truncated ROCK1 used in these experiments is previously described 98 and is termed A3 
ROCK1 in that publication. This truncation was made by Xho-1 digestion o f the full-length 
myc-ROCKl pCAGGS construct described above. This results in the removal o f the C- 
terminus o f ROCK1 leaving the sequence coding amino acids 1-727 remaining. The 
shortened plasmid was re-ligated using T4 ligase as described above.
Truncated myc-ROCKl CAAX
This construct was clone from the truncated myc-ROCKl detailed above. The CAAX 
sequences o f K-Ras and RhoA were cloned onto the C-terminus. Complimentary oligo 
primers were ordered from SIGMA to create sticky ends complimentary to Xho-I 
restrictions sites.
Forward K-Ras CAAX primer:
T  CGA AAA AAG ATG  AGC AAG GAC GGC AAG AAG AAG AAG AAG AAG AGC AAG ACA  AAG T G T  GTA  A T T  A TG  TA A  GC
Reverse K-Ras CAAX primer:
TCG  AGC T T A  CAT A A T TAC ACA C T T  T G T  C T T  G C T C T T  C T T  C T T  C T T  C T T  C T T  G CC G T C  C T T  G C T  C A T C T T  T T T
Forward RhoA CAAX primer:
T CGA ATG GCT ACG AGA GCT GCT C TG  CAA GCT AGA CGT GGG AAG AAA AAA T C T  GGG TGC C T T  G TC TTG  TAA GC
Reverse RhoA CAAX primer:
TCG AGC TT A  CAA GAC AAG GCA CCC AGA T T T  T T T  C T T  CCC ACG T C T AGC TT G  CAG AGC AGC T C T CGT AGC CAT
The oligos were annealed by mixing equal amounts o f each oligo primer (100 pg) together in 
50 |il annealing buffer (50 mM HEPES, 100 mM NaCl, pH 7.4) The annealing mixture was 
heated to 95 °C for 10 min. Then the annealing mix was transferred to a glass beaker 
containing water heated to boiling point. The mix was allowed to cool to room temperature.
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The annealed oligos were then phosphorylated by adding 1 |il polynucleotide kinase (PNK) 
to the annealing reacdon and incubadng for 30 minutes at 37 °C. The kinase was denatured 
by heating the reaction to 65 °C for 5 min. The annealed and phosphorylated oligos were 
then run out on a 2.5 % agarose gel. The band was cut out and extracted using the GFX kit 
according to the manufacturers instructions (see above) and eluted in 50 pi deionised water. 
The concentration o f D N A  was measured using the Nanodrop spectrometer. Meanwhile the 
truncated pCAGGS myc-ROCKl was digested with Xho-I to linearise it by opening the 
vector at the C-terminal end o f ROCK1, and dephosphorylated with Calf intestinal 
phosphatase (CIP). The vector was also run out on an agarose gel and the band was cut out 
and purified using the GFX kit as described above. Ligations were set up so as to ensure that 
in each reaction there were 2X as many ‘ends’ o f the annealed primers as the free ends o f the 
vector. This was calculated from the measured DNA concentrations and the known sizes o f 
each fragment. Ligations were carried out and transformed in E.coli as described below. 
Mvc-ROCKl 11009A
This mutation o f ROCK1 is in the Rho-binding domain in the C-terminus o f ROCK1 and 
has previously been reported to disrupt the binding o f ROCK1 to RhoA 98. This mutation 
was introduced by 2-step PCR that is described above. The C-terminus o f ROCK1 that is 
contained within 2 Xho-I restriction sites was the fragment used for the PCR mutagenesis. 
The mutagenic primers were as follows:
Original sequence: ACAAATTGGCAGAAATAATGAATCG
Mutagenesis primer forward: ACAAATTGGCAGAAGCAATGAATCG
Mutagenesis primer reverse: CGATTCATTGCTTCTGCCAATTTGT
Myc-ROCKl T-A mutations in the activation loop and hydrophobic motif.
All the mutations o f ROCK1 in the activation loop or the hydrophobic m otif were carried 
out by 2-step PCR utilising an 1597 bp Xba-I digested fragment which cuts within ROCK1 
and also in the pCAGGS vector prior to the N-terminal myc-tag.
T233A original sequence: CATGGTACGATGTGATACAGCGGTTGGAACACC
Mutagenesis primer forward: CATGGTACGATGTGATGCAGCGGTTGGAACACC
Mutagenesis primer reverse: GGTGTTCCAACCGCTGCATCACATCGTACCATG
D232A original sequence: CATGGTACGATGTGATACAGCGGTTGGAACACC
Mutagenesis primer forward: CATGGTACGATGTGCTACAGCGGTTGGAACACC
Mutagenesis primer reverse: GGTGTTCCAACCGCTGTAGCACATCGTACCATG
The double mutant D232A T233A was cloned using T233A myc-ROCKl as a template.
D232A T233A original sequence: CATGGTACGATGTGATGCAGCGGTTGGAACACC
Mutagenesis primer forward: CATGGTACGATGTGCTGCAGCGGTTGGAACACC
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Mutagenesis primer reverse: GGTGTTCCAACCGC rGCAGCACATCGTACCATG
T380A original sequence: GATAAAGGAGAGGAAGAAACATTC CCTATTCCTAAAGCT
Mutagenesis primer forward: GATAAAGGAGAGGAAGAAGCATTCCCTATTCCTAAAGCT
Mutagenesis primer reverse: AGCTTTAGGAATAGGGAATGCTTCTTCCTCTCCTTTATC
T398A original sequence: TCAACTACCTTTTGTAGGATTTACATATTATAGCAATCG
Mutagenesis primer forward: TCAACTACCTTTTGTAGGATTTGCATATTATAGCAATCG
Mutagenesis primer reverse: CGATTGCTATAATATGCAAATCCTACAAAAGGTAGTTGA
T380D original sequence: GATAAAGGAGAGGAAGAAACATTCCCTATTCCTAAAGCT
Mutagenesis primer forward: GATAAAGGAGAGGAAGAAGACTTCCCTATTCCTAAAGCT
Mutagenesis primer reverse: AGCTTTAGGAATAGGGAAGTCTTCTTCCTCTCCTTTATC
T398E original sequence: TCAACTACCTTTTGTAGGATTTACATATTATAGCAATCG
Mutagenesis primer forward: TCAACTACCTTTTGTAGGATTTGAATATTATAGCAATCG
Mutagenesis primer reverse: CGATTGCTATAATATTCAAATCCTACAAAAGGTAGTTGA
T398D original sequence: TCAACTACCTTTTGTAGGATTTACATATTATAGCAATCG
Mutagenesis primer forward: TCAACTACCTTTTGTAGGATTTGACTATTATAGCAATCG
Mutagenesis primer reverse: CGATTGCTATAATAGTCAAATCCTACAAAAGGTAGTTGA
Truncations o f  the T -A  mutants were cloned as above, by digest with X ho-I and re-ligation 
o f  the shorter vector.
Mvc-ROCKl T518A
This mutation o f ROCK1 was cloned by 2-step PCR using a fragment o f pCAGGS ROCK1 
(2415 bp) cut out by digestion with Nsi-I and Sph-I.
T518A original sequence: GTAGAAAATGAAGTTTCTACATTAAAGGATCAGTTGGAA
Mutagenesis primer forward: GTAGAAAATGAAGTTTCTGCATTAAAGGATCAGTTGGAA
Mutagenesis primer reverse: TTCCAACTGATCCTTTAATGCAGAAACTTCATTTTCTAC
pCAGGS Mvc-ROCK2
This construct is was a gift from M. Olson and contains the ROCK2 sequence from Bos 
Taurus.
e G F P C l/C 3
These constructs were purchased from Clontech (6084-1).
GFP RhoE
The human RhoE was cloned from pG EX  2T into eGFP C3 by digestion with EcoRI.
GFP MLC
MLC2 was cloned by PCR from the image clone into eGFP C l by Erik Sahai.
GFP ROCK1
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ROCK1 was cloned by PCR from pCAGGs myc-ROCKl into eGFP by PCR by Cristina 
Hidalgo.
Flag-PDKl siRNA resistant
The human PDK1 sequence was cloned by PCR from a vector, which was a gift David Stoke 
at UCSF into pRK5.1 Flag. pRK5.1 (Genentech, Inc.) was previously modified by Steven 
Hooper to include an N-terminal Flag tag sequence. The PCR primers were designed to 
include EcoRI sequences at both the N-terminus and the C-terminus. The PCR product and 
the vector were digested with EcoRI. The vector was also treated with CIP. Once the PDK1 
sequence had been cloned into the appropriate backbone vector, the sequence was then 
modified by mutagenesis to allow expression o f the construct in the presence o f siRNA 
targeted against PDK1 by changing ttt tcp aca am  tcc eta to tie tcc ac? aw  tct ctt.
Flag-PDKl siRNA resistant KD
Further mutation o f pRK5.1 Flag PDK1 was undertaken to introduce a mutation on the 
kinase domain to inhibit kinase activity.
K111A original sequence: CCTCCAGAGAATATGCGATTAAAATTCTGGAGAAGC
Mutagenesis primer forward: CCTCCAGAGAATATGCGATTGCAATTCTGGAGAAGC
Mutagenesis primer reverse: GCTTCTCCAGAATTGCAATCGCATATTCTCTGGAGG
Flag-PDKl siRNA resistant PH deleted
The C-terminus o f siRNA resistant PDK1 was deleted by PCR so that the last amino acid 
now encoded was S408. The PCR primers were designed to include EcoRI sequences at both 
the N-terminus and the C-terminus. The PCR product and the vector were digested with 
EcoRI. The vector was also treated with CIP.
2.4.2 Bacterial expression constructs
pG EX  KG MLC
MLC2 was cloned by PCR from the image clone into pG EX  K G  using the restriction sites
Xba-I and H indlll.
pGEX KG Rhotekin
This construct is previously described 227.
pG EX  2T RhoE
This construct was a gift from Michael Way. 
pG EX  6P3 ROCK sequences
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All o f the following constructs were cloned by PCR into pGEX 6P3 using EcoRI and N otl 
restriction sites.
pG EX  6P3 ROCK2 (358-421 a.a.) 
pGEX 6P3 ROCK1 (338-415 a.a.) 
pGEX 6P3 ROCK1 (338-378 a.a.) 
pG EX  6P3 ROCK1 (375-415 a.a.) 
similar constructs o f ROCK1 were cloned from the T-A mutants to include the mutations in 
the hydrophobic motif.
2.4.3 Viral expression constructs
pBabe puro GFP CAAX
The CAAX sequence o f K-Ras was cloned onto the C-terminus o f the GFP sequence in the 
vector eGFP Cl (Clontech) using the annealed oligos described above. (Steven Hooper 
carried out this step o f the cloning). GFP CAAX was first linearised by digestion with Nco-1 
and this digested end was blunted by incubation with the D N A  polymerase 1, Large 
(Klenow) fragment (NEB) for 30 mins at 25 °C. The blunted product was then digested with 
EcoRI to release the GFP sequence with its C-terminal CAAX sequence. The vector pBabe 
puro was digested with SnaBI and EcoRI and treated with CIP. The ligation was carried out 
in the standard way described above. 
pBabe puro mRFP CAAX
Using eGFP Cl CAAX (CAAX sequence from K-Ras as above) vector as a starting point, 
this vector had been modified to remove the GFP and replace this with the sequence 
encoding mRFP (this cloning had been carried out by Cristina Hidalgo). mRFP CAAX was 
cloned from this by PCR using primers incorporating a SnaBI restriction site at the N- 
terminal end and an EcoRI restriction site at the C-terminal end. Both the PCR product and 
pBabe puro vector were digested with SnaBI and EcoRI. The vector was also treated with 
CIP.
pSuperRetro shRNA PDK1#1
Double stranded oligos were annealed and cloned into pSuper Retro using Bglll and H indlll 








This construct that labels membranes with Cherry was a gift from Frank Gertler 
pLentilox4.4 CAG-Gap-eGFP
This construct that labels membranes with GFP was a gift from Frank Gertler.
2.5 Bacterial techniques
2.5.1 Bacterial media and plates
Competent E.coli were grown in suspension in LB broth containing the appropriate 
antibiotic to select for the construct they were expressing. Transformations were plated onto 
10 cm dishes containing Agar also containing the appropriate antibiotic, either ampicillin (50 
ug/ml) or kanamycin (50 ug/ml).
2.5.2 Bacterial strains
Competent Novablue, originally purchased from Novagen were used for transformations o f 
all plasmids for minipreps and maxipreps. BL21 (DE3)pLysS were used for the expression o f 
GST fusion proteins.
Competent E.coli were generated as follows.
Firstly the E.coli taken from glycerol stock were grown over night in 20 ml LB broth at 37 
°C with shaking. The following morning 5 ml o f the 20 ml culture was added to 500 ml o f 
fresh LB broth and the culture was grown at 37 °C with shaking until the optical density 
(measured at a wavelength o f 600 nm) o f the culture reached 0.6, indicating that the culture 
was in an exponential growth phase. At this point the flasks containing the cultures were 
chilled on ice. The bacteria were then spun down at 4,000 rpm at 4 °C for 20 minutes. The 
supernatant was removed and the pelleted bacteria resuspended in 3 ml sterile 
Transformation buffer 1 (TFB1). Make up to 100 ml with TFB1. Pellet bacterial by
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centrifuging at 4,000 rpm at 4 °C for 15 minutes. Remove supernatant and resuspend pellet 
in 20 ml sterile chilled Transformation Buffer 2 (TFB2). Keep bacterial suspension on ice for 
10-15 minutes, before aliquoting the bacteria into 1.5 ml eppendorf tubes and snap freezing 
the in dry ice.
Transformation Buffer 1 (TFB1)
Potassium Acetate, CH3COOK 30 mM
Manganese Chloride, MnC12 50 mM
Potassium Chloride, KC1 100 mM
Calcium Chloride, CaC12 10 mM
Glycerol 15 %
Transformation Buffer 2 fTFB2)
MOPS 10 mM
Calcium chloride, CaC12 76 mM
Potassium Chloride, KC1 10 mM
Glycerol 15 %
Adjust to pH 7 with HC1
2.5.3 Transformation of E. coli
Competant Nova blue or BL21(DE3)pLysS were thawed on ice for 15 minutes. 100 ul o f 
bacterial suspension was mixed with 10 ng o f plasmid DN A or ligated D N A  fragments and 
incubated on ice for a further 15 minutes. The bacteria and DN A were then heated to 42 °C 
in a water bath for precisely 1 min. Then returned to ice for 2 minutes. 1 ml LB broth was 
added to the eppendorf tube and the bacteria were incubated for 45 min at 37 °C with 
shaking. The bacteria were then pelleted by centrifugation at 4,000 rpm for 5 minutes and 
resuspended in 200 ul LB. The 200 ul o f bacteria was then added to an agar plate containing 
the appropriate antibiotic resistance and spread over the surface. The plate was incubated 
over night at 37 °C and colony formation was then observed.
2.5.4 Production of GST fusion proteins
BL21(DE3)pLysS E.coli were transformed with pGEX vectors containing the cDNA 
sequences for the protein o f interest. One o f the resulting colonies was then added to 20 ml 
LB broth containing both ampicillin (50 mg/ml) and chloramphenicol (34 mg/ml), and 
grown over night. The following morning 5 ml o f this culture was added to 500 ml fresh LB
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broth containing ampicillin (50 m g/ml) and chloramphenicol (34 m g/m l), and grown until 
the O D  600 o f the culture reached 0.6. At this point IPTG  was added to a final 
concentration o f 0.3 mM and the culture was incubated for a further 4 hours at 37 °C. The 
bacteria were then pelleted by centrifugation at 4000 rpm for 20 minutes at 4 °C. The 
bacterial pellet was resuspended in 30 ml TBS containing 1 mM DTT, 5 mM MgCl2, and 
protease inhibitors, then frozen at -80 °C. Bacteria were lysed by thawing in cold water 
followed by sonication on ice. Bacterial lysates were then further centrifuged to remove 
insoluble cellular debris. The cleared bacterial lysate was then aliquoted and stored at -80 °C. 
When the protein was required for an assay, one aliquot was defrosted on ice and glutathione 
agarose beads were added. Binding was carried out at 4 °C for 1 hour rotating the tube 
constandy. After binding the beads were washed 3 times with TBS containing 1 mM DTT, 5 
mM MgC12 and protease inhibitors. A final wash was carried out in whichever buffer was 
being used for the subsequent experiment.
2.5.5 Cleavage and purification of recombinant MLC protein from 
bacterial lysates
GST-MLC was synthesised in E.coli transformed with the plasmid pG E X  K G  MLC. Protein 
expression was induced as above. The bacterial lysate containing GST-MLC was first 
incubated with glutathione agarose beads for 2 hours. The supernatant was removed and the 
beads washed 3 times with TBS containing 1 mM DTT, 5 mM MgCl2 and protease 
inhibitors. The beads were then resuspended in 5 ml TBS + 1 mM D T T  + 1 mM MgCl2 + 1 
mM CaCl2 + 30 units thrombin over-night at 4 °C to cleave the MLC from the GST. The 
supernatant was removed and incubated with p-aminobenzamidine beads for one hour. The 
supernatant containing MLC was then aliquoted and snap frozen.
2.6 Protein manipulations
2.6.1 Preparation of cell lysates for biochemical assays or western 
blotting
Plates containing cells for lysis were washed with cold PBS. Lysis buffer (see 2.1.2) was 
added to the plate and cells were scraped and collected in a 1.5 ml eppendorf tube. For 10 
cm dishes 300 pi o f lysis buffer was used. Lysates were incubated on ice for 10 minutes then
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centrifuged at 2000 rpm for 5 minutes to remove nuclear debris. The supernatant was then 
used for the biochemical assay. To make lysates for western blotting directly, 2X SDS sample 
buffer was added to the cell lysate and the sample was boiled at 95 °C for 5 -10  min.
Tum our samples were prepared for western blotting by taking frozen tum our tissue and 
adding lysis buffer. The tissue was dissociated by maceration. The concentration o f the 
resulting lysates was tested by Bradford assay in order to load equal amounts on the SDS- 
page gels.
2.6.2 Immune precipitation and kinase assays
Myc-tagged ROCK1 constructs were immune precipitated from A375 cells plated in 10 cm 
cell culture dishes at 80 % confluence 48 hours after they had been transfected using 
effectene (see 2.2.4). Cell lysates were prepared as above (2.6.1). To each cell lysate (300 pi) 
20 pi protein G  agarose beads and 10 pg 9E10 monoclonal antibody were added. The lysate, 
beads and antibody were incubated for 2 hours at 4 °C whilst being rotated constantly. After 
this time the beads were washed 3 times with 500 pi lysis buffer.
For kinase assays an extra wash in kinase assay buffer was included at the end. The beads 
bound to myc-ROCKl were then used to phosphorylate recombinant MLC. 50 pi kinase 
assay buffer containing 1 pg MLC was added to each tube o f beads and the reaction was 
incubated at 30 °C for 30 minutes. Reactions were stopped by adding 50 pi o f 2X SDS 
sample buffer to each reaction and boiling at 95 °C for 5 minutes. The kinase assay were 
then analysed by SDS-PAGE followed by western blotting for p-MLC (Cell signalling 3671). 
Total kinase was measured by blotting with 9E10.
2.6.3 Radioactive kinase assays
Recombinant kinases ROCK1 (Upstate, 14-601) and PDK1 (Calbiochem, 521270) were 
used to phosphorylate recombinant substrates Aktl (gift from Peter Parker), GST-RhoE (see 
2.5.4), and MLC2 (see 2.5.5). Each reaction was carried out in 50 pi kinase assay buffer 
containing 0.1 pi 32P ATP in addition to the normal concentration o f ‘cold’ ATP. Reactions 
were incubated for 30 mins at 30 °C, 2X SDS sample buffer was added to stop the reactions. 
Samples were analysed by SDS-PAGE and the gel was stained as detailed below. The gel was
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then dried by placing it onto a sheet o f 3MM paper in a gel dryer at 70 °C for 6 hours. The 
dried gel was then placed in a cassette and was used to expose X-ray film.
2.6.4 Protein quantification using Bradford reagent
Bradford reagent was obtained from BioRad, and was diluted 1:5 with H 20  diluted protein 
samples. A standard curve was made using bovine serum albumin (BSA) with concentrations 
o f 0, 50, 100, 200, 500, 1000 pg/m l. Cell lysates to be tested were diluted so as to fall within 
the range o f  the standard curve. Assays were carried out in 96-well plates, each well 
contained 200 pi o f BSA solution or diluted cell lysate + 50 pi o f Bradford reagent. The 
absorbance o f each well was read on a spectrophotom eter at a wavelength o f 595 nm. 
Concentrations o f samples were calculated relative to the standard curve. The volumes o f the 
cell lysates were then adjusted so as to load equal quantities o f each onto the SDS-PAGE gel 
for analysis by western blotting.
2.6.5 SDS-PAGE
Polyacrylamide gels were poured into mini-gel systems manufactured by BioRad. Generally
1.5 mm gels with 10 wells loaded with up to 50 pi o f sample were used. Gels were made to 
the following protocol: 0.1 % SDS, 375 mM TRIS HC1 pH 8.8, 8-15 % poly acrylamide, 0.1 
% APS, 0.001 % TEM ED . Once poured the gel was over-laid with dH 20 to ensure it was flat 
and allowed to set for 10 min. When set, the dH 20 was removed and stacking gel was 
overlaid: 0.1 % SDS, 125 mM TRIS HC1 pH  6.8, 5 % acrylamide, 0.1 % APS, 0.001 % 
TEM ED . The comb was inserted. W hen the stacking gel was set the gel was set up in a 
running tank (BioRad). The comb was removed and the wells washed with SDS running 
buffer. The cassette was then filled with SDS running buffer and enough buffer was added to 
the outer com partm ent to cover the bottom  o f the gels. Up to 50 pi o f  sample was loaded 
into each well. O ne well was used to run a prestained ladder (Benchmark, Invitrogen). The 
gel was run at 70 mA for 2 hours.
2.6.6 Staining of proteins in SDS PAGE gels
After running, the gel was removed from the glass plates and washed in dH 20 .  The gel was 
then stained using, 45 % Methanol, 10 % acetic acid containing 0.25 g/1 Brilliant Blue R 
(SIGMA) for 30 minutes at room temperature. The gel was then washed in dH 20 ,  and then
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destained over-night using, 33 % Methanol, 10 % acedc acid. The bands o f  separated 
proteins were then visible. The gel could then be photographed or dried.
2.6.7 Western Blotting procedure
After running, the proteins in the gel were transferred to Polyvinylidene Fluoride membrane 
(PVDF). The gel was placed on top o f 2 sheets o f 3MM chromatography paper (Whatmann), 
the PVDF membrane, which had been pre-wet in methanol, was then laid on top if the gel, 
followed by 2 more sheets o f 3MM paper. This ‘sandwich’ was then loaded into the transfer 
cassette (BioRad). The tank was filled with transfer buffer and the gel was transferred for 3 
hours at 150 mA. After transfer the membrane was washed with dH 20  then blocked by 
incubated the membrane with blocking buffer (TBS + 5 % milk (Marvel), + 2 % BSA) for 2 
hours. Primary antibodies were generally incubated with the membrane overnight at 4 °C at a 
dilution o f 1:1000 in TBS + 1 % milk). Primary antibodies were washed o ff with 3X 5 min 
washes in TBS + 1 % milk + 0.01 % TW EEN-20. HRP-labelled secondary antibodies 
(PIERCE) were used at a dilution o f 1:50,000 in TBS + 1 % milk and incubated with the 
membrane for 1 hour. Secondary antibodies were washed o ff the membrane in 3X 5 min 
washes with TBS. The blot was then developed by rinsing the blot for 1 min in 2 ml o f ‘west 
dura’ ECL (PIERCE). The blot was then used to expose chemoluminescent film (GE 
Healthcare).
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2.6.8 Antibodies for western blotting
Target Antibodv Source Dilution
Myc-tag 9E10 in house monoclonal 1:1000
FLAG-tag anti-FLAG M2 SIGMA (FI 804) 1:3000
PDK1 anti-PDK l Cell Signalling (3062) 1:1000
ROCK1 anti-ROCKl Chemicon (AB3885) 1:1000
MLC2 Myosin Light Chain 2 Cell Signalling (3672) 1:1000
pMLC2 Phospho-pMLC (serl9) Cell Signalling (3671) 1:1000
RhoE monoclonal anti-RhoE SIGMA (R6153) 1:1000
Tubulin anti-P-Tubulin 1 SIGMA (T7816) 1: 10000
GFP anti-GFP Roche (11814460001) 1:1000
pSMAD2 phospho-Smad2 Cell signalling (3101) 1:1000
RhoA RhoA (26C4) Santa Cruz (sc-418) 1:500
2.6.9 Preparation of protein samples for mass spectrometry analysis
For mass spectrometry analysis, pre-cast gels (Nupage Bis-Tris 4-12 %, Invitrogen) were 
used to run the samples. Each lane contained 2 pg recombinant ROCK1 (Upstate, 14-601) 
which had been incubated in kinase assay buffer + / -  Y27632 for 30 minutes at 30 °C then 
mixed with SDS sample buffer as described above. The precast gels were run in tanks also 
from Invitrogen using Nupage MOPS SDS running buffer (Invitrogen). After running gels 
were taken out o f the casing and stained as detailed above. The mass spectrometry laboratory 
then cut the protein out o f the gel and digested it with trypsin ready for analysis.
2.6.10 RhoGTP pull down assays
A375 cells transfected with either control siRNA oligos or oligos targeted against PDK-1, 
were serum starved for 6 hours then stimulated with 20% FCS for 5 minutes before cells 
were lysed in lysis buffer. The Rho-binding domain o f Rhotekin was tagged with GST and 
expressed in E.coli Expression was induced as above. The bacterial lysate containing GST- 
RBD Rhoteckin was incubated with Glutathione agarose beads for 2 hours at 4 C. Beads 
were extensively washed with cell lysis buffer before incubation with cell lysates from A375 
serum stimulated cells for 2 hours at 4 °C. Beads were then extensively washed with lysis 
buffer and bound proteins were eluted with 2X SDS sample buffer. RhoG TP levels were 
determined by western blotting these samples for RhoA, and comparing the results with the 
levels o f RhoA in the total cell lysate.
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2 .6.11 GST pull down assays
Bacterial lysates containing GST RhoE were incubated with glutathione agarose beads at 4 
°C for 2 hours. Beads were washed extensively with lysis buffer, before incubation with 
A375 cell lysates expressing myc-ROCKl or myc-ROCKl and siRNA resistant PDK1 for 3 
hours 4 C (cell lysates were also modified by the addition o f recombinant PDK1 
(Calbiochem, 521270). Beads were washed extensively with lysis buffer. Bound protein was 
eluted using 2X SDS sample buffer, then binding was analysed by western blotting using 
9E10.
For analysis o f  the binding between ROCK1 fragments and PDK1, bacterial lysates 
containing GST ROCK fragments or GST alone as a control, were incubated with 
glutathione agarose beads as above followed by extensive washing. Beads were incubated 
with 100 ng purified PDK-1 (521270 Calbiochem) diluted in kinase assay buffer for 2 hours 
at 4 °C. beads were then washed 3X with kinase assay buffer. Proteins were eluted with 2X 
SDS sample buffer, and binding was determined by western blot using PDK1 antibody 
(3062, Cell Signalling Technology)
2.6.12 Competition binding assays
Bacterial lysates containing GST-RhoE were incubated with glutathione agarose beads as 
above and washed 3X in kinase assay buffer. The beads were then incubated with 
recombinant ROCK1 (Upstate, 14-601) either alone or in combination with recombinant 
PDK1 (Calbiochem, 521270), in kinase assay buffer for 3 hours at 4 °C. the solutions 
containing recom binant ROCK1 and PDK1 were incubated for 20 minutes on ice before 
adding the mixture to the beads bound to GST-RhoE. After the binding, the beads were 
washed 3 times with kinase assay buffer and 2X SDS sample buffer was added. The samples 
were boiled for 5 minutes and then analysed by western blotting.
2.6.13 Co-immunoprecipitation of ROCK1 and RhoE
A375 cells expressing either the empty pSuper Retro vector or stably depleted o f PDK1 were 
plated in 15 cm dishes. When 80 % confluent, Cells were lysed in 20mM H EPES pH7.5, 
2mM ED TA, 150mM NaCl, ImM  D T T + protease inhibitors and passed through a 19G
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needle repeatedly before centrifugation at 1000G for 5 minutes at 4°C. NP40 was added to 
0.05% before addition o f 2ug ROCK1 antibody (Santa Cruz sc-6056) and protein G  agarose 
beads. This mixture was then rotated for 3 hours at 4°C before 3 washes with the same lysis 
buffer above + 0.05%NP40. 2X SDS sample buffer was added to the beads and the samples 
were analysed by western blotting for endogenous ROCK1, PDK1 and RhoE (see antibodies 
for western blotting for details).
2.7 In vivo techniques
All the following procedures were carried out under the project licence 70/6164 held by D r 
Erik Sahai.
2.7.1 Generation of xenograft tumours
In order to grow xenograft tumours for in vivo imaging, A375 cells or B16F2 cells were 
engineered in vitro to stably express fluorescent markers GFP-MLC or GFP-CAAX. 1 X 106 
fluorescent cancer cells were then injected subcutaneously into the flank o f nude mice, in 100 
pi PBS. A375 tumours grew to 5 mm in diameter in approximately 4 weeks, B16F2 tumours 
grew to 5 mm in diameter in approximately 10 days.
2.7.2 Labelling cell lines with cell tracker dyes
A375 cells expressing GFP-MLC and either the empty pSuper Retro vector or stably 
depleted o f PDK1 were used for lung colonisation assays (see below). To distinguish the two 
different cell populations either the controls or the PDK1 depleted cells were labelled with 
the red cell tracker dye SNARF (Molecular Probes). The cells to be labelled were washed 
with PBS and then incubated with PBS containing SNARF (1:500 dilution) for 15 minutes at 
37 °C. After this time the cells were washed with PBS, and trypsinised. The successful 
labelling o f the cells was determined by checking a small amount on a glass cover slip under 
the fluorescence microscope.
2.7.3 Lung colonisation assays
These lung colonisation experiments were carried out in 3 different ways.
1) 500,000 A375 cells expressing the empty pSuper Retro construct or stably
depleted o f  PDK1 as well as expressing GFP-MLC were injected into the tail
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vein o f nude mice. After 4 weeks, the mice were culled and the lungs were 
dissected. The lungs were imaged using confocal microscopy. The total numbers 
o f metastases were counted for each cell line injected. 3 mice were used for each 
cell line.
2) In this internally controlled experiment, control A375 GFP-M LC cells were 
labelled with cell tracker dye SNARF (see above) and mixed in equal numbers 
with PDK1 depleted A375 GFP-MLC cells. A total o f 500,000 cells were injected 
into the tail vein o f nude mice. As controls, labelled control cells were mixed with 
unlabelled control cells and also the staining o f the cells was carried out in the 
reverse to ensure there was no effect o f the cell tracker dye on the ability o f  the 
cells to colonise the lungs. 24 hours after injection the mice were culled and the 
lungs were dissected. In each field o f view the ratio o f the number o f  control 
cells to PDK1 depleted cells was calculated. 2 different PDK1 depleted cell lines 
were used and 2 mice were used for each combination o f cell lines injected.
3) MTLn3E cells expressing with CAG-gap Cherry or CAG-gap eG FP were 
transfected in vitro with either control siRNA or siRNA oligos against PDK1 
(oligo 2). Differently coloured control and PDK1 depleted cells were then mixed 
in equal numbers and injected into the tail vein o f nude mice (total 250,000 cells). 
Mice were culled at either 2 hours or 24 hours post injection and the lungs were 
dissected and imaged as above. In each field o f cells the numbers o f control cells 
and PDK1 depleted cells were compared.
2.8 Microscopy techniques
2.8.1 Immunofluorescence
Cells were fixed using 4% paraformaldehyde, and permiabilised using 0.25 % Triton X I00. 
Samples were blocked for 1 hour with 3% BSA, 0.1% Triton, in PBS before incubation with 
primary antibody in PBS + 1 % BSA + 0.1 % TW EEN . Primary antibody was incubated on 
samples over-night at 4 °C then washed off in 3 washes o f 10 minutes with PBS containing 
0.1 % Tween-20 and 1 % BSA. Fluorescent Alexa secondary antibodies (Molecular probes) 
were used diluted 1:200 in PBS + 3 % BSA + 0.1 %  Tween-20 for 2 hours, then washed off
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using 3 washes o f  PBS containing 0.1 % TW EEN-20. Immune fluorescence o f cells on glass 
cover-slips and on matrigel/collagen gels was carried out in the same way.
Myc- ROCK1 and myc-ROCK2 were visualised using monoclonal antibodies 9E10 (mouse) 
or Jak6 (rat). Endogenous ROCK1 was stained using Rockl(C-19): sc-6055 (Santa Cruz 
Biotechnology) (rabbit). Phospho-MLC was stained using phospho-myosin light chain 2 
(T hrl8 /Serl9) antibody (Cell Signalling Technology 3674)(rabbit). FLAG-PDK1 was stained 
for using monoclonal ANTI-FLAG M2 antibody (SIGMA F-1804)(mouse). F-actin was 
visualised using FITC or TRITC labelled phalloidin (SIGMA). Images were taken using 
confocal microscopy.
2.8.2 Phase contrast time lapse microscopy
Cells were plated on top o f a deformable matrigel/collagen gels on glass bottom ed cell 
culture plates (MatTek) 24 hours before imaging. Cells were incubated at 37°C with 10% 
C 0 2in DM EM  media contain 10% FCS during imaging. Imaging was carried out on a Nikon 
microscope with a motorised stage for multiple positions (controlled by Metamorph 
software) using a 20X phase 1 objective.
2.8.3 Confocal time-lapse microscopy
A375 cells transiently transfected with RO CK -G FP or GFP-CAAX were plated on top o f 
deformable collagen gels as detailed above, and imaged using a Zeiss LSM510 confocal 
microscope. In assays in which inhibitors were added, for example cytochalasinD or 
blebbistatin, these drugs were mixed at 3X concentration in media and added by syringe with 
care during the imaging process. The final concentration o f each o f these inhibitors was 5 
pM. Images were taken at 2 sec intervals.
2.8.4 Multiphoton in vivo imaging of primary tumours
The xenograft tumours (described above) were imaged when they reached between 4-6 mm 
in diameter. The mice were anesthetised using isofluorane carried on oxygen, and anaesthetic 
was maintained during imaging using a mouthpiece, which the head o f the mouse was laid 
inside. O ur licence permits imaging in this way for a period o f 3 hours, during this time, 4-5 
time-lapse movies were captured, each covering a depth o f approximately 50 microns with 7
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z-sections. Images were captured every 90 s for A375 tumours and every 30 s for B16F2 
tumours, as B16F2 cells moved at faster speeds. The tumour was pardally separated from the 
flank in order to lay the tumour on a cover slip and image it from underneath. The blood 
vessels remained intact and blood flow could be monitored by intravenous injecdon o f 
fluorescendy labelled dextran. After imaging the mouse was culled by dislocation o f the neck 
(one o f the allowed schedule 1 methods). The tumour material was dissected and snap frozen 
to be used to make tum our cell lysates or for sectioning.
The in vivo imaging was carried out using a femto-second-pulsed Ti-Sapphire laser from 
Chameleon using wavelengths between 820 and 900 nm. Collagen fibres were imaged by 
second harmonic signals that are collected at half the multi-photon excitation wavelength. 
Other matrix components and some host cells could be imaged by reflectance using a single 
photon laser. A375 GFP-M LC tumours and A375 GFP-MLC PDK1-depleted tumours were 
imaged by Erik Sahai. A375 GFP-MLC tumours treated either with or without ROCK 
inhibitor Y27632 were imaged partly by Erik Sahai and partly by myself. B16F2 tumours 
were imaged by myself.
A375 GFP-MLC tumours treated with Y27632 were analysed by in vivo multi-photon 
imaging 48 hours after the initial dose o f the inhibitor. Inhibitor was administered in 3 intra- 
peritoneal doses o f  40 m g/kg  in 100 pi sterile PBS (48, 24 and 1 hour before imaging).
2.8.5 Spectral analysis of melanin pigment in B16 cells
The emission on the pigment containing vesicles was analysed using a META detector 
attached to a Zeiss510 confocal microscope following excitation using 800 nm wavelengths. 
Speckles with different spectra are coloured either red, green or blue based on the pattern o f 
their emission. The excitation spectra were obtained by scanning through wavelengths 
between 690 and 1050 nm. The emission was collected in each o f the different emission 
channels and this was not found to alter the excitation max.
Lifetime imaging was also carried out using a FLIM detector on the same microscope. 
Emitted photons were collected for 30 seconds following continuous excitation with a 
femto-second-pulsed Ti-Sapphire laser. The photon count is shown as a scatter graph against 




2.9.1 Quantification of cell morphology
Phase contrast images o f  A375 or MTLn3E cells plated on collagen/matrigel gels were used 
for this analysis. Using Volocity software, the cell shape was drawn around by hand and the 
measurements o f perimeter and area were calculated. Over 100 cells were analysed for each 
different cell population. These measurements were then used to calculated the ratio o f 
(perimeter)2/47t(area). Box and whisker plots showing the range o f these values were drawn 
using Prism (Graphpad). The box and whisker plots show the following values: min, 25th 
percentile, median, 75th percentile, max.
The same analysis was carried out on still images taken from the in vivo multiphoton movies. 
A375 cells within the tumour were drawn around manually as above when the cell shape 
could be distinguished clearly. Over 400 cells from either control or PDK1 depleted tumours 
from 4 different mice were analysed. Data was presented in box plots as above.
2.9.2 Cell tracking
Tracking o f A375 or M TLn3E cells plated on collagen/matrigel cells was carried out using 
data from phase contrast time-lapse movies captured using MetaMorph software. Images 
were taken o f each position chosen every 2-5 minutes. These time-lapse stacks then 
underwent automatic cell tracking, again using MetaMorph software. Briefly, in the first 
frame the cells are selected with the mouse and an area around the cell is identified. Through 
each frame the software determines the new position o f each cell. I f  the software fails to 
identify the cell in the next frame, for example when a cell undergoes a division, or if the cell 
moves out o f the frame, the user is able to pause the analysis and instruct the program as to 
the accurate position o f the cell, or to terminate that track. The tracking data is stored as a 
log file. The calculation o f  cell speed was carried out using Mathmatica (Wolfram research). 
The data from the tracking, stored in log files was inputted to a template designed by Daniel 
Zicha. The cell speed is presented by Mathematica as box and whisker plots. The box and 
whisker plots show the following values: min, 25th percentile, median, 75th percentile, max.
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2.9.3 Co-localisation
A375 cells expressing both myc-ROCKl and FLAG-PDK1 and stained with both JAK6 and 
anti-FLAG, and followed by Alexa fluorescent secondary antibodies, were imaged by 
confocal microscopy. The images were then analysed using LSM image examiner (Zeiss). 
Using the threshold tool, pixels with high signal (above 100 units (max 250)) o f both myc 
and FLAG staining were selected and highlighted. The images showing the highlighted pixels 
revealed the degree o f  co-localisation, and where in the cells this colocalisation occurred.
B16F2 cells plated on glass cover slips were imaged using a combination o f fluorescence, 
reflectance and transmitted light using a confocal microscope. The transmitted light images 
showed the melanin containing vesicles as black dots. This greyscale transmitted light images 
were inverted and pseudocoloured. This new image was then overlaid with the reflectance 
image and the degree o f colocalisation was determined in the same manner as above.
2.9.4 Kymographs
Confocal time-lapse movies o f  A375 cells expressing GFP-ROCK1 were analysed using LSM 
image examiner. A narrow rectangle, which traversed the cell cortex was drawn using the 
overlay tool. This region was extracted using the overlay tool and individual images o f  the 
selected section were saved, each one 2 seconds later in real time than the previous one. 
These narrow images were then lined up in sequence to show the change in GFP-ROCK 
localisation over time in that region.
2.9.5 Quantification of spread area
Confocal images o f  A375 cells expressing myc-ROCKl or myc-ROCK mutant constructs 
and stained with 9E10 and alexa fluorescent secondary antibodies, were analysed using 
ImageJ. The area covered by the transfected cells was calculated by drawing round the cell 
shape and then using the measure tool. This area was then compared to the area o f  the 
untransfected cells in the same field. The ratio o f the area compared to the untransfected 
cells was used to compare the contractile ability o f  the different ROCK1 constructs 
expressed. Between 20 and 30 cells were quantified from 2 independent experiments. The 
data is presented as a histogram plotting the mean and the standard deviation.
93
2.9.6 Quantification of relative melanin expression
In vivo movies o f B16F2 cells stably expressing GFP-CAAX were analysed using LSM image 
examiner. Using the region o f  interest tool, firstly the background level o f signal intensity o f 
the melanin expression was quantified in a region containing no tumour cells. Next the same 
tool was used to quantify the mean melanin expression in the area containing tumour cells. 
The background measurement was subtracted from this value. Motile cells within the movie 
were identified and the intensity o f the melanin expression was measured by drawing around 
the cell shape in the first frame the cell was seen to be moving. The relative melanin 
expression was calculated by subtracting the background measurement and determining the 
ratio between the expression o f melanin in the cell and the average o f the tumour field. The 
same analysis was carried out for non-motile cells where the cell shape could be determined 
clearly. This analysis was carried out for over 150 motile cells and over 300 non motile cells 
from 16 movies from 5 different mice. Data is presented as a frequency distribution showing 
relative values on the Y-axis.
2.9.7 Statistical Analysis
To analyse the statistical significance o f changes in cell morphology the non-parametric 
Mann Whitney-U test was used. Phenotypic category data was analysed by chi-squared tests. 
The microarray results were analysed by the bioinformatics department by Phil East. The 
ranges o f values for each chip were normalised to each other and then points with very low 
intensity were excluded from the analysis. The results show genes that were consistently up 
or down regulated in all three o f  the replicates. Results are presented as average fold change.
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3 Chapter 3 - Analysis of potential phospho-acceptor 
sites in ROCK1
3.1 Chapter summary
ROCK activity in a cell has drastic consequences on cell morphology, cell motility and many 
other processes such as the completion o f cytokinesis and regulation o f the cell cycle l02. 
Considering the significant consequences o f aberrant ROCK activity, it is logical that ROCK 
activity would be tightly controlled. The activation o f ROCK downstream o f the Rho family 
GTPases is well confirmed, however this may not be enough to finely tune ROCK activity 98, 
104. It could be conceived that R hoG TP binding to ROCK is only an initiating step in the 
regulation o f these kinases. O ther members o f the AGC family o f kinases are regulated by 
phosphorylation. To check whether ROCK1 is also regulated in this way sequence 
alignments with other AGC family members were conducted and candidate potential 
phospho-acceptor sites were identified (T233, T380, T398). These amino acids were mutated 
to alanine residues and the resulting mutants were analysed. Changes in localisation and /o r 
kinase activity were determined. It was found that mutation o f T233 in the activation loop 
did not affect the function o f  ROCK1 and there was no evidence that phosphorylation o f 
the activation loop was required to activate ROCK1. Mutation o f T380 caused ROCK1 to 
mislocalise and was less able than wild-type ROCK1 to induce membrane blebbing, however 
the kinase activity o f T380A ROCK1 was not altered. Mutation o f  T398 caused ROCK1 to 
become mislocalised similarly to T380A ROCK1 however the phenotype was more severe 
and kinase activity was also compromised. It was further found that T380A ROCK1 bound 
better to RhoE, a negative regulator o f  ROCK1, which provides a potential mechanism as to 
why this site is able to regulate RO CK  function. Acidic substitutions o f T380 and T398 were 
also cloned to examine whether these mutations could render ROCK1 constitutively active. 
This chapter details these findings.
3.2 ROCK kinase activity does not require binding to RhoGTP
W T ROCK1 when over-expressed causes A375 cells to round up and exhibit membrane 
blebs, as a result o f  increased contractile forces. The requirement for RhoA binding for 
ROCK1 to cause this phenotype was examined, as published research to date had focused 
mainly on the interaction o f  Rho with ROCK1 as the mechanism for activation o f the kinase.
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The binding o f RhoA to ROCK was blocked in 3 different ways, and the resulting 
phenotypes o f over-expressed proteins were compared to wild type (WT) ROCK1 (Figure
3.1 A). WT ROCK1 when over-expressed causes A375 cells to round up and exhibit 
membrane blebs, as a result o f increased contractile forces. Firstly the phenotype o f the 
truncated ROCK1 (1-727 a.a.) was examined (Figure 3.1 B). This truncation removes the 
Rho-binding domain and the PH domain in the C-terminus. Over-expression o f myc- 
RO CK l (1-727 a.a.) in A375 cells caused a concentration o f thickened stress fibres in the 
cytoplasm but transfected cells did not become contracted and exhibit membrane blebs. 
Secondly a mutation was made in the Rho-binding domain o f  ROCK1 (11009A) that has 
been previously reported to inhibit the interaction o f ROCK1 and RhoA 98. Over-expression 
o f myc-ROCKl (11009A) in A375 cells resulted in cells that contained thickened stress fibres 
but remained spread, and did not exhibit membrane blebs (Figure 3.1C). Thirdly, wild-type 
ROCK1 was over-expressed in A375 cells that had been transfected with siRNA oligos 
targeted against RhoA. The efficiency o f siRNA transfection is shown by the western blot in 
Figure 3.IE. The depletion o f RhoA also resulted in cells expressing ROCK1 exhibiting 
thickened stress fibres but not membrane blebbing as seen when wild-type ROCK1 is 
expressed alone (Figure 3.ID). The combination o f these experiments suggests that the 
interaction o f ROCK1 with RhoA is critical for ROCK1 to cause cell contraction and 
membrane blebbing. It was also observed that the membrane localisation o f  wild-type 
ROCK1 was lost when binding to RhoA was inhibited (see arrow). Interestingly, although 
cell blebbing was inhibited, the over-expression o f ROCK1 still caused thickening o f stress 
fibres suggesting that RhoA binding was not absolutely required for ROCK1 kinase activity.
To confirm this, immunoprecipitaion kinase assays were performed with wild type ROCK1 
and ROCK1 (II009A). The ability o f ROCK1 to phosphorylate recombinant MLC in vitro 
did not appear to be significantly altered by this mutation (Figure 3.2). There may perhaps be 
a slight change in activity but having repeated this experiment several times, no consistent 
increased or decrease was observed. This confirmed that RhoA-binding is not required for 
ROCK1 kinase activity, but instead controls the sub-cellular localisation o f ROCK1.
3.2.1 Localisation of truncated ROCK1 to the plasma membrane is 
not sufficient for full functionality
Initial results had identified that localisation in addition to kinase activity was important for 
full function o f ROCK1. We speculated that restoring membrane localisation should restore
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full function. This was achieved by cloning the C-terminal CAAX sequence o f K-Ras or 
RhoA onto the C-terminus o f truncated ROCK1 (1-727 a.a.). This tag caused ROCK to be 
localised diffusely over the plasma membrane in contrast to myc-tagged truncated ROCK1 
that was localised diffusely in the cytoplasm (Figure 3.3). When the active truncated ROCK 
was at the plasma membrane it was able to induce some membrane blebbing. However this 
blebbing was not the same as the blebbing that is induced by full-length wild type ROCK1. 
Wild type ROCK 1 causes blebbing by causing contraction o f the whole cell. The cells over­
expressing ROCK1 become rounded, as some o f the cell adhesions holding the cell spread 
flat are overcome by excess contractile forces. The blebbing induced by membrane tagged 
truncated ROCK1 was restricted to some areas o f cell membrane and the cells generally 
remained well spread suggesting that the level o f contractile force induced in those cells was 
less than in cells expressing wild type ROCK1, or that the contractile force generated was 
less well coupled to the membrane and was not able to induce such dramatic blebbing. 
Considering that the deletion o f the C-terminus o f ROCK1 results in a more active kinase in 
vitro 98, it was surprising that localisation o f this construct to the membrane was not enough 
to induce strong cell contraction and cell rounding. This experiment was strong evidence that 
localisation to the membrane was not enough for contraction and blebbing activity o f 





Figure 3.1 ROCK kinase activity is independent of binding to 
RhoGTP. Myc-tagged ROCK 1 constructs over-expressed in A375P cells 
plated on glass coverslips. Cells were fixed and stained with 9E10 and 
TRITC phalloidin. A) Arrow shows membrane localisation of wild type 
ROCK1. B)C) ROCK1 mutants were expressed in A375 cells D) RhoA 
was depleted by siRNA transfection, siRNA oligos were transfected using 
oligofectamine 24 hours before DNA transfection, (scale bar indicates 50 
pm) E) Western blot showing knockdown of RhoA by siRNA transfection.
Figure 3.2 Mutation of the Rho-binding domain does 
not inhibit ROCK1 kinase activity. A375 cells were 
transfected with either WT myc-ROCK1 or myc-ROCK1 
I1009A. The ROCK constructs were immunoprecipitated 
using 9E10 and used to phosphorylate recombinant MLC 
in vitro. The phosphorylation was analysed by western 
blotting for pMLC (S19).
9E10 F-actin Merge
Figure 3.3 The phenotype of truncated ROCK1 when 
localised to the plasma membrane. Truncated R0CK1 
(1-727 a.a.) is unable to reach the plasma membrane 
because it is missing the Rho-binding domain. The CAAX 
sequence of KRas or RhoA was tagged to the C-terminus 
of this construct and it was expressed in A375 cells plated 
on glass cover slips. Cells were fixed and stained with 9E10 
and FITC phalloidin. Scale bar indicates 20 pm.
3.3 Analysis of potential phospho-acceptor sites in ROCK1
3.3.1 Identification of candidate sites
An investigation into other mechanisms o f ROCK1 regulation was begun. The next 
hypothesis was that following membrane localisation through the interaction with RhoA, 
ROCK1 might be further modified to enhance its kinase activity. The most common 
mechanism o f regulation o f kinase activity is through phosphorylation. Possible 
phosphorylation sites on ROCK1 were investigated to test this hypothesis.
Scan-site analysis o f ROCK1 was performed (http ://scansite.m it.edu/). Threonine residues 
in the activation loop and the hydrophobic m otif o f the kinase domain were identified as 
they were conserved in other AGC family kinases, and in some cases have been shown to be 
required for kinase activity (Figure 3.4) 123, 228. ROCK1 shows a high level o f sequence 
homology with A kt/PK B  in the activation loop and the hydrophobic domain. T233, T237, 
T380 and T398 were chosen as potential phospho-acceptor sites to investigate further by 
mutagenesis (Figure 3.4). T233 and T237 are situated in the activation loop and T380 and 
T398 are found in the hydrophobic extension o f the kinase domain. T-A mutations o f these 
4 residues were made by PCR site-directed mutagenesis. The resulting constructs were over­
expressed in A375 cells and the phenotypes o f transfected cells were compared to cells 
expressing Wild-type ROCK1 and GFP only as a control transfection. However, mutation o f 
T237 resulted in a construct that would not express, so this was not followed further.
3.3.2 Phenotypic categories used to classification of ROCK mutants
Cells expressing myc-ROCKl constructs were fixed and stained with 9E10 antibody and 
TRITC labelled phalloidin. The phenotypes o f transfected cells were categorised based on 
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Figure 3.4 Sequence analysis shows that ROCK1 
contains residues conserved in other AGC family 
members which have been shown to be required for 
kinase activity. Sequences were aligned using ClustalW 
software. Conserved residues were noted and 4 candidate 
phospho-acceptor sites were targeted for analysis by 
mutagenesis.
Actin organisation was defined as: 1. Blebbing, 2. Increased stress fibres, 3. Normal, 4. 
Reduced stress fibres, 5. Collapsed; blebbing being the strongest ROCK-driven phenotype, 
and collapsed being the result o f  reduced ROCK activity (Figure 3.5). Blebbing is the result 
o f  strong contractile forces in the acto-myosin cell cortex, which over-comes some o f the cell 
adhesions and causes cells to round up. Parts o f the cell membrane are forced out into blebs 
probably due to increased hydrostatic pressure. This phenotype requires ROCK kinase 
activity and interaction o f ROCK1 with Rho to promote membrane localisation o f ROCK1 
(see also Figure 3.1). Increased stress fibres are also due to an increase in ROCK activity 
however it seems to be independent o f a requirement for Rho binding (Figure 3.1). Actin 
cables in the cytoplasm appear thicker and are occasionally clustering in one part o f the 
cytoplasm. Normal actin is defined as a spread cell with some stress fibres as this is how 
m ost A375 cells appear when untransfected or transfected with GFP. Reduced stress fibres is 
defined as fewer actin cables in the cytoplasm compared to untransfected cells, in some cases 
no actin cables are seen except for around the cell periphery, however the spread area o f the 
cell remains similar to untransfected cells. ‘Collapsed’ cells are defined as cells that contain 
litde filamentous actin and appear elongated or stretched so that their spread area is reduced 
compared to control cells. Cells can become elongated because they are unable to co­
ordinate contraction to release the rear o f the cell as they migrate. This phenotype is caused 
by a lack o f ROCK activity and cells treated with a ROCK inhibitor Y27632 can also exhibit 
this collapsed phenotype.
The localisation o f  myc-ROCKl constructs was categorised as: 1.Membrane diffuse, 2. 
Membrane punctate, 3. mixed, 4. Cytoplasmic. Blebbing cells generally also showed 
membrane diffuse localisation o f over-expressed ROCK1, meaning that the majority o f the 
expressed protein was localised uniformly over the plasma membrane. Membrane punctate 
localisation was defined as patches o f intense ROCK1 staining which was at the plasma 
membrane. Mixed localisation was when the ROCK construct was partially at the cell 
membrane but a significant portion o f the staining was also cytoplasmic
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Figure 3.5 Examples of myc-ROCK1 over-expression in 
A375 cells. The phenotype of over-expressed myc-ROCK1 
in A375 cells was categorised based on the effect on the 
actin cytoskeleton and the localisation of the ROCK 
construct based on immunofluorescence of cells stained 
with 9E10 antibody followed by anti mouse alexa 488 
secondary antibody and TRITC phalloidin. Arrowheads 
indicate the transfected cells in the upper panel. Highlighted 
squares in the lower panel indicate regions which are shown 
at higher magnification below. Scale bar indicates 20 pm.
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Figure 3.6 Examples of phenotypes seen when myc- 
ROCKl mutants are over-expressed in A375 cells.
Immune fluorescence showing localisation and f-actin 
organisation of A375 cells expressing myc-ROCK1 
constructs. Cells were fixed and stained with 9E10 and 
TRITC phalloidin. Representative images of the predominant 
phenotype are shown. Arrows indicate difference in myc- 
ROCKl localisation. Scale bar indicates 20 pm.
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Figure 3.7 Analysis of phenotypes of myc-ROCK1 
mutants. Constructs were over-expressed in A375 cells. 
48 hours later cells were fixed and stained with 9E10 and 
TRITC phalloidin. Cells expressing myc-ROCK1 mutants 
were counted and separated into categories as shown in 
figure 3.5. A) quantification of actin phenotypes, B) 
quantification of myc-ROCK1 localisation. Graphs show 
pooled results from 3 independent experiments, each 






Figure 3.8 I.P. kinase assay showing the kinase activity 
of myc-ROCK1 mutants in vitro. Myc-ROCK1 constructs 
were transiently transfected into A375 cells using effectene. 
48 hours following transfection, cells were lysed and myc- 
ROCKl was immune-precipitated from the cell lysate using 
9E10 and protein G coated agarose beads. Beads were 
washed extensively and then incubated with recombinant 
MLC and 10 pM ATP in kinase assay buffer for 30 mins at 
30°C. Reaction was stopped by addition of 5X SDS sample 
buffer and heating to 95 °C. Samples were then analysed by 
SDS PAGE and western blotting. Myc-ROCK1 was detected 
with 9E10 antibody.
3.3.3 Phenotypes of T233A, T380A, T398A myc-ROCK1 mutants
The myc-tagged ROCK1 mutant constructs were over-expressed in A375 melanoma cells. 
The phenotypes o f the transfected cells were compared the phenotype o f over-expressed 
wild-type myc-ROCKl (Figure 3.6, Figure 3.7). T233A ROCK1 was able to cause cell 
contraction and membrane blebbing, similar to over-expression o f wild-type ROCK1. It also 
diffusely localised to the plasma membrane (Figure 3.6, see arrow heads, Figure 3.7). T380A 
ROCK1 was less able than wild type ROCK1 to cause cell contraction and membrane 
blebbing, and the protein was not diffusely localised on the plasma membrane. Instead, 
T380A ROCK1 was observed either diffusely in the cytoplasm or in punctate patches. It 
therefore seems that T380A ROCK1 is both mislocalised and less able to stimulate 
contractility o f acto-myosin. The phenotype o f T398A ROCK1 was similar to T380A 
ROCK1, but over-expression was slightly more detrimental to the integrity o f the cell 
cytoskeleton as the proportion o f cells classified in the ‘collapsed’ category was increased 
compared to T380A ROCK1 expressing cells. T398A ROCKlwas also mislocalised and was 
observed in puncta rather than diffusely over the plasma membrane. Combinations of 
mutations T233A T398A and T380A T398A tended to have a more severe phenotype than 
the single mutations. This suggested that perhaps T233 did have some function although 
there was no obvious phenotype when 'T233 was mutated alone.
3.3.4 Kinase activity of T233A, T380A, T398A myc-ROCK1 mutants
T233A ROCK1 in addition to showing a wild-type phenotype when over expressed also 
showed kinase activity against MLC in vitro in an I.P. kinase assay that was similar to that o f 
WT (Figure 3.8). In repeats o f this experiment there was occasionally a marginal decrease in 
kinase activity but this was not completely consistent and if there is a small change in activity 
then this method o f measuring activity is not sensitive enough to conclude whether there is a 
real difference. Therefore there is little evidence to suggest that mutation o f T233 in the 
activation loop affects either ROCK1 localisation or kinase activity, and therefore T233 is 
unlikely to be a regulatory phosphorylation site. T380A although showing altered localisation 
and reduced cell blebbing in A375 cells had full kinase activity in an I.P. kinase assay against 
MLC. T398A showed reduced kinase activity in vitro against MLC, which is consistent with 
the phenotype o f  reduced stress fibres and collapsed cytoskeleton seen in some A375 cells. 
T398A therefore has potential to be a regulatory phosphorylation site in ROCK1.
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3.3.5 Phenotype of D232AT233A ROCK1
It is possible that there was no phenotype seen with T233A ROCK1 because there is a 
charged residue, D232, adjacent to this threonine, which might be able to act as a substitute 
for the positive charge o f a phosphorylated threonine in the T233 position. D232 is perhaps 
able to confer an active conformation o f the kinase domain even when T233 is not 
phosphorylated. To check this possibility, a further mutation o f ROCK1 was cloned: 
D232AT233A ROCK1. However this ROCK1 mutant did not show reduced membrane 
blebbing either, when expressed in A375 cells. Arrows indicate blebbing cells (Figure 3.9).
3.3.6 Inhibition of PI3K causes mislocalisation of over-expressed 
ROCK1
Results to this point had shown that both localisation and kinase activity were required for 
the function o f ROCK1. We had already seen that inhibiting the interaction with RhoA 
caused ROCK to be located in the cytoplasm rather than at the plasma membrane (Figure 
3.1). Mislocalisation was also observed when T380 and T398 were mutated to alanine. 
However, these mutations did not prevent ROCK1 from reaching the plasma membrane so 
presumably these mutants were still able to interact with RhoA adequately. However, at the 
plasma membrane, these mutant ROCK1 constructs were not able to spread diffusely over 
the membrane and were sometimes observed in puncta instead.
ROCK1 and ROCK2 also contain a PH domain in the C-terminus and in the case o f 
ROCK2 it had been reported that the PH domain was able to bind to PI(3,4,5)P3103. 
Additionally phosphorylation o f the residue analogous to T398 in ROCK1 in A kt/PK B  is 
dependent on PI(3,4,5)P3 229. To test what cell signalling events might be required for the 
diffuse membrane localisation o f ROCK1, and whether phospho-inositol lipids were 
involved, full length wild-type ROCK1 was transfected into A375 cells and the cells were 
subsequently treated with an inhibitor o f PI3K (Figure 3.10). Interestingly when PI3K was 
inhibited, full-length wild type ROCK1 sometimes became localised in puncta similar to 
what had been seen when T380A or T398A had been over-expressed. The cells treated with 
LY294002 were less contracted and did not exhibit membrane blebs (Figure 3.10). This 
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Figure 3.9 D232A T233A ROCK1 is still able to 
induce membrane blebbing. A) A375 cells were 
transfected with myc-ROCK1 D232A T233A then fixed 
and stained with 9E10. Transfected cells were 
observed. Arrows indicate cells still able to contract and 
exhibit membrane blebs. Scale bar indicates 50 pm. B) 
Graph showing quantification of actin phenotypes of 
A375 cells over-expressing D232A and D232A T233A 
myc-ROCK1 mutants, from 3 independent experiments, 
each experiment include >50 cells for each condition.
WT myc-ROCK1 WT myc-R0CK1 + LY294002
A
Figure 3.10 Inhibition of PI3K prevents over-expressed 
ROCK1 from inducing membrane blebbing. A375 cells 
plated on glass coverslips were transfected with WT myc- 
ROCKl and then treated with either DMSO as a control or 
10 pM LY294002 for 12 hours. Cells were then fixed and 
stained with 9E10 to highlight transfected cells and analyse 
their phenotype. Arrow indicates membrane puncta. Scale 
bar indicates 20 pm.
Myc-ROCK1
Figure 3.11 Inhibition of PI3K does not inhibit kinase activity 
of ROCK1. A375 cells were transfected with Myc-ROCK1 
constructs or GFP as a control. Myc-ROCK1 constructs were 
immune precipitated with 9E10 and used to phosphorylate 
recombinant MLC in vitro. Phosphorylation was determined by 
western blotting for pMLC (S19). Level of kinase was determined 
by western blotting with 9E10.
3.3.7 Inhibition of PI3K does not inhibit kinase activity of ROCK1.
Having seen that inhibition o f PI3K caused over-expressed ROCK1 to become mislocalised, 
it was next tested whether LY294002 caused any change to ROCK1 kinase activity. Myc- 
ROCKl was over-expressed in A375 cells treated with either DMSO or LY294002 for 12 
hours. The immune precipitated myc-ROCKl was used to phosphorylate recombinant MLC 
in vitro. It was found that inhibition o f PI3K signalling in the A375 cells did not alter the 
kinase acdvity o f W T ROCK1 or T380 mutants o f ROCK1 (Figure 3.11).
3.3.8 Acidic substitution of T380 restored blebbing activity of ROCK1
We next investigated the effect o f substituting the threonine residue for an acidic residue. In 
this way it is possible to model a constitutively phosphorylated amino acid as the negative 
charge o f acidic amino acid can mimic the charge o f a phosphorylated threonine residue. 
Acidic substitution o f T380 was able to restore the phenotype to resemble the wild type. 
Both T380D ROCK1 and T380E ROCK1 were able to cause cell contraction and cell 
blebbing unlike T380A (Figure 3.12). This phenotypic data suggested that T380 might be a 
phospho-acceptor site that played a role in the regulation o f ROCK1. However the acidic 
mutation o f T380 did not increase the ability if ROCK1 to cause membrane blebbing so 
perhaps is not constitutively active. Another possibility is that W T ROCK1 is actually 
constitutively phosphorylated at T380 in vivo and therefore T380D or T380E do not appear 
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Figure 3.12 Mutation of T380 to acidic residues does not 
inhibit membrane blebbing. A375 cells plated on glass 
coverslips were transfected with either WT myc-ROCK1 or 
T380D or T380E mutant myc-ROCK1 constructs. Cells were 
fixed and stained with 9E10 40 hours after transfection and 
the phenotypes of the transfected cells was analysed. Graph 
contains data from 3 independent experiments, each 
experiment includes >50 cells for each condition.
WT ROCK1 T380D
□  normal
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Figure 3.13 T380E myc-ROCK1 is able to cause membrane 
blebbing in the presence of LY294002. A375 cells plated on 
glass coverslips were transfected with either WT myc-ROCK1 
or T380E myc-ROCK1. Cells were treated with either DMSO 
or 10 pM LY294002 for 12 hours then fixed and stained with 
9E10. The phenotype of the transfected cells was analysed. 
Graph contains data from 2 independent experiments, each 
experiment contains > 50 cells for each condition.
w t w t + T380E T380E +
DMSO LY294002 DMSO LY294002
3.3.9 T380E ROCK1 is resistant to mislocalisation caused by 
inhibition of PI3K.
As T380A ROCK1 had been shown to be mislocalised in a similar way to the mislocalisation 
o f WT ROCK1 when cells were treated with LY294002, it was hypothesised that T380 might 
be regulated/sensitive to PI3K signalling. It was tested what effect LY294002 treatment had 
on over-expressed T380E ROCK1. It was found that in addition to avoiding the 
mislocalisation o f T380A ROCK1, T380E ROCK1 was still able to cause cell rounding and 
membrane blebbing even when cells have been treated with LY294002 (Figure 3.13). This is 
again strong evidence that T380 might be phosphorylated and that this modification allows 
ROCK1 to localise diffusely at the plasma membrane. The hypothesis would now be that 
T380 is phosphorylated downstream o f PI3K signalling and that the acidic mutation o f T380 
to aspartate or glutamate mimics the presence o f a phosphorylated threonine and therefore is 
resistant to the inhibition o f PI3K (Figure 3.13).
3.3.10 T380A ROCK1 binds to RhoE and is inhibited
One reason that ROCK1 could become mislocalised is that it becomes bound to an 
inhibitory binding partner. One such binding partner could be RhoE. To test this possibility 
A375 cells were transfected with myc-ROCKl mutants and lysates o f these cells were 
incubated with GST-RhoE bound to glutathione agarose beads. It was found that full length 
wild type ROCK1 interacted poorly with RhoE in these conditions however T380A ROCK1 
bound to RhoE much more strongly (Figure 3.14). This suggests that if T380 is a 
phosphorylation site in ROCK1 then its function could be to inhibit the interaction with the 
negative regulator RhoE.
As T380E ROCK1 had been able to rescue the phenotypic defects o f T380A ROCK1 and 
was also resistant to mislocalisation caused by inhibition o f PI3K, the binding o f  T380E to 
RhoE was also tested in the same assay. However in contrast to other assays, T380E 
behaved similarly to T380A and bound more strongly to RhoE than wild type ROCK1 
(Figure 3.14). This was surprising as in other tests T380E had behaved similarly to the WT 
myc-ROCKl in over-expression assays and also the T380E myc-ROCKl construct had been 
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Figure 3.14 T380A ROCK1 binds to RhoE better than 
WT ROCK1. A375 cells were transfected with myc-ROCK1 
constructs. Cell lysates were then incubated with GST- 
RhoE. The amount of each ROCK construct bound to RhoE 
was determined by western blotting.
The interaction o f T380 ROCK1 mutants with RhoE was also tested in a cellular context by 
over-expressing the myc-ROCKl constructs with GFP-RhoE in A375 cells (Figure 3.15). 
Addition o f GFP-RhoE to cells expressing WT myc-ROCKl caused an inhibition o f cell 
blebbing presumably because RhoE is binding to and inhibiting ROCK1. However the 
addition o f G FP-RhoE had a less detrimental effect when T380E myc-ROCKl were over­
expressed suggesting that these mutants were more resistant to inhibition by RhoE (Figure 
3.15). This is contradictory to the data from the binding assay.
3.3.11 Phenotype of T398D and T398E ROCK1
As the mutation o f T398 to alanine disrupted the localisation and also kinase activity o f 
ROCK1 it was a potential phospho-acceptor site. Further mutagenesis was conducted to 
change T398 to an acidic residue. However it was found that when T398D or T398E 
ROCK1 were transfected into A375 cells, that rather than causing cell blebbing, the 
phenotype was similar to T398A ROCK1 (Figure 3.16). Cells expressing T398D ROCK1 
remained spread and the number and thickness o f the stress fibres they contained was 
reduced compared to untransfected cells. It was clear that T398D ROCK1 was also acting as 
an inactive ROCK1 mutant. It was found that T398E ROCK1 was also not able to restore 
the contractile phenotype lost when T398 was mutated to alanine, and cells expressing 
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Figure 3.15 Quantification of myc-ROCK1 over­
expressed phenotypes with co-expressed GFP RhoE.
The first graph shows the actin phenotype of the cells 
expressing myc-ROCK1 constructs and cells expressing 
myc-ROCK1 constructs and GFP-RhoE. The lower graph 
categorises the localisation of the myc-ROCK1 construct. 
Graphs contain data pooled from 2 independent 
experiments, each experiment contains data from >50 





Figure 3.16 Acidic mutation of T398 does not restore a wild- 
type-like ROCK1 phenotype. A375 cells were transfected with 
T398D or T398E myc-ROCK1 plated on glass cover slips and 
stained with 9E10 and TRITC phalloidin. Scale bar indicates 50 
pm.
4 Chapter 4 - Mass Spectrometry analysis of ROCK1
4.1 Chapter summary
As the candidate based approach to finding phosphorylation sites in ROCK1 was proving 
more complicated than first thought, an alternative approach for investigating potential 
phosphorylation sites on ROCK1 was undertaken. Recombinant ROCK1 (17-535 a.a.) was 
incubated with radio-labelled ATP and it was found that ROCK1 would robustly 
autophosphorylate itself and that this autophosphorylation could be blocked by treatment 
with the ROCK inhibitor Y27632. The phosphorylated protein was analysed by mass 
spectrometry to determine on which sites these phosphorylation events occurred. One site 
identified using this method was T518. This amino acid was then mutated to alanine to 
analyse what function phosphorylation at this site might have. It was found that T518A 
ROCK1 localised to the plasma membrane and also had full kinase activity in vitro but was 
less able to induce membrane blebbing that WT myc-ROCKl. This chapter details these 
initial findings.
4.2 ROCK1 will autophosphorylate itself in vitro
Recombinant ROCK1 (17-537 a.a.) was incubated in kinase assay buffer containing 32P- 
labelled ATP and also 10 pM Y27632 or recombinant PDK1. PDK1 was included because it 
has been previously shown that PDK1 will phosphorylate other members o f the AGC family 
o f kinases 119. Samples were separated by SDS-PAGE and the gel was then dried and used to 
expose X-ray film. As the recombinant ROCK1 used only included the first part o f the 
protein, ROCK1 migrated at a size o f approximately 60 kDa and the recombinant PDK1 ran 
just above ROCK1 at approximately 62 kDa. Results showed that ROCK1 will robusdy 
autophosphorylate itself and that this autophosphorylation can be almost completely 
inhibited by the addition o f Y27632 to the reaction (Figure 4.1). The third lane o f the gel 
shows two bands, as both ROCK1 and PDK1 will autophosphorylate themselves. However, 
the intensity o f the ROCK1 phosphorylation is not altered suggesting that ROCK1 (17-537 




Figure 4.1 Recombinant ROCK1 will autophosphorylate 
itself in vitro. Recombinant ROCK1 was incubated in kinase 
assay buffer with 32P ATP with either 10 pM Y27632 or 
recombinant PDK1. Samples were run on SDS-PAGE, gel was 
used to expose x-ray film.
4.3 Autophosphorylation sites in ROCK1
To investigate which sites were auto-phosphorylated in recombinant ROCK1, the kinase 
reaction was repeated this time without 32P labelled ATP. The samples were separated by 
SDS-PAGE and the gel was stained as above. The bands were cut out o f the gel and digested 
with trypsin. The resulting peptide fragments were fractionated by HPLC and then analysed 
by mass spectrometry (Protein analysis laboratory, Nick Totty). Results showed that the 
following peptides were found to be phosphorylated at serine/threonine residues. The 
results were then compared to a ROCK1 sample incubated with Y27632 to identify sites that 
were present only in the sample without inhibitor treatment. Several phosphorylation sites 
were also found in the Y27632 treated sample, which indicated that these sites are already 
phosphorylated on the kinase before the in vitro assay. This phosphorylation most probably 
occurs during protein production in the insect cell system used.
Y 27632  trea ted  sa m p le  Control sa m p le  SITES
YLSSANPNDNR YLSSANPNDNR S398, S399




Table showing the phosphorylated peptides identified by mass spectrometry in the control 
sample and the sample treated with Y27632. Residues highlighted in red show the 
phosphorylated sites in that peptide.
O ther phosphorylation sites were also identified but at this point have not been identified 
more than once. The peptides above have been seen several times in 3 independent runs and 
therefore the data for these sites are fully convincing and we are confident that these sites are 
real.
The data in Figures 4.2-4.5 shows the spectra o f the fragmented peptides. The first three 
peptides listed in table 4.1 flew well in the 6510 Agilent Q T O F machine and so we were able 
to get a good spread o f both ‘b ’ and ‘y’ fragmentation ions to confirm these results. For 
some unknown reason, the last peptide above although easily identified, did not fragment 
and fly on this machine. The pattern o f fragmentation ions was therefore shown by analysing 
fractionated peptide on the Applied Biosystems 4000 Q trap machine, in a process called
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precursor ion scanning. For all o f the above peptides we were able to identify a fragment 
whose mass was 98 kDa smaller than the parent peptide. This mass corresponds to the loss 
o f phosphoric acid (H3P 0 4) and means that the parent peptide did contain a phosphate 
group. The fragment seen that is 80 kDa smaller than the parent corresponds to the loss o f 
the phosphate group alone. A broad range o f ‘b’ and ‘y’ i°ns were also identified for all 
peptides. The b series corresponds to fragmentation starting at the N-terminus o f the 
peptide, and the y series o f ions corresponds to fragmentation starting at the C-terminus o f 
the peptide. Having a large range o f these ions provides further strong evidence that the 
identity o f the peptide is really the phosphorylated peptide that matches the mass o f the 
parent ion.
T518 was initially chosen to investigate further as it was one o f the two sites clearly 
phosphorylated by ROCK1 itself and could potentially be a regulatory autophosphorylation 
site.
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MS/MS Fragmentation of TSSNADKSLQESLQK
Found in g l l l l l l l l l l , his-tagged ROCK 17-535aa fhuman]
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Figure 4.2 Mass spectrometry analysis of ROCK1.
TSSNADKSLQESLQK. A) the parent ion is shown with the blue 
diamond. These masses were measured using 6510 Agilent 
QTOF with integrated chip cube. B)shows the ions of the peptide 
when fragmented. C) table of the fragmented ions of the peptide.
MS/MS Fragmentation of Y LSSA NPNDNR
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Figure 4.3 Mass spectrometry analysis of ROCK1.
YLSSANPDNDNR. A) the parent ion is shown with the blue 
diamond. These masses were measured using 6510 Agilent QTOF 
with integrated chip cube. B)shows the ions of the peptide when 
fragmented. C) table of the fragmented ions of the peptide.
MS/MS Fragmentation of NLESTVSQIEK
Found in g i l l l l l l l l l ,  his-tagged ROCK 17-535aa fhuman]
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Figure 4.4 Mass spectrometry analysis of ROCK1.
NLESTVSQIEK. A) the parent ion is shown with the blue 
diamond. These masses were measured using 6510 Agilent 
QTOF with integrated chip cube. B)shows the ions of the peptide 
when fragmented. C) table of the fragmented ions of the peptide.
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Figure 4.5 Mass spectrometry analysis of ROCK1.
NVENEVSTLKDQLEDLKK. This peptide was pound using 
radiolabelled R0CK1. The digested protein was fractionated the 
Edman sequences and the hot fractions analysed. A) the parent 
ion was found by running the fraction on Applied Biosystems 4700 
proteomics analyser B)shows the ions of the peptide when 
fragmented. This analysis was carried out on the Applied 
biosystems 400 Q trap.
4.4 Analysis of T518A ROCK1
T518 in full length myc-ROCKl was mutated to alanine by PCR site directed mutagenesis. 
The resulting mutant construct was transfected into A375 cells plated on glass coverslips. 
Cells were fixed and stained with 9E10 and TRITC phalloidin and the phenotypes o f the 
transfected cells were quantified and compared to WT ROCK1 (Figure 4.6, Figure 4.7). 
T518A myc-ROCKl was able to localise diffusely to the cell membrane, and expression o f 
this construct was also able to induce thickened stress fibres in the transfected cells. 
However it was found that T518A was less able to induce membrane blebbing than WT 
myc-ROCKl (Figure 4.6, 4.7). The number o f blebbing cells was reduced and also the extent 
o f membrane blebbing was reduced. Instead o f contracting the whole cell the membrane 
blebs induced tended to be smaller and more localised. Many cells expressing T518A myc- 
RO CK l resembled cells over-expressing I1009A myc-ROCKl. The mutation in the Rho- 
binding domain also prevented cells from contracting and generating membrane blebs. 
However the localisation o f the I1009A and T518A mutants was different, I1009A remained 
cytoplasmic; T518A was able to reach the plasma membrane (Figure 4.7).
4.5 T518A is less able to cause cell contraction than WT ROCK1
T518A myc-ROCKl was able to induce membrane blebbing in a proportion o f the 
transfected cells, however the degree o f blebbing was markedly reduced. Blebbing in cells 
expressing T518A ROCK1 was usually restricted to part o f the cells membrane and did not 
cause contraction o f the whole cell. To try to quantify this difference, the spread area o f 
transfected cells was compared to untransfected cells in the same image. It was found that 
W T myc-ROCKl was able to contract the transfected cells so that their spread area was only 
approximately 20% o f surrounding untransfected cells (Figure 4.8). Meanwhile although 
T518A myc-ROCKl expressing cells were able to induce localised membrane blebbing, the 
cells remained generally spread and this was confirmed by the quantification showing that 
cells expressing T518A myc-ROCKl were spread over the same area as untransfected cells. 
This phenotype o f restricted, localised cell blebbing is similar to the phenotype seen when 
truncated ROCK1 is localised to the plasma membrane by the addition o f the K-Ras CAAX 
sequence (Figure 3.3).
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Figure 4.6 Phenotype of T518A ROCK1. A375 cells were 
transfected with either wild type myc-ROCKl, the Rho-binding 
mutant I1009A ROCK1 or T518A ROCK1. cells were fixed and 
stained with 9E10 and TRITC phalloidin. Scale bar indicates 50 pm.
1009fr
normal 
■inc stress fibres 
■blebbing






wild type I1009A T518A
ROCK1 ROCK1 ROCK1
Figure 4.7 Analysis of the phenotype of T518A myc- 
ROCKl. A375 cells were transfected with either WT myc- 
ROCKl or the Rho-binding mutant of ROCK1 (I1009A) and 
also T518A ROCK1. Cells were fixed and stained 48 hours 
after transfection and the transfected cells were analysed 
and placed into categories based on their morphology and 
F-actin staining, and the localisation of the ROCK construct. 
Graphs show data pooled from 3 independent experiments, 
each experiment contains >50 quantified cells.
T518A Wild Type
Figure 4.8 Quantification of spread area of cells over 
expressing ROCK constructs. A375 cells expressing 
either WT ROCK1 or T518A ROCK1 were fixed and stained 
with 9E10. Using ImageJ software the area covered by each 
transfected cell was measured against the area of 
untransfected cells in the same field. The histogram shows 
the mean of these ratios and standard deviation. A ratio of 1 
indicates no difference in area from the untransfected cells. * 
indicates p<0.001 T-test.
4.6 T518A mutation does not inhibit kinase activity of ROCK1
So far the mutation o f T518A had been shown to reduce the ability o f over-expressed 
ROCK1 to cause cell contraction. However T518A myc-ROCKl was localised correcdy to 
the plasma membrane and was also able to induce thick stress fibres in transfected cells. It 
was next tested whether mutation o f T518 affected kinase activity o f ROCK1 in vitro (Figure 
4.9). Myc-ROCKl was immunoprecipitated from A375 cells and used to phosphorylate 
recombinant MLC in vitro. It was found that mutation o f T518A did not alter the ability o f 
ROCK1 to phosphorylate MLC (Figure 4.9). The kinase activity o f T518A ROCK1 was 
tested along side I1009A ROCK1 as these two mutants had shown similar phenotype when 
over expressed in A375 cells. The kinase assay also showed that both these mutants had full 
kinase activity in vitro, further evidence that for ROCK1 to co-ordinate contraction o f the 
cell body, more regulatory steps than just kinase activity are required.
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9E10
Figure 4.9 I.P. kinase assay of myc-ROCK1 mutants.
A375 cells were transfected with either WT myc-R0CK1 or 
the rho-binding mutant I1009A myc-R0CK1 or T518A myc- 
ROCKl . The ROCK protein was immune precipitated using 
9E10 and used to phosphorylate recombinant MLC in 
vitro.Samples were analysed by western blotting for pMLC 
(S19) and 9E10.
5 Chapter 5 - siRNA screen of potential regulators of 
ROCK-driven cortical actin contractility and amoeboid 
motility in A375 cells
5.1 Chapter summary
This chapter summarises the identification o f PDK1 as a novel regulator o f ROCK-driven 
acto-myosin contractility. To try to elucidate the signalling pathways which regulate ROCK- 
driven contractility and potentially also cell motility, an siRNA screen o f proteins involved in 
cytoskeletal dynamics, cell adhesion, cell motility and other signalling pathways was carried 
out in A375 cells. In conjunction with this A375 cells were also treated with a range o f 
pharmacological inhibitors. A375 cells were used for this screen, as it has been previously 
shown that they utilise amoeboid cell motility in vivo and are dependent on Rho and ROCK 
signalling for their rounded cell morphology 153. Cells were plated on a deformable matrix o f 
collagen and matrigel to model a 3D environment more similar to the in vivo situation. In 
this environment, A375 cells are, in the majority, rounded and exhibit membrane blebs. 
Treatments that disrupted this rounded cell morphology were listed as ‘hits’ as potential 
novel regulators o f ROCK-driven cell contractility.
Several proteins with roles in cell motility and /o r actin dynamics were identified in this 
screen, however it was chosen to investigate PDK1 further as it had not previously been 
linked with amoeboid cell motility or the regulation o f R ho/R O C K  signalling. It was found 
that PDK1 was required for ROCK to co-ordinate contraction o f the cortical acto-myosin 
network and membrane blebbing. Furthermore PDK1 was required for cell motility in two 
cell lines utilising amoeboid morphology (A375 and MTLn3E).
5.2 siRNA screen for regulators of ROCK-driven cortical acto- 
myosin contractility
A selection o f genes were hand-picked to be included in the siRNA screen for analysing 
changes in cell morphology. The whole o f the Rho family o f GTPases was included as these 
proteins have been shown to play a critical role in controlling the actin cytoskeleton and 
therefore also cell morphology. Other actin regulators such as cortactin, cofilin, WAVE and
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N-WASP were included for the same reasons. The screen also included genes involved in cell 
adhesions such as integrin subunits, and their associated proteins such as paxillin. Kinases 
known to be involved in regulation o f myosin were included such as MRCK and because o f 
the interesting data in chapter 3 implicating PI3K signalling in the regulation o f  ROCK1, 
PDK1 and Akt isoforms were also included. This group o f gene targets would hopefully 
reveal some o f the regulatory mechanisms involved in rounded cell morphology and 
potentially amoeboid cell motility.
A375 cells transfected with either siRNA smart pools from Dharmacon, or treated with 
inhibitors and were plated onto collagen/matrigel gels. Cells were fixed 48 hours after 
transfection or after 18 hours o f treatment with inhibitor. Cells were then stained with 
TRITC phalloidin and propidium iodide to show organisation o f actin and also overall cell 
morphology (Figure 5.1, Figure 5.2).
Control, non-targeting siRNA transfected cells were mostly rounded with membrane blebs 
when plated on collagen/matrigel (see the first 2 panels in Figure 5.1, Figure 5.3). 
Reassuringly, siRNA knockdown o f RhoA, ROCK1 or ROCK2 caused cells to become 
elongated and so served as positive controls (Figure 5.1, second panel on page 1 and right 
hand panels in the middle row on page 2). This was also the case when Rho and ROCK were 
inhibited with TAT-C3, Y27632, H I 152, or HA1077 (Figure 5.2).
Knockdown o f  RhoC caused a phenotype similar to that o f RhoA depletion but the 
phenotype was not as obvious. This was not unexpected because RhoA and RhoC have been 
previously shown to interact with the same downstream effectors 59. RhoC has also been 
previously reported to be over-expressed in some metastatic tumour cells 66. The difference 
in the severity o f the phenotype may be due to the efficiency o f knockdown. The only other 
Rho family member to cause a change in morphology in this screen was RhoU, which caused 
the cells to become flatter and in some cases slightly elongated. RhoU has been reported to 
play a role in the regulation o f cell adhesions 230, 231. N o elongation was noted with 
knockdown o f R ndl, Rnd2 or RhoE, cells remained rounded and contracted. Likewise no 
dramatic change was seen when Racl Rac2, Rac3, or Cdc42 were knocked down (see middle 
panels on page 1 o f Figure 5.1), although in the case o f  the Rac family it is possible that 
knockdown caused cells to become more rounded, though this is difficult to quantify judging 
only by eye.
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Knockdown o f D ial or Dia2 caused A375 cells to become flattened and more spread and in 
some cases elongated. These proteins can also signal downstream o f RhoA 62,232. A strong 
disruption o f rounded cell morphology was seen when paxillin or vinculin were depleted. 
They may perhaps play a role in the attachment o f the actin cytoskeleton the cell membrane 
and the cell adhesions to the extracellular matrix.
It was interesting to see that knockdown o f any o f the integrins tested did not disrupt 
rounded cell morphology. Other groups have reported that amoeboid moving cells do not 
require integrin for their invasion 164,221. It seems that A375 cells do not require integrins for 
rounded morphology in 3D culture conditions. The unexpected hit from this analysis was 
PDK1. Knockdown o f PDK1 caused A375 cells to become elongated with multiple 
protrusions similar to knock down o f RhoA or inhibition o f ROCK signalling. Interestingly 
knockdown o f A ktl, Akt2 or Akt3 did not phenocopy the knockdown o f PDK1. The role o f 
PDK1 in amoeboid cell morphology is investigated in detail below.
Knockdown o f MRCK isoforms also had no obvious effect on rounded cell morphology. 
MRCK is able to regulate myosin light chain and so also cell contractility in some 
circumstances 170 but it seems that in A375 cells MLC is regulated through pathways other 
than by MRCK. Results from the inhibitor treated cells show that contraction in A375 cells is 
mostly regulated through RhoA and ROCK as these were the only inhibitors to cause 





Figure 5.1 continued overleaf
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Figure 5.1 siRNA screen for regulators of cortical acto-myosin 
contractility in A375 cells. A375 cells were transfected with siRNA 
smartpools targeted against a variety of cytoskeletal proteins and other 
signalling pathways and then plated on top of 3d collagen/matrigel 
gels. 2 panels are shown for each gene knocked down in the screen. 
Cells are stained with TRITC phalloidin and propidium iodide to show 
the actin cytoskeleton and the overall cell morphology.
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Figure 5.2 Small molecule inhibitor screen for regulators of 
cortical acto-myosin contractility in A375 cells. A375 cells were 
plated on top of 3d collagen/matrigel gels and treated with various 
inhibitors for 18 hours. 2 panels are shown for each treatment. Cells 
are stained with TRITC phalloidin and propidium iodide to show the 
actin cytoskeleton and the overall cell morphology.
5.3 PDK1 depletion causes disruption of rounded blebbing 
morphology
5.3.1 Analysis of changes in actin organisation
In order to continue the investigation into the role o f PDK1 in the control o f rounded cell 
morphology further, firsdy the 4 oligos used to deplete PDK1 in the screen were tried 
separately. The deconvulution o f the smartpool showed that 3 out for the 4 oligos caused the 
same disruption o f the rounded cell morphology. Oligos 1 and 2 were chosen for remainder 
o f the experiments as they were able to knock down PDK1 most efficiently. The depletion 
o f PDK1 in A375 cells plated on deformable collagen/matrigel matrix caused a disruption o f 
rounded blebbing morphology. Cells depleted o f PDK1 became elongated with long, 
filopodia-like protrusions (Figure 5.3 please also see supplementary movies for more detailed 
images o f the actin organisation). 3D reconstruction o f multiple confocal z-sections o f cells 
stained with TRITC phalloidin revealed that in control cells, actin was arranged in thick 
bundles all around the cell cortex. When PDK1 was knocked down, actin became arranged 
in long cables running the length o f the cell, and was no longer co-ordinated around the 
whole cortex. The membrane blebs seen in control cells were not observed in the elongated, 
PDK1 depleted cells indicating a reduction in cell contractility and a reduction in hydrostatic 
pressure. These changes in morphology could indicate that ROCK is impaired in its ability to 
co-ordinate cell contractility when PDK1 is absent. Please also refer to the supplementary 
movies that accompany Figure 5.3 for more detail o f the actin cytoskeleton.
5.3.2 Quantification of changes in morphology caused by siRNA 
depletion of PDK1
The changes in morphology were quantified in order to statistically compare the effect o f 
PDK1 depletion to control morphology o f A375 cells and also to the morphology o f A375 
cells treated with an inhibitor o f ROCK (Y27632). To compare cell morphology, low 
magnification phase images o f A375 cells on collagen/matrigel gels were analysed (Figure 
5.4). The area and perimeter o f cells was calculated by manually drawing around the cell 
shape using Volocity software. The ratio o f (perimeter2)/(47tarea) was then compared. For a 
circle this ratio = 1. The higher the number, the more elongated the cell is and /o r the more 
protrusions the cell has. The ratio o f control transfected cells is around 1.2 indicating that
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they are mostly rounded (Figure 5.4). Cells transfected with two different siRNA oligos 
against PDK1 were more elongated and had more protrusions. The median rados o f cells 
depleted o f PDK1 were around 2.5, significandy higher than the controls (p<0.001 Mann 
Whitney U test). A1 though the median values o f PDK1 depleted cells and Y27623 cells are 
fairly similar the spread o f the values is different. Both cause cells to become more elongated 
and /o r protrusive, but treatment with the inhibitor Y27632 has a more uniform effect on the 
whole population o f cells. Western blots o f A375 cell lysates transfected with siRNA against 
PDK1 showed an overall level o f knockdown in the cell population o f approximately 80%, 
(Figure 5.8), however siRNA transfection to deplete PDK1 had a much more variable effect 
on cell morphology than treatment with ROCK inhibitor. This might be an indication that 
transfection with siRNA does not effectively knockdown PDK1 in all cells.
Similar morphological changes were also observed in MTLn3E cells (Figure 5.5). The 
changes in morphology were less pronounced as cells depleted o f PDK1 had a ratio o f 
around 1.5, compared to 2.5 in A375 cells, however this was still statistically significantly 
higher than controls (p<0.001) (Figure 5.5).
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Figure 5.3 Actin phenotypes of A375 cells plated on 
deformable 3D matrix. A)A375 cells were transfected with 
either control siRNA or oligos targeted against PDK1. 24 hours 
after transfection cells were plated on a 3D collagen matrigel 
gel. 24 hours later cells were fixed and stained with TRITC 
phalloidin. Upper panel shows 3D reconstruction of cells and 
lower panels show one slice through the cell. Scale bar 
indicates 20 pm. Also see supplementary movies. B) Western 
blot showing the knockdown of PDK1 with 4 difference siRNA 
oligos.























Figure 5.4 Quantification of changes in overall cell 
morphology of A375 cells plated on 3D matrix. Low power 
phase images of A375 cells transfected with either control or 
PDK1 targeting siRNA and plated on 3D matrix were used to 
analyse cell shape. Using Volocity software, cells were drawn 
around manually and measurements of the cell perimeter and cell 
area were collected. Ratios were calculated as 
(perimeter)2/(2TTarea). For circular objects this ratio=1. As cells 
become more elongated this ratio increases. Scale bar indicates 
100 pm.
Control siRNA PDK1 #2 siRNA
Figure 5.5 Changes in cell morphology of MTLn3 cells 
when PDK1 is depleted. Mtln3 cells transfected with siRNA 
oligo 2 targeting PDK1 were plated on collagen/matrigel gels 
and stained with TRITC phalloidin. Scale bar indicates 50 pm.
Figure 5.6 Quantification of changes in morphology of 
Mtln3 cells depleted of PDK1. Low power phase images of 
Mtln3 cells transfected with either control or PDK1 targeting 
oligos plated on collagen/matrigel matrix were used to calculate 
morphology using the ratio described previously. Star indicates 
p<0.05 Mann Whitney U test.
5.4 PDK1 is required for cell motility in deformable 3D 
environments
5.4.1 PDK1 is required for rapid acto-myosin driven blebbing motility 
in 3D environments
A375 cells plated on collagen/matrigel gels form large membrane blebs that are able to drive 
cell motility. This type o f cell motility is extremely rapid but fairly inefficient and chaotic. To 
examine this type o f cell motility in detail, individual cells expressing GFP-CAAX were 
imaged at high resolution using confocal microscopy at a rate o f 1 frame every 2 seconds. 
Translocation o f the cell centroid was measured to determine cell speed (Figure 5.7 and 
supplementary movies).
Control cells are able to move at rates up to 10 [im per minute. This rapid chaotic cell 
blebbing requires both actin organisation and myosin ATPase activity as treatment of 
blebbing cells with either 2 pM cytochalasin D  or 2 pM Blebbistatin halted cell blebbing and 
motility (Figure 5.7 and supplementary movies). A375 cells depleted o f PDK1 were 
elongated as had been previously seen. The rapid translocation o f  the cell centroid seen in 
control cells was completely lost and instead small filopodia protrusions were extended and 
retracted. The cell body was not moved at all in the same time period. This indicated that 
PDK1 depleted cells were defective in their ability to co-ordinate contractile forces through 
the actin cell cortex, and drive blebbing cell motility.
5.4.2 PDK1 is required for persistent cell motility
A375 cells move very inefficiendy on deformable matrices, and only rarely were able to move 
any significant distance in any one direction. To determine whether PDK1 was required for 
more persistent cell motility as well as chaotic blebbing motility, A375 cells were plated on 
collagen/matrigel gels and tracked over 10 hours. Tracking was carried out using MetaMorph 
software, analysing the phase contrast movies. Taking images at 5-minute intervals is under 
sampling so much that the rapid blebbing is missed. Despite this, there was still a significant 




Figure 5.7 High resolution of amoeboid movement of A375 cells in 
vitro A375 cells stably expressing the membrane marker GFP-CAAX, 
were transfected with either control or PDK1 targeting siRNA were 
plated on 3D matrix. Cells were imaged at a rate of 1 frame every 3 
seconds in order to visualise rapid blebbing motility. Treatment of these 
cells with either 2.5 pM blebbistatin or 2 pM cytochalasin D, or 
knockdown of PDK1, inhibited this form of motility.The upper panels for 
each treatment show the GFP signal, the lower panels show the 
tracking of the cell centroid. Please also see accompanying 
supplementary movies. Scale bar indicates 10 pm.
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Figure 5.8 Low resolution analysis of cell movement. Low
resolution phase contrast time-lapse sequences were analysed 
to determine the effect of PDK1 depletion on cell motility. 
Compared here are two different cell lines A375 and Mtln3. 
Below are the western blots analyses showing the level of PDK1 
knockdown in the cell lysates. ** indicates p<0.001, * indicates 
p<0.01 (Mann Whitney U test).
To examine the effect o f PDK1 depletion on cell motility in more detail, a different cell line 
was analysed, that exhibits more efficient, directed cell motility. MTLn3E are rat breast 
carcinoma cells and have also been previously shown to require ROCK-driven contractility 
for their motility and invasion in vivo 154. The organisation o f cortical actin in MTLn3E cells 
is also sensitive to depletion of PDK1 (Figure 5.6). When plated on collagen/matrigel gels, 
MTLn3E cells are rounded and have prominent cortical actin. They exhibit membrane blebs, 
but not as often or as prominently as A375 cells. They move in vivo and in deformable 
matrices in vitro, by extending a small pseudopod whilst keeping the rest of the cell round 
and contracted 154. MTLn3E cells were plated on collagen/matrigel gels, and similar to A375 
cells were imaged over 10 hours at 5 minute intervals.
MTLn3E cells move more directionally than A375 cells. The cells speeds measurable under 
these conditions are much higher in MTLn3E cells than A375 cells meaning that the 
differences in cell motility seen when PDK1 is depleted are more easily determined (Figure 
5.8). Oligo 2 had a more significant effect than oligo 1 in MTLn3E cells. MTLn3E are rat 
cells and oligol has one mismatched base, and so depletes PDK1 less efficiently (Figure 5.8). 
Oligo 2 is perfectly matched against both rat and human PDK1 (Figure 5.8). This was 
determined by western blotting to check the efficiency o f knockdown in MTLn3E cells. It 
seems that the effects on cell motility are directly related to the total levels o f PDK1 in a 
dose-dependant manner. It is also clear that at least 2 different cell lines, capable o f moving 
in a ROCK-dependent amoeboid manner require PD K1.
5.4.3 PDK1 is not required for cell motility on 2D substrates
Considering that PDK1 is involved in many much studied signalling pathways yet a role for 
cell motility had not previously been described, at the time these experiments were 
conducted. It was perhaps possible that PDK1 was only required for amoeboid cell motility 
which is only seen in 3D environments or in vivo. To check this hypothesis the role of 
PDK1 depletion on the morphology and motility o f cells on 2D surfaces was examined. 
A375 cells were transfected with either control or PDK1 targeting siRNA oligos and plated 
onto glass-bottomed cell culture dishes. Time-lapse microscopy was carried out and cells 
were tracked automatically using MetaMorph software, as above. O n glass A375 cells have 
broad lamellipodia and are able to move more persistently than in 3D environments. The 
most striking finding in 2D in vitro assays was that knockdown o f PDK1 did not cause any 
measurable change in cell morphology (Figure 5.9). Also knockdown o f PD K  did not reduce
150
this type o f 2D cell motility, if anything cells moved slighdy faster but this was not 
statistically significant (Figure 5.10).
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Figure 5.9 Depletion of PDK1 does not alter cell 
morphology on 2D substrates. A375 cells were 
transfected withh siRNA oligos and plated onto glass cover- 
slips. 36 hours after transfected cells were fixed and stained 
with TRITC phalloidin and imaged were taken using confocal 














Figure 5.10 Analysis of cell motility in 2D environments.
A375 cells were transfected with either control or PDK1 
targeting oligos and plated onto glass-bottomed cell culture 
dishes. Low power phase contrast time-lapse sequences were 
analysed to determine cell speed.
6 Chapter 6 - PDK1 is required for A375 cell invasion in 
vivo
6.1 Chapter summary
This chapter describes the investigations into the possible roles o f PDK1 and ROCK in 
amoeboid cell motility o f cancer cells in vivo. Cell motility was monitored in primary 
xenograft tumours using multi-photon intravital imaging o f anaesthetised mice. Firstly the 
role o f ROCK1 and ROCK2 signalling in cancer cell motility in vivo was examined by 
treating mice with the inhibitor Y27632. A375 cells were injected subcutaneously in nude 
mice and the resulting tumours were imaged after 48 hours treatment with 3 doses o f 
Y27632. It was found that Y27632 treated tumours showed a reduction in cell motility o f 
approximately 50 % compared to control tumours treated with PBS. In more detailed 
analysis it was found that the reduction in motility was mostly caused by an inhibition o f 
amoeboid cell motility.
The results from the siRNA screen had highlighted PDK1 as a potential regulator o f cortical 
actin and rounded cell morphology. Further investigation confirmed this result and also 
found that PDK1 was required for cell motility, specifically on 3-dimensional, deformable 
environments. To confirm the relevance o f  these findings, the effect o f PDK1 knockdown 
on cancer cell motility and invasion was examined in vivo. A375 cell lines stably depleted o f 
PDK1 and also stably expressing GFP-MLC were generated and injected subcutaneously 
into the flank o f nude mice. It was found that PDK1 caused elongated morphology and 
reduced cell motility in vivo as had been predicted by the in vitro studies. The ability o f cells 
to colonise the lungs was also examined and it was also found that knockdown o f PDK1 
reduced the ability o f cells to persist in the lung parenchyma. The results in this chapter 
reveal that PDK1 is required for cancer cell motility in vivo and potentially indicate that 
PDK1 may also play a role in other stages o f metastasis.
6.2 Inhibition of ROCK signalling reduces cancer cell motility in 
vivo.
A375 cells within the xenograft tumours were visualised by their stable expression o f GFP- 
MLC. The A375 cells within the tumour were generally densely packed and surrounded by a 
capsule o f dense collagen fibres, which were imaged using 2nd harmonic signals following 2-
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photon excitation. Control mice were treated with 3 intraperitoneal doses o f PBS during the 
48 hours prior to imaging. The A375 xenograft tumours imaged in mice treated with ROCK 
inhibitor, were injected with 3 doses o f Y27632 (40 mg/kg) (note that this compound also 
inhibits PRKs) in PBS in the 48 hours prior to imaging, the last dose was given just before 
imaging was begun. Analysis o f the resulting time-lapse movies was undertaken manually and 
the number o f cells moving in each frame were counted and categorised as below. The 
number o f movement events was then standardised to m ovem ents/mm 2/hour. The 
categories used for cell movement events were:
1. Rapid amoeboid movement
2. Elongated/ protrusions
3. Chaotic/ blebbing motility
Rapid amoeboid movement was defined as cells moving in a reasonably directed manner at 
speeds o f between 1-5 p/m in. Elongated/ protrusions, was defined as cells making a 
significant protrusion, but it was not always followed by translocation o f the whole cell body 
within the time period o f the imaging. Chaotic/ blebbing motility was defined as cells 
moving with membrane blebs, but not in a directed manner. Cells o f this type would exhibit 
membrane blebs similar to what we had seen when A375 cells were plated on a 3D 
deformable matrix in vitro. We were also able to observe switching between chaotic blebbing 
and rapid amoeboid movement, indicating that these categories are an over simplification o f 
the cell motility phenotypes in vivo. Examples o f amoeboid and elongated cell motility are 
shown in Figure 6.2 and in the supplementary movies that accompany Figure 6.2. The speed 
at which cells moved in vivo was calculated from the in vivo movies and it was found that 
cells moving in an amoeboid manner moved much faster than those moving in an elongated 
manner (median speed 3.5 p /m in  compared to 1.3 p /m in  (Figure 6.4)).
155
Control tumours Y27632 treatment
Figure 6.1 Inhibition of ROCK signalling in vivo reduced cancer 
cell motility. A375 GFP-MLC xenograft tumours were grown 
subcutaneously in nude mice. Y27632 was dosed I.P. in 3 doses in 
the 48 hours prior to imaging. Timelapse movies were analysed and 
cell movement events in each z-section were counted. Results are 
shown in a scatter plot, bars indicate mean number of movement 
events per imaged z-section.
Figure 6.2 Images from in vivo multi-photon intravital 
microscopy of A375 subcutaneous tumour. Both areas 
shown are from the same tumour area. Panels i) and ii) 
show fast moving amoeboid motility. Panels iii) and iv) show 
elongated cell motility (please see accompanying 
supplementary movies). Panels ii) and iv) show overlaid 
images of 3 consecutive time points in red, green and blue. 
White pixels indicate stationary objects. The spatial 
separation of the coloured layers highlights the motile cells 
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Figure 6.3 Inhibition of ROCK activity in vivo causes a 
reduction in amoeboid cell motility. A375 cells expressing 
GFP-MLC were injected subcutaneously into the flank of nude 
mice. When tumours reached 4-6 mm in diameter mice were 
given 3 doses of Y27632 in PBS (40 mg/kg) I.P. in the 36 
hours prior to imaging. Control mice were doses with PBS 
alone. Time lapse movies were analysed and cell movement 
events were classified into amoeboid or elongated categories. 
Data is presented as movement events per z-section imaged. 



















Figure 6.4 Comparison of cell speeds between different 
forms of cell motility in vivo. The above box plots show the 
quantification of cell speed in microns/minute. In vivo movies were 
analysed using LSM510 image examiner and the distance moved 
by motile cells was measured and divided by the time in minutes 
to give cell speed.
Control tumours cells moved in a mostly amoeboid manner with a smaller proportion o f 
cells moving with an ‘elongated’ morphology. Y27632 treated tumours generally showed less 
cell movement events than control tumours (Figure 6.1). The reduction was around 50%, 
measured by the average number o f movement events per 2-section imaged. In both the 
control and Y27632 treated tumours, there were many areas o f the tumour which showed no 
cell motility (note the many points plotted at zero), and overall it was estimated that only 
around 1 % o f cells imaged were motile.
It was observed that the reduction in cell motility caused by Y27632 was mostly due to an 
inhibition o f amoeboid cell motility and that cells moving in an elongated manner were not 
affected. It seems that R O C K /PR K  signalling is required for amoeboid cell motility but 
dispensable for more elongated forms o f cell motility (Figure 6.3).
It was next tested what role PDK1 had in cancer cell motility in vivo.
6.3 PDK1 depletion causes elongated cell morphology in 
primary tumours
6.3.1 Generation of stably PDK1 depleted A375 clones
A375 cells stably expressing GFP-MLC were also engineered to stably express an shRNA 
sequence targeted against PDK1. The Vector pSuper Retro containing a PDK1 targeting 
cassette was transfected into the amphotropic packaging cell line phoenixAMPHO to 
generate virus that was then used to infect the A375 GFP-MLC expressing cells. Infected 
cells were selected with puromycin and plated at low density. Colonies that formed were 
expanded and the level o f  PDK1 in each monoclonal cell line was determined by western 
blotting (Figure 6.5). Two different PD K  knockdown clones (clone 3 and 8 (Figure 6.5)) 
were selected for the in vivo experiments along with a control monoclonal cell line that had 
been infected with an empty cassette pSuper Retro and a non infected polyclonal cell line 
expressing GFP-MLC alone. These cell lines were then used for generation o f xenograft 
tumours in nude mice and imaged using intravital multi-photon microscopy to analyse their 
morphology and motile behaviour.
160






Figure 6.5 Testing monoclonal shRNA A375 cell lines for 
depletion of PDK1. Once colonies had formed following 
selection with G418, single cells clones were picked and 
grown in 6 well plates. Their expression of PDK1 was 
subsequently tested by western blotting. Clone 3 and clone 8 








Figure 6.6 Western blot analysis of tumour lysates. A375 cells 
stably expressing GFP-MLC and also stably expressing pSuper 
retro shRNA constructs containing either control empty cassettes 
or PDK1 targeting cassettes were used to generate sub-cutaneous 
tumours in nude mice. Following imaging tumours were dissected 
out and homogenized in lysis buffer. Protein content was 
determined by bradford assay. Tumour lysates were then analysed 
by western blot to determine that PDK1 levels were stably depleted 
in vivo.
6.3.2 Depletion of PDK1 is maintained in vivo
Cells within the xenograft tumours were visualised by their expression o f GFP-MLC. 
Tumours o f A375 cells depleted o f PDK1 grew at similar rates and reached 4-6 mm in 
diameter in about 3 weeks, similar to the controls (Figure 6.7). This was not unexpected at 
no differences in proliferation had been seen in vitro. Xenograft tumours were dissected 
after they had been imaged and stored at —80 °C until the imaging o f all the tumours had 
been completed. Tumour samples were then homogenised in lysis buffer and the protein 
content was determined by Bradford assay. Equal amounts o f tumour derived proteins were 
then analysed by western blotting to ensure that PDK1 levels remained depleted in tumours 
at the time o f imaging (Figure 6.6). The results showed that PDK1 was depleted in 4 
knockdown tumours compared to 4 control tumours, albeit less effectively in tumour 
number 4. (PDK1 knockdown tumours o f clone 3 and clone 8 cells were tested for PDK1 
expression). Equal loading was determined by ponceau staining.
6.3.3 Quantification of cell morphology in primary tumours
Cells within PDK1 depleted tumours appeared more elongated than controls, this was 
similar to what had been observed and quantified in 3D in vitro environments (Figure 6.8). 
To quantify cell morphology in vivo, still images from the intravital multi-photon 
microscopy were used and the area and perimeter o f these cells were measured manually 
using Volocity software. Over 400 controls cells were compared to over 400 PDK1 
knockdown cells from a variety o f different areas from 4 different mice, using the same ratio 
o f area to perimeter as had been used previously. Results showed that PDK1 depleted cells 
were significantly more elongated/protrusive than control cells (p<0.001) (Figure 6.9). This 
is in agreement with the result from the initial siRNA screen and the subsequent detailed 
morphological analysis in vitro.
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Figure 6.7 Growth of A375 GFP MLC xenograft tumours in 
nude mice. Shown above are measurements of 5 examples of 
control tumours and PDK1 depleted tumours. Tumours growth 
was measured and recorded every 2-4 days by the biological 
resources unit staff. Graphs show the maximum measured 




Figure 6.8 Cell morphology o f A375 GFP-MLC tumours in vivo.
Images of subcutaneous tumours in live nude mice. Tumours are 
imaged using multi-photon confocal microscopy. Cells expressing 
GFP-MLC are shown in green. Collagen fibres are shown in red and 
are imaged using second harmonic signal. Scale bar indicates 50 
pm (images are from tumours imaged by Erik Sahai)
0J . 1-------
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Figure 6.9 Quantification of cell morphology in vivo. A375 
GFP-MLC subcutaneous tumours were analysed. Upper graphs 
shows cell morphology as quantified by the ratio 
(perimeter)2/(2TTarea). Cells were drawn around manually and 
perimeter and area were calculated using Volocity software. Over 
400 cells were analysed for each condition. ** indicates p<0.001 
(Mann Whitney U test).
6.4 PDK1 depleted tumours show reduced cell motility in vivo
6.4.1 Quantification of cell movement events in primary tumours
A375 cells in xenograft tumours were visualised by their expression o f GFP MLC as above. 
The first observation was that A375 cells within the tumour are mosdy non-motile. Only 
approximately 1 % o f imaged cells were able to move.
20 different areas from 4 mice growing control tumours and 4 mice containing PDK1 
depleted tumours were analysed. The mean number o f movement events observed in control 
tumours was approximately 3 (per mm2, per hour), which is similar to the control data for 
the tumours treated with PBS in the previous analysis (Figure 6.1). These data sets are slighdy 
complicated to analyse as they are not normally distributed, and many tumour areas showed 
no motility at all in the period o f imaging. Despite the large variation in cell motility between 
different areas o f control tumours, it was clear that PDK1 depleted tumours showed much 
less cell motility (Figure 6.10). The average number o f movement events in PDK1 deleted 
tumours was less than 0.5 (per mm2, per hour), around 6 fold less than in the controls. Many 
imaged areas o f PDK1 depleted tumours showed no movement events at all, and areas with 
many cells moving within the same area were never observed (please see accompanying 
supplementary movies for examples o f cell motility in vivo).
6.4.2 Analysis of different types of cell movement
In control tumours, over half o f all movement events were classified as rapid amoeboid 
movement, compared to just a quarter o f movement events in PDK1 depleted tumours 
(Figure 6.11). The majority o f movement events in PDK1 depleted tumours fell in the 
elongated/protrusions category, a larger proportion than in the control tumours (~40%). 
Chaotic/blebbing motility was the least common type o f cell motility in both control 
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Figure 6.10 Quantification o f cell m otility in vivo. A375 GFP- 
MLC subcutaneous tumours were analysed, graph shows 
quantification of cell movements from over 20 different areas of 
tumours from 4 control and 4 PDK1 knockdown tumours. Data is 
normalised to movements events per mm2 per hour. ** indicates 
p<0.001 Mann Whitney U test. Please see supplementary movies for 
examples of cell motility in vivo.
Control PDK1 KD
0
|  Rapid amoeboid movement 
|  Elongated/ protrusions
]  Chaotic/blebbing motility
|  Movement within tumour
Movement into matrix
Figure 6.11 Analysis of types of cell motility observed in 
A375 tumours in vivo. Cell movement events were classified in 
the categories above depending on the type of cell movement and 
whether this movement was observed within the tumour or moving 
away from the tumour into the surrounding matrix.
Even though there was a significant reduction in overall cell motility, there was an even 
higher proportional difference in the numbers o f cells exhibiting rapid amoeboid motility. 
This further indicates that PDK1 is specifically required for amoeboid cell movement, and 
that cells lacking PDK1 are still capable of extending protrusions. These data are similar to 
the results from the ROCK inhibitor treated tumours as it was also found that ROCK was 
specifically required for amoeboid cell motility. However the Y27632 treated tumours 
showed a slight increase in elongated cell movement and this is not seen in the PDK1 
depleted tumours.
Movement events were also sub-categorised depending on whether the movement event was 
within the primary tumour and between other non-motile cells, or whether the motile cells 
were moving outside o f the tumour mass and into the surrounding matrix (Figure 6.11). In 
control tumours, cell motility was observed both within the bulk o f tumour cells and also 
within the surrounding matrix. In PDK1 depleted tumours there was a proportional decrease 
in the cell movement events into the surrounding matrix. This decrease correlates with the 
decrease in rapid amoeboid movement, suggesting that the rapid amoeboid movement is the 
type o f cell motility required to break away from the primary tumour and invade the 
surrounding matrix successfully.
6.5 PDK1 depleted cells are less able to colonise lungs and 
form metastases
6.5.1 Lung colonisation of A375 cells
To determine whether the reduced cell motility that had been observed in PDK1 depleted 
cells in vitro and in vivo might also impact the overall metastatic potential o f these cells, the 
ability o f A375 cells to colonise the lungs o f mice was determined. lxlO 6 GFP-MLC A375 
cells (control or stably PDK1 depleted as previously described) were injected into the tail 
vein o f nude mice in 100 pi PBS. After 4 weeks, the lungs o f these mice were removed and 
the number o f metastases was determined by fluorescence imaging. After 4 weeks we found 
that very few metastases had begun to form, and in most mice, no metastases were found 
(Figure 6.12). It may be because A375 cells are not able to survive transit in the blood 
circulation. This was surprising considering that published data had shown that A375 cells 
should be capable o f  colonising the lungs 66. Perhaps the A375 cells we used for these
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experiments were altered from the originally described cell lines due to time in cell culture 
conditions. Although this experiment did not yield statistically significant results, there were 
no metastases at all in any o f the mice injected with PDK1 depleted cells, suggesting that this 
might be worth investigating further.
The ability o f A375 cells to lodge in the lungs and extravasate was compared in a short-term 
assay. Control and PDK1 depleted A375 cells were labelled with either red or green cell 
tracking dyes and mixed in equal numbers before injection into the tail vein o f nude mice. As 
an internal control, control cells were dyed both red and green then mixed and injected as 
above. This would indicate if there were any effects o f the different dyes on the ability o f 
cells to extravasate, lodge and survive in the lungs, or whether there was any bias in which 
colour cells were more visible and therefore counted more often. 4 hours after i.v. injection, 
the lungs were removed and imaged as above (Figure 6.12). The ratio o f PDK1 depleted cells 
to control cells was counted and calculated for each o f 20 20X fields, then averaged and 
standardised to control vs. control, to account for differences in detecting red or green cells. 
The actual value for control versus control was 1.12, showing that they are roughly equal as 
would be expected. Observing cells at a 4 hour time point meant that there were more cells 
to count and it was therefore possible to determine whether any differences were statistically 
significant. In mice injected with a mixture o f control and PDK1 depleted cells, there was a 
smaller number o f PDK1 cells than control cells per field, although the reduction was only 
marginal, and the numbers o f cells were relatively small, it was statistically significant 
(p<0.05).
6.5.2 Short-term lung metastasis assay MTLn3E cells
To see whether PDK1 could affect the extravasation and lung colonisation in other cell lines, 
the short-term lung metastasis assay was repeated using MTLn3E cells that are more 
effective at colonising the lungs than A375 cells. The MTLn3E cells were stably expressing 
the membrane labels CAG-gap Cherry, or CAG-gap eGFP, and were then transiently 
transfected with either non-targeting control siRNA oligos or PDK1 targeting siRNA oligo
2. The two different coloured MTLn3E cells were mixed in equal numbers and lxlO6 cells 
were injected into the tail vein o f nude mice in 100 pi PBS. To ensure no bias from the 
different sensitivity o f  the different fluorescent labels, the experiment was performed both 
ways around, with the control cells labelled green or red on different occasions. 2 hours after
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injection half o f the mice were culled and their lungs were imaged (Figure 6.14). At this time 
point equal numbers o f both control and PDK1 depleted cells were observed in the lungs 
and they appeared to be localised in small capillaries. However after 24 hours, significantly 
more control cells than PDK1 depleted cells had entered the lung tissue; the ratio o f control 
to PDK1 depleted cells was around 7:3.
The colonisation o f the lung assays suggested that PDK1 also played a role in other stages of 
the metastatic process. It is difficult to determine the exact role as successful colonisation of 
the lungs might require several factors such as survival in the blood stream, cell motility for 
extravasation, and also survival in a new host tissue. These mechanistic issues remain 
unanswered at present.
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Cell line injected I.V. repeat Number of 
lung mets.
A375 GFP-MLC parental polyclonal 1 1
2 1
3 0
A375 GFP-MLC pSuper control clone 1 1
2 0
3 0
A375 GFP-MLC pSuper PDK1 shRNA 1 0
clone 3 2 0
3 0
A375 GFP-MLC pSuper PDK1 shRNA 1 0
clone 8 2 0
3 0
Figure 6.12 Number of lung metastases arising 4 weeks following 
tail vein injection of A375 cells. 1 x 106 A375 cells stably expressing 
GFP-MLC and pSuper retro containing either an empty control 
cassette or PDK1 targeting cassette were injected in 100pl PBS into 
tail veil of nude mice. 3 mice were used for each cell line tested. 4 
weeks following injection mice were sacrificed, the lungs were 
removed and imaged to determine the number of lung metastases 
arising.




Figure 6.13 Comparison of the ability of A375 cells to lodge and 
extravasate into lungs in short term assay. A375 cells stably 
expressing GFP-MLC and pSuper retro containing either an empty 
control cassette or PDK1 targeting cassette were labeled with either 
cell trackers dyes SNARF1 or CFSE in suspension in vitro. Equal 
numbers of control and PDK1 KD cells were mixed and a total of 1 x 
106 were injected in 100pl PBS into tail veil of nude mice. Control 
(green) mixed with control (red) was used to standardise differences 
between the sensitivity of the dyes. The ratio of control cells to test 
cells is shown in the graph, normalised to control versus control 
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Figure 6.14 Analysis of the ability of MTLn3E cells to colonise 
the lungs following i.v. injection. MTLn3E cells labeled with either 
GFP or Cherry were transiently transfected with either control 
siRNA(GFP) or PDK1 targeting siRNA(Cherry). The two populations 
were mixed in equal numbers and 500 000 cells were injected into 
the tail vein of nude mice. The lungs were dissected at 2 and 24 
hours and the numbers of GFP and Cherry cells were compared. 
Scale bar indicates 50 microns.
7 Chapter 7 - PDK1 regulates ROCK1 localisation 
independently of PDK1 kinase activity
7.1 Chapter Summary
Having determined that PDK1 was required for the regulation o f cortical F-actin and 
rounded cell morphology, and furthermore that PDK1 depletion significantly reduced cancer 
cell motility both in vitro and in vivo, it was then interesting to continue this investigation to 
try to elucidate a mechanism through which PDK1 was causing these effects.
As amoeboid cell motility has been previously reported to be dependent on signalling 
through Rho GTPases and their effectors ROCK1 and ROCK2 154, the effect o f PDK1 on 
this pathway was investigated. It has also been shown that the phosphorylation o f MLC is 
controlled by Rho and RO CK in A375 cells (see chapter 5 — siRNA screen results) 17°. Cells 
lacking PDK1 were defective in their ability to correctly localise and phosphorylate MLC so 
the interaction between PDK1 and the R ho/R O C K  signalling pathway was investigated. It 
was found that PDK1 was not required for RhoA activation, but that PDK1 was required 
for the correct membrane localisation o f ROCK1. PDK1 did not alter ROCK kinase activity 
and furthermore PDK1 kinase activity was not required for PDK1 to regulate ROCK1 
suggesting that ROCK1 is not a PDK1 substrate. However it was discovered that PDK1 
does directly bind to ROCK1 utilising a sequence in the hydrophobic m otif o f ROCK1. It is 
therefore suggested that PDK1 regulates amoeboid motility by acting as a scaffold and 
promoting the localisation o f  ROCK1 at the cell periphery where ROCK is able to co­
ordinate contractile forces around the cell cortex, promoting cell blebbing and allowing 
amoeboid motility.
7.2 PDK1 regulates MLC organisation and phosphorylation in 
A375 cells
7.2.1 Depletion of PDK1 causes mislocalisation of pMLC
Contractile forces require polymerised actin to incorporate myosin in non-muscle cells. The 
limiting step in this process is the phosphorylation o f the myosin light chain, which
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completes the machinery and allows contraction 165. Having seen that depletion o f PDK1 
disrupted the cortical actin organisation and the ability o f amoeboid cells to contract and 
form membrane blebs, the effect o f PDK1 on the phosphorylation o f myosin light chain 
(MLC) was examined. A375 cells were transfected with either control or PDK1 targeting 
oligos and then plated on collagen/matrigel gels. The localisation o f phosphorylated myosin 
light chain was determined by I.F. using antibodies against both the single (SI 9) and double 
(T18S19) phosphorylated forms (Figure 7.1). In control cells both pMLC and ppMLC are 
localised around the cell cortex in a similar arrangement to what was observed for actin 
staining. Both actin and pMLC were seen in the cell cortex but were not present in blebs that 
appeared to be comprised o f mostly membrane and little actin. When PDK1 was knocked 
down, the cell became more elongated and pM LC/ppM LC was no longer efficiently 
localised to the cell cortex. pMLC and ppMLC were more diffusely localised in the 
cytoplasm or in patches at the tips o f protrusions (Figure 7.1). The total levels o f 
pM LC/ppM LC also seemed reduced overall compared to the controls. The reduction and 
mislocalisation o f MLC could explain the less contracted cell morphology and reduced 
blebbing motility observed.
7.2.2 Depletion of PDK1 causes reduction in levels of pMLC in both 
2D and 3D culture conditions
The I.F. analysis o f MLC suggested that the phosphorylation o f MLC was impaired when 
PDK1 was knocked down. A375 cells plated on collagen/matrigel and depleted o f PDK1 
were analysed by western blot for levels o f pMLC (SI 9). As seen by I.F., western blot 
analysis confirmed that pMLC was indeed reduced by 60-70 % in PDK1 depleted cells 
compared to controls (Figure 7.2). Reduced pMLC could either be a cause or a consequence 










Figure 7.1 Immunofluorescence showing pMLC and ppMLC 
are mislocalised when PDK1 is depleted. A375 cells were 
transfected with either control or PDK1 targeting siRNA prior to 
plating cell on 3D matrix. 24 hours later cells were fixed and 
stained for pMLC and ppMLC. Scale bar indicates 50 pm.
pMLC/MLC 1 0 .34  0.25 1 0.4 0.63
Figure 7.2 MLC phosphorylation is reduced when PDK1 is 
depleted. Western blot analysis of A375 cell lysates taken from 
both 2D and 3D culture. For 3D conditions, cells were plated 
onto a layer of collagen/matrigel matrix similar to that used for 
the analysis of morphology. Cells lysates were used to determine 
the levels of pMLC. The ratios of pMLC/total MLC were 
calculated by measuring densitometry and are shown beneath 
the blots.
To answer this question, levels o f pMLC were analysed in A375 cells plated on a 2D 
substrate where no change in morphology is observed when PDK1 is depleted. Even in the 
absence o f changes in cell morphology there is a still approximately a 50% reduction (Figure 
7.2) in levels o f pMLC meaning that reduced phosphorylation o f MLC is likely to be an 
initiating event and the probable cause o f the changes in morphology seen when cells are on 
3D deformable microenvironments.
7.3 Deletion of PDK1 does not impair activation of Rho A
P D K l could be signalling to contractile machinery by interfering with the activation o f 
RhoA. To test this the levels o f RhoGTP were measured in A375 cells. A375 cells were 
plated onto cell culture dishes and transfected with either control or PD K l siRNA oligos. 
Cells were serum starved for 12 hours then stimulated with 20 % serum for 5 minutes. Cell 
lysates were taken from these cultures and the lysates were incubated with GST-RBD 
Rhotekin to pull down the active, GTP-bound RhoA. Under these conditions there was no 
obvious decrease in the levels o f active RhoA. If  anything there was a slight increase in active 
RhoA when PD K l was depleted (Figure 7.3). This means that insufficient activation of 
RhoA is not the cause o f the elongated morphology and reduced cell motility that is 
observed when PD K l is depleted. So that even with high levels o f activated RhoA, signalling 
downstream, leading to contractility, is disturbed when PD K l is depleted.
7.4 ROCK1 localisation is altered when PDK1 is depleted
7.4.1 Over-expression of ROCK1 and ROCK2 in PDK1 depleted ceils
A375 cells when plated on a rigid 2D substrate such as glass appear as spread cells with some 
stress fibres. When ROCK is over expressed the contractile forces in the cell are increased 
and are able to overcome the adhesions holding the cell flat. This causes the cell to become 
rounded and exhibit membrane blebs. The function o f ROCK kinases can be tested using 
this assay (as described in chapter 3). As it had been seen that the activation o f RhoA was 
not inhibited when P D K l was depleted, the effect o f PD K l depletion on the ability o f 





Figure 7.3 RhoA activation in A375 cells depleted for PDK1.
A375 cells were transfected with either control, PDK1 targeting 
siRNA and plated onto 10cm cell culture dishes. 48 hours 
following transfection cells were serum starved over night then 
serum stimulated for 5 minutes. Cell lysates were incubated with 
glutathione agarose beads bound to GST rhotekin RBD to pull 
down GTP-bound RhoA. Results of pull downs were analysed by 
western blot and levels of RhoA GTP were compared to levels of 
total RhoA in the cell lysate.
R0CK1 R 0C K 2
G FP R0CK1 PDK1 siRNA R 0C K 2 PDK1 siRNA
Figure 7.4 PDK1 is required for ROCK1 membrane localisation 
and ROCK1 driven membrane blebbing in A375 cells. A375 
cells were transfected with either control or PDK1 targeting siRNA. 
24 hours later cells were transfected with myc-ROCK1 or ROCK2 
constructs. 24 hours later cells were fixed and stained with 9E10 
and FITC phalloidin. Scale bar indicates 20 pm.




Figure 7.5 PDK1 is required for ROCK1 membrane localisation 
and ROCK1 driven membrane blebbing in A375 cells. A375 cells 
were transfected with either control or PDK1 targeting siRNA. 24 
hours later cells were transfected with myc-ROCK1 and plated onto 
3D collagen/matrigel matrix. 24 hours later cells were fixed and 
stained with 9E10 and FITC phalloidin. Scale bar indicates 20 pm.
Transfection o f either ROCK1 or ROCK2 resulted in membrane blebbing in approximately 
60% o f A375 cells transfected with control siRNA, compared to around 10% o f A375 cells 
transfected with GFP as a control (Figure 7.4, 7.5, 7.6). However the ability o f ROCK1 to 
cause membrane blebbing was dramatically reduced when A375 cells had previously been 
transfected with siRNA oligos targeting P D K l. Interestingly, the ability o f ROCK2 to cause 
membrane blebbing and cell contraction was unaffected by the depletion o f PD K l (Figure 
7.4, Figure 7.6). In control cells, the over-expressed myc-ROCKl was mostly localised at the 
plasma membrane and this localisation correlated with the phenotype o f membrane 
blebbing. When PD K l was absent, the over-expressed myc-ROCKl was localised either in 
the cytoplasm or in unidentified puncta within the cell, which may be a kind o f vesicle. 
Interestingly, even though membrane blebbing was reduced in the absence o f P D K l, the 
generation o f thick actin stress fibres was still observed (Figure 7.4), which indicated that 
although the localisation o f ROCK1 is altered in the absence o f P D K l, it is retaining some 
activity.
The same assay was carried out in A375 cells plated on collagen/matrigel gels to determine 
how the rigidity o f the matrix affected the cell morphology o f cells over-expressing 
ROCK1 (Figure 7.5). Over-expression o f  myc-ROCKl in these conditions causes very 
dramatic cell blebbing, perhaps because the matrix is deformable, the result o f increased 
contractile forces is more readily converted to cell rounding, whereas on rigid substrates, 
contraction is mostly seen as increases in tension and thickening o f stress fibres. When myc- 
R O CK l was over expressed in A375 cells depleted o f PD K l plated on collagen/matrigel 
matrix, the cells still remained elongated and actin filaments ran from one end to the other, 
indicating the lack o f contractile forces when PD K l is absent. Numerous actin rich 
filopodium-like structures were also observed (Figure 7.5).
7.4.2 Localisation of endogenous ROCK1 is altered in the absence of 
PDK1
To test whether P D K l also regulated the localisation o f endogenous ROCK1, A375 cells 
transfected with a control siRNA or PDK1#1 siRNA plated on glass coverslips were fixed 
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Figure 7.6 Quantification of phenotypes of myc-ROCK1 and 
myc-ROCK2 over-expressed in A375 cells transfected with 
either control or PDK1 siRNA oligos. A375 cells were 
transfected with either control or PDK1 targeting siRNA. 24 
hours later cells were transfected with myc-ROCK1 or ROCK2 
constructs. 24 hours later cells were fixed and stained with 
9E10 and FITC phalloidin. Cells were counted and allocated 
into categories for f-actin organisation and ROCK construct 
localisation as described in figure 3.6. ** indicates p<0.001 (Chi 
squared tests).




Figure 7.7 PDK1 is required for membrane localisation of 
endogenous ROCK1. A375 cells were transfected with either 
control of PDK1 targeting siRNA oligos and plated onto glass 
cover slips. 48 hours later cells were fixed and stained with an 
antibody against endogenous ROCK1 and FITC phalloidin. Scale 
bar indicates 20 pm.
Endogenous ROCK1 localised in the cell periphery in control transfected cells. This 
peripheral localisation was reduced in A375 cells transfected with PDK1#1 siRNA. As noted 
previously, knockdown of PD K l in A375 cells on rigid substrates did not alter cell 
morphology. Similar analysis o f the localisation o f endogenous ROCK1 in A375 cells plated 
on deformable collagen/matrigel matrix was carried out by Erik Sahai and it was shown that 
under these conditions endogenous ROCK1 was also localised to the cell periphery and 
colocalised with a membrane marker 233.
7.5 ROCK1 is unable to co-ordinate contractile forces and cell 
motility in the absence of PDK1
7.5.1 GFP-ROCK1 localises at the rear of blebbing cells to coordinate 
motility
To gain dynamic insight into how the localisation o f ROCK1 co-ordinates contractile forces 
and membrane blebbing, GFP-ROCK1 was transfected into A375 cells plated on 
collagen/matrigel matrix, and these cells were then imaged individually by confocal 
microscopy (Figure 7.8). In control cells where PD K l expression was not altered, GFP- 
ROCK1 localised to the plasma membrane and membrane blebbing was observed. The 
contractile forces cause large blebs to be rapidly formed and as a result the cell body was 
translocated at speeds o f up to 5 microns per minute. Although the cells imaged were rapidly 
changing direction, during translocation in any direction, GFP-ROCK1 accumulated at the 
back o f the cell as shown in the kymograph in Figure 7.8 (see also supplementary movie 7.8).
When P D K l was depleted, A375 cells were elongated as had been previously seen. In PD K l 
depleted cells, GFP-ROCK1 was distributed in the cytoplasm and sometimes at the cell 
periphery, however the over-expression o f GFP-ROCK1 did not cause the cells to bleb as in 
control cells (note examples in Figure 7.8 iii and iv and in the accompanying supplementary 
movies). This corresponds with the results o f over-expressing myc-tagged ROCK1 in A375 




GFP ROCK1 + PDK1#1
Fig 7.8 Dynamic analysis of GFP-ROCK1 localisation in 
control or PDK1 depleted cells. A375 cells were transfected 
with either control of PDK1 targeting siRNA and subsequently 
transfected with GFP-ROCK1. The cells were then plated in a 3D 
matrix and imaged by confocal microscopy at a rate of 1 frame 
every 3 seconds. Highlighted sections indicated slices of the 
image used to generate kymographs in panels ii and iv. Panels iii 
and iv show the range of localisation seen when GFP-ROCK1 is 
expressed in A375 cell depleted of PDK1.
Even in cases where GFP-ROCK1 was localised asymmetrically at the cell periphery, this did 
not result in translocation o f the cell body (shown in kymograph in Figure 7.8). These results 
confirm that PD K l is required for the correct localisation of ROCK1 and that when 
ROCK1 is not correctly localised, it is not able to coordinate contractile forces for amoeboid 
movement.
7.6 PDK1 does not alter ROCK1 kinase activity
Results have indicated that PD K l is required for the correct localisation and function of 
ROCK1. ROCK1 is a member o f the AGC family o f kinases and other members o f this 
family such as PK B /A kt have been shown to be phosphorylated by PD K l in the activation 
loop and /o r the hydrophobic motif. One possibility is that PD K l is required to modify 
ROCK1 to activate ROCK1 kinase activity. Although results from chapters 3 and 4 show no 
data to support the hypothesis that ROCK1 is phosphorylated in either the activation loop 
or the hydrophobic motif, results in this chapter suggested that it was worth testing in an 
additional assay.
7.6.1 Effect of addition of PDK1 to ROCK1 kinase activity
To confirm that P D K l did not regulate ROCK1 by activating ROCK1 kinase activity, 
recombinant ROCK1 was used to phosphorylate recombinant MLC either with or without 
the addition o f exogenous PD K l (Figure 7.9). I f  PD K l was able to modify ROCK1 and 
increase its kinase activity then this could explain the reduction in cell contraction and 
blebbing when P D K l was depleted. However the addition o f PD K l did not alter the kinase 
activity o f RO CK 1. Furthermore, we were unable to detect any phosphorylation o f ROCK1 
by PD K l in this assay, although PD K l was able to strongly phosphorylate Akt under these 
conditions and so was active (Figure 7.10) (see also chapter 4 Figure 4.4).
7.6.2 Endogenous I.P. kinase assay
To confirm the results o f  the above experiments, it was tested whether the depletion of 
PD K l affected the kinase activity o f endogenous ROCK1. Endogenous ROCK1 was 
immunoprecipitated from A375 cells transfected with either control non-targeting oligos, or 
PD K l targeting oligos (Figure 7.11). The isolated kinase was then used to phosphorylate 
recombinant MLC in vitro.
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ROCK1 + + + +
Y27632 - + - +
PDK1 - - + +
32P MLC
Figure 7.9 Recombinant ROCK1 does not have altered 
kinase activity in vitro in the presence of exogenous PDK1.
Recombinant ROCK1 was used to phosphorylate recombinant 
MLC in vitro in the presence of 32P-labelled ATP. The addition 
of recombinant PDK1 to the reaction did not alter the ability of 
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Figure 7.10 In vitro kinase assay showing the effect of 
addition of PDK1 on ROCK kinase activity. Recombinant PDK1 
and ROCK1 were used to phosphorylate recombinant substrates 
(Akt/PKB, RhoE,). Degree of phosphorylation is shown by the 
incorporation of 32P ATP. Total protein is shown by coomassie 
stain.
ROCK1
Figure 7.11 Endogenous I.P. kinase assay. ROCK1 
phosphorylating recombinant MLC. Endogenous ROCK1 was 
immune precipitated from A375 cells which had been transfected 
with either control siRNA or PDK1 targeted siRNA. Endogenous 
ROCK1 was then used to phosphorylate recombinant MLC in 
vitro. Degree of phosphorylation was determined by the degree 
of incorporation of 32P ATP.
There was perhaps a subtle decrease in kinase activity o f ROCK1 to phosphorylate the 
substrate MLC when the kinase had been purified from cells depleted o f P D K l, but this was 
almost undetectable in most repeats o f this experiment, and it was unlikely that PD K l was 
regulating ROCK kinase activity. This suggested that the loss o f the rounded, blebbing 
phenotype was not caused by loss o f ROCK kinase activity, but more likely a loss o f 
membrane localisation, or a loss o f activity only at the plasma membrane. ROCK1 can be 
active within cells and yet not able to co-ordinate blebbing motility. This is also the case 
when truncated ROCK1 is transfected into cells (see chapter 3). In vitro, truncated ROCK1 
(1-727 a.a.) is more active that the wild type, but because it has no Rho-binding domain and 
cannot localise to the membrane, it remains in the cytoplasm and is only able to induce stress 
fibres instead o f membrane blebbing. The generation o f stress fibres and the lack o f blebbing 
is also observed in cells over-expressing ROCK1 in the absence o f PD K l.
To this point there is no evidence that PD K l regulates the kinase activity o f ROCK1, and 
there is also no evidence that ROCK1 is a substrate o f PD K l for modification by 
phosphorylation.
7.7 PDK1 kinase activity is not required for the regulation of 
ROCK1
7.7.1 Rescue of ROCK-driven cell blebbing with FLAG-PDK1 mutants
When PD K l has been depleted from A375 cells, over-expressed ROCK is less able to drive 
contraction o f the acto-myosin cortex and cause membrane blebbing. To rescue this loss o f 
ROCK function, myc-ROCKl was co-transfected with siRNA resistant FLAG-tagged 
PD K l constructs into cells depleted o f PD K l. WT, KD, and also PH-deleted PD K l 
constructs were compared to gain insight into which properties o f PD K l were required for 
PD K l to regulate ROCK1 (Figure 7.12).
Cells depleted for P D K l and expressing both myc-ROCKl and either WT or KD  FLAG- 
PDK1 were able to exhibit membrane blebbing similar to that observed when ROCK1 alone 
was over-expressed in cells still expressing endogenous PD K l. Only the mutant PD K l in 
which the PH domain had been deleted was unable to rescue the membrane blebbing when 
co-expressed with ROCK1 (Figure 7.12).
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Figure 7.12 The effect of expression of siRNA resistant PDK1 
to rescue the blebbing phenotype of ROCK1 expressed in 
PDK1 depleted A375 cells. A375 cells were transfected with 
either control or PDK1 targeting siRNA sequences. Subsequently 
they were then transfected with myc-ROCK1 either alone or in 
combination with siRNA resistant Flag-PDK1 constructs (WT, KD, 
PH deleted). 48 hours after DNA transfection, cells were fixed and 
stained with JAK6 and anti-Flag. The phenotypes of cells 
expressing both constructs were classified using the f-actin 
categories described previously. ** indicates p<0.001 (Chi- 
squared test).
7.7.2 Rescue of cell morphology with siRNA resistant FLAG-PDK1 
mutants
To test whether siRNA resistant PD K l could rescue the defects in cortical acto-myosin 
contraction controlled by endogenous ROCK, siRNA resistant FLAG-tagged PD K l was 
transfected into A375 cells 24 hours after they had been transfected with siRNA against 
PD K l (Figure 7.13). A375 cells plated on collagen/matrigel and depleted o f PD K l were 
mosdy elongated as had been previously seen. It was found that both WT and KD PD K l 
were able to revert A375 cells plated on collagen/matrigel matrix to a rounded morphology 
with membrane blebs. eG FP was transfected as a control and as expected expression o f this 
construct did not change the cell morphology, and PD K l depleted cells remained elongated 
(Figure 7.13, Figure 7.14). This experiment shows that kinase activity o f PD K l is not 
required for P D K l to regulate endogenous ROCK1.
7.8 PDK1 and ROCK1 co-localise at the cell periphery
Having found that P D K l did not regulate the kinase activity o f ROCK1 but required its PH 
domain, and therefore presumably its membrane localisation, to regulate ROCK1 it was next 
tested whether ROCK1 and PD K l co-localised. To test the hypothesis that PD K l could 
regulate ROCK1 at the plasma membrane, A375 cells plated on 2D and expressing both 
myc-ROCKl and FLAG-PDK1 were stained with antibodies against their specific tags and 
imaged by confocal microscopy (Figure 7.15). Analysis if the immune fluorescence showed 
that the localisation o f  ROCK1 and PD K l overlaps at the cell cortex and around the cell 
periphery. This was also true for kinase dead PD K l. However PH-deleted PD K l was 
localised in the cytoplasm and did not overlap with ROCK1 localisation at the plasma 
membrane. In this case the over-expressed ROCK1 is at the plasma membrane presumably 
interacting with endogenous PD K l that was still present in these cells. The degree o f co­
localisation was analysed using Zeiss LSM510 image examiner software and pixels with high 
intensity o f both myc and FLAG staining are show in the right hand panel o f Figure 7.15.
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Figure 7.13 Phenotypic rescue by expression of SIRNA 
resistant FLAG-PDK1 constructs. A375 cells were transfected 
with PDK1 targeting siRNA oligo sequences and plated on to 3D 
collagen/matrigel matrix. Subsequently they were then transfected 
with GFP or Flag-PDK1 constructs resistant to siRNA. 24 hours 
following DNA transfection cells were fixed and stained with anti- 
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Figure 7.14 Expression of siRNA resistant PDK1 constructs 
are able to restore rounded cell morphology to A375 cells 
depleted of PDK1. A375 cells were transfected with PDK1 
targeting siRNA oligo sequences and plated on to 3D 
collagen/matrigel matrix. Subsequently they were then transfected 
with Flag-PDK1 constructs resistant to siRNA. 24 hours following 
DNA transfection cells were fixed and stained with anti-Flag and 
TRITC phalloidin. The phenotype of cells expressing Flag-PDK1 
constructs was classified as rounded, intermediate or elongated. 
Graph shows pooled data from 3 independent experiments, each 









Figure 7.15 Flag-PDK1 and myc-ROCK co-localise at the cell 
periphery. A375 cells were co-transfected with myc-R0CK1 and 
Flag-PDK1 constructs. Cells were fixed and stained with JAK6 
and anti-FLAG antibodies. Co-localisation was determined by 
analysis with LSM 510 software. Scale bar indicates 20 |jm.
Flag-PDK1 WT Flag-PDK1 KD Flag-PDK1 APH
7.9 PDK1 directly binds to ROCK1
Finding that PD K l and ROCK1 are both required to be localised at the plasma membrane 
in order for PD K l to positively regulate ROCK1, it was next tested whether PD K l and 
ROCK1 were able to interact and form a complex. Even though there was no evidence that 
ROCK1 was a PD K l substrate, P D K l may still direcdy or indirecdy act to help maintain 
membrane localisation o f ROCK1 by binding and acting as a scaffold.
The hydrophobic region o f ROCK1 was tested for binding to PD K l as sequence analysis on 
Scansite, had predicted a potential P D K l binding site centred on T398 o f ROCK1 (chapter 3 
shows investigations into whether T398 is a regulatory phosphorylation site).
To test whether ROCK1 did bind to PD K l in this region, short fragments o f ROCK1 
hydrophobic m otif were cloned into GST-protein expression vectors. Recombinant protein 
was produced and purified from E. coli and used in an in vitro binding assay with 
recombinant PD K l (Figure 7.16).
It was found that the region o f ROCK1 spanning 338-415 a.a. strongly interacted with 
PD K l in vitro (Figure 7.16). Interestingly the corresponding region o f ROCK2 did not bind 
to P D K l in this assay even though Scansite predicted a similar binding site centred on the 
hydrophobic motif. This was in agreement to previous data in which it was found that 
depletion o f P D K l did not affect the ability o f over-expressed ROCK2 to cause membrane 
blebbing.
The binding region o f ROCK1 was further narrowed down to 375-415 a.a. A GST-fragment 
o f ROCK1 containing 358-380 a.a. did not bind to PD K l (Figure 7.16). This raised the 
question whether P D K l was able to positively regulate ROCK1 through direct binding at 
the plasma membrane thereby promoting ROCK1 signalling at this location.
7.9.1 PDK1 binds equally well to ROCK1 mutated at conserved 
threonine residues in the hydrophobic motif
Having found that P D K l binds directly to ROCK1 using a region that was previously 
investigated in chapter 3 for the presence o f regulatory phosphorylation sites, it was next 
tested whether mutation o f  these sites affected the binding o f PD K l to the ROCK1 
hydrophobic motif. The binding assay above was repeated using GST fragments o f ROCK1
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containing T380A, T398A or both T380A T398A mutations (Figure 7.17). It was found that 
PDK1 bound equally well to all o f the fragments tested and that the mutations introduced 
did not inhibit the interaction between PDK1 and ROCK1.
The region o f ROCK1 required for binding to PDK1 direcdy overlapped with one o f the 
regions o f ROCK1 required for binding to the negative regulator RhoE. RhoE requires both 
375-420 a.a. and also a site in the extreme N-terminus (0-50 a.a.). It was also investigated 
whether PDK1 was able to bind RhoE, and it was found that this was not the case (see lane 
3 in Figure 7.16). Therefore, it was unlikely that PDK1, ROCK1 and RhoE were all able to 
interact in one large complex. As PDK1 and RhoE require the same sequence o f amino acids 
to interact with ROCK1 the next hypothesis to test was whether PDK1 and RhoE compete 
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Figure 7.16 GST-tagged fragments of ROCK1 are able to 
bind recombinant PDK1 in vitro. Recombinant GST fragments 
of ROCK1 were expressed in E.coli and purified. Glutathione 
agarose beads bound to ROCK1 fragments were then incubated 
with recombinant PDK1 in kinase assay buffer without ATP. 
Beads were washed extensively and binding was determined by 
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Figure 7.17 GST tagged fragments of ROCK1 containing T/A 
mutations are able to bind recombinant PDK1 in vitro.
Recombinant GST fragments of ROCK1 were expressed in E.coli 
and purified. Glutathione agarose beads bound to ROCK1 
fragments were then incubated with recombinant PDK1 in kinase 
assay buffer without ATP. Beads were washed extensively and 
binding was determined by western blot. Levels of GST proteins 
are determined by ponceau staining.
8 Chapter 8 - PDK1 regulates cancer cell motility in 3D 
environments by antagonising the inhibition of 
ROCK1 by RhoE
8.1 Chapter Summary
Previous results had indicated that PDK1 was able to regulate the localisation o f ROCK1 at 
the plasma membrane by direcdy binding to a region around the hydrophobic motif of 
ROCK1. The binding domain directly over-lapped with a region o f ROCK1 reported to be 
required for interaction with the negative regulator RhoE. This chapter describes the detailed 
investigation o f the mechanism behind this regulation o f ROCK1. It was found that PDK1 
and RhoE are able to direcdy compete for binding to ROCK1 and that their binding was 
mutually exclusive. Further to this it was also found that exogenous or over-expressed PDK1 
was able to disrupt the interaction o f ROCK1 and RhoE. The final proof o f this mechanism 
was that in A375 cell lines stably depleted o f  PDK1, endogenous ROCK1 was found to be 
bound to endogenous RhoE, and this complex could be isolated by co-immune 
precipitation.
If  the changes in cell morphology and the reduction in cell motility observed when PDK1 is 
depleted, are due to the inhibition and mislocalisation o f ROCK1 by RhoE, then knockdown 
o f RhoE in conjunction with PDK1 should be able to at least partially rescue the phenotype. 
The final part o f this chapter details experiments showing that double knockdown o f PDK1 
and RhoE is able to restore the ability o f over-expressed ROCK1 to localise at the plasma 
membrane and cause membrane blebbing. Furthermore, double knockdown is able to 
restore cortical acto-myosin contraction, which was measured by rounded morphology and 
also the restoration o f phosphorylation o f MLC in the cell cortex. The final experiment was 
able to show that double knockdown o f both PDK1 and RhoE was able to restore cell 
motility to M TLn3E cells.
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8.2 PDK1 directly competes with RhoE for binding to the same 
region of R0CK1
8.2.1 In vitro binding competition assay
To test whether PDK1 and RhoE direcdy competed with each other for the binding to and 
regulating o f  ROCK1, GST-tagged RhoE was used in an in vitro binding assay. Recombinant 
ROCK1 (17-557 a.a.) bound strongly to GST-RhoE, but as increasing concentrations of 
recombinant PDK1 were included in the binding assay, the interaction between GST-RhoE 
and ROCK1 was disrupted (Figure 8.1). The molar concentration o f RhoE was estimated by 
coomassie staining compared to known concentrations o f other proteins o f similar size. 
However the exact amount o f RhoE in the binding assay would vary depending on the 
efficiency o f the pulldown from the bacterial lysate on the day o f the assay. The average 
amount o f GST-RhoE used in each individual binding assay was approximately 1 pg. 0.2 jig 
o f recombinant ROCK1 was added, and this interaction was able to be disrupted with PDK1 
(between 0.6 and 1.2 pg) (Figure 8.1). This is the equivalent o f approximately 1012mol - 20 
12mol PDK1 being able to compete with 2X10 12mol GST RhoE for binding to ROCK1.
8.2.2 RhoE ROCK1 interaction is disrupted by PDK1 in cell lysates
To further test the hypothesis o f a direct competition between PDK1 and RhoE, GST-RhoE 
was used to pull down over-expressed myc-ROCKl from A375 cell lysates (Figure 8.2). The 
interaction o f  GST-RhoE and full-length ROCK1 is poor in this assay; this has also been 
reported by Ridley A. and colleagues 85. This result suggests that under normal conditions 
ROCK1 is not associated with RhoE but is binding to PDK1 instead, at least in the cell lines 
tested here. The binding o f GST-RhoE to myc-ROCKl can be significantly increased when 
PDK1 is depleted from the cell lysates by siRNA (compare lanes 1 and 2 Figure 8.2). This 
can be reversed either by the addition o f recombinant PDK1 to the binding assay (lanes 3 
and 4), as we had previous seen in the in vitro binding assay (Figure 8.1). We were also able 
to reverse the binding o f myc-ROCKl to RhoE by over-expressing siRNA resistant FLAG- 
tagged PDK1 in the A375 cells (lanes 5 and 6).
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Figure 8.1 GST-RhoE binding to recombinant ROCK in 
vitro is disrupted by the addition of PDK1. GST-RhoE, 
bound to glutathione agarose beads was incubated with 
combinations of ROCK1 and PDK1. Binding of ROCK1 to 
GST RhoE was determined by western blot. The input of 
ROCK1 and PDK1 to the binding assay was also 
determined by western blot. Level of RhoE bound to 








Figure 8.2 GST-RhoE is able to bind myc-ROCK1 in A375 
cell lysates depleted of PDK1. GST-RhoE bound to 
glutathione agarose beads was incubated with cell lysate 
form A375 cells transfected with PDK1 targeting siRNA and 
transiently transfected with either myc-ROCK1 alone or in 
combination with siRNA resistant Flag-PDK1. Lanes 3 and 4 
show samples in which recombinant PDK1 was added to the 
cell lysate during incubation with GST RhoE (note slightly 
higher band). Levels of myc-ROCK1 and PDK1 in the lysate, 
and the binding of myc-ROCK1 to GST RhoE were 
determined by western blotting. Levels of GST RhoE were 





Figure 8.3 Endogenous ROCK1 with co-I.P. with 
endogenous RhoE in A375 cells stably depleted of 
PDK1. A375 cell lines stably expressing pSuper 
constructs encoding shRNA against PDK1, or a control 
empty cassette were lysed and endogenous ROCK1 
was immune precipitated. Cell lysates and i.p.s were 
analysed by western blot to check for levels of 
endogenous ROCK1, PDK1 and RhoE.
These results indicate that in A375 cells the competition between PDK1 and RhoE for 
binding to ROCK1 is able to occur, and that the system can be manipulated to sway the 
binding in favour o f  either PDK1 or RhoE by altering the levels o f PDK1 available for 
ROCK1 to interact with.
8.3 In the absence of PDK1 ROCK1 forms a complex with RhoE 
and is inhibited
8.3.1 Endogenous Co-I.P. of ROCK1 and RhoE in PDK1 depleted cells
The final test o f  this hypothesis was to be able to show that the competition between PDK1 
and RhoE was happening in the case o f the endogenous proteins. Using the stably depleted 
A375 cell lines that had been used for the in vivo experiments, it was possible to show that in 
cells depleted o f PD K 1, ROCK1 was complexed and therefore mislocalised and inhibited by 
RhoE. Endogenous ROCK1 was co-immune precipitated with endogenous RhoE, only from 
the A375 cells stably depleted o f PDK1 (Figure 8.3). The two stably depleted cell lines 
shown in this assay contain slightly different amounts o f PDK1 and as a result the amount of 
RhoE complexed with RhoE is also altered. This result is evidence that when PDK1 is not 
available to bind ROCK1 at the plasma membrane, ROCK1 is found in a complex with 
RhoE.
8.3.2 The localisation of ROCK1/RhoE complexes
GFP-RhoE when over-expressed in A375 cells is located mostly at the plasma membrane 
but also on some intracellular membranes (Figure 8.4). Myc-ROCKl over-expressed alone is 
also localised to the plasma membrane as previously shown in chapter 3, 4, and 5. When 
GFP-RhoE is over-expressed, this biases the competition between PDK1 and RhoE in 
favour o f ROCK1 binding to RhoE, as there is more RhoE available. Therefore, similar a 
similar phenotype to depletion o f PDK1 should be observed. A375 cells expressing both 
myc-ROCKl and G FP RhoE were analysed by immune fluorescence (Figure 8.4). Myc- 
ROCK l was no longer membrane localised, and the over-expression o f myc-ROCKl was no 
longer able to induce membrane blebbing. It was also interesting that GFP-RhoE might be 





Figure 8.4 Myc-ROCK1 and GFP-RhoE co-localise in 
membrane puncta/vesicles. A375 cells expressing myc- 
ROCKl and/or GFP-RhoE and plated on glass coverslips 
were fixed and stained with 9E10. A) GFP RhoE expressed 
alone is membrane localised. B) myc-ROCK1 expressed 
alone is membrane localised. C) Confocal imaging 
identified that myc-ROCK1 and GFP-RhoE when 
expressed together, partially co-localised in punctate 
structures or vesicles, as shown in the lower panel by the 
arrow heads. Scale bar indicates 20 pm.
The analysis o f  the localisation o f ROCFCl and RhoE in this assay was useful to be able to 
give an indication o f the regulation o f R O C K 1 when it is not interacting with PDK1 at the 
plasma membrane. Analysis o f the im m une fluorescence showed that ROCK1 and RhoE 
were partially co-localised in puncta (Figure 8.4). Although the nature o f these vesicles was 
unclear, this analysis was able to show th a t  in cases where the cellular concentration o f RhoE 
is higher than the concentration o f P D K l,  that ROCK1 and RhoE are co-localised and 
presumably in a complex as indicated by th e  above in vitro data. The puncta observed in this 
assay are similar to those observed w h en  cells over-expressing ROCK1 are treated with 
LY294002 (see Figure 3.13) or have P D K l depleted.
8.4 Double knockdown of PDK1 and RhoE restores rounded cell 
morphology and amoeboid cell motility
8.4.1 Control of knockdowns by western blotting
If the model that P D K l and RhoE are able to compete for binding to ROCK1 is correct, 
and that in the absence o f P D K l, RO C K 1 is inhibited by interacting with RhoE, then 
knocking down RhoE with siRNA in cells already depleted o f PD K l should partially rescue 
the defects observed. Throughout this w ork , 2 different PD K l siRNA sequences targeting 
different sites in the P D K l gene sequence have been used to verify the phenotypes 
described. It is now  shown that 2 d ifferen t RhoE targeting siRNA sequences are able to 
successfully knockdown a significant p ropo rtion  o f RhoE both when used in isolation and 
also in conjunction with siRNA targeting P D K l. The western blot in figure 8.5 confirms the 
efficient double knockdown.
8.4.2 Rounded cell morphology is restored by double knockdown
A375 cells were used to examine the cell morphology in 3D collagen/matrigel matrix when 
both P D K l and R hoE  were depleted by" siRNA transfection. As had been seen previously, 
knockdown o f  P D K l caused the cells to  become more elongated with long protrusions. The 
ratio o f perimeter2/47tarea was used as previously to measure how round the cell 
morphology was. The closer this ratio is  to 1, the rounder the cell morphology. In some 
cases the ratio was as high as 8 when P D K l was depleted (Figure 5.4). When RhoE was 
knocked down alone, there was not a significant difference in cell morphology compared to 





Figure 8.5 Western blot to show the efficient 
knockdown of PDK1 and RhoE with siRNA oligos.
A375 cells were transfected with combinations of PDK1 
and RhoE targeting siRNA oligos. Efficient knockdown was 

















Figure 8.6 Quantification of rescue of ceil morphology 
when cells are depleted of both PDK1 and RhoE. A375 
cells were depleted of PDK1 or RhoE or a combination of 
both. Cells were then plated on a collagen/matrigel matrix. 
Measurements of area and perimeter were taken from 
>100 cells. The ratio of 4uarea/perimeter2 is shown in the 
form of a box plot, showing min, max, median and 25th 
and 75th percentiles. * indicates p<0.001 (compared to 
the control) Mann Whitney U test.
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Figure 8.7 Morphology of MTLn3E cells. Similar to 
A375 cells, depletion of PDK1 causes elongated cell 
morphology. Double knockdown of PDK1 and RhoE 
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Figure 8.8 Quantification of changes in morphology 
in MTLn3E cells . Measurements of area and perimeter 
were taken from >100 cells. The ratio of 
4Trarea/perimeter2 is shown in the form of a box plot, 
showing min, max, median and 25th and 75th percentiles. 
* indicates p<0.01 (compared to control) Mann Whitney 
U test.
As the A375 cells on the 3D matrix are already mosdy rounded and have high levels o f 
contractile forces, further reduction o f RhoE, a negative regulator o f ROCK-driven 
contraction did not cause any increase in contraction. However when PD K l and RhoE were 
knockdown together, the quantification o f the cell morphology showed that there was no 
significant difference from control cells. This means that double knockdown of PD K l and 
RhoE was able to reverse the changes in cell morphology caused by knockdown o f PD K l 
alone. Looking in detail at the spread o f values (ratio o f perimeter2/47tarea), there are some 
cells transfected with siRNA against both PD K l and RhoE that remain more elongated than 
the controls. So even though the majority are able to become rounded again, it seems that if 
there is still an imbalance between P D K l and RhoE, then the morphology is not completely 
rescued (Figure 8.6). It seems that a very fine balance between these two proteins and their 
effects on ROCK1 determines cell morphology. These results were also seen using MTLn3E 
cells (Figure 8.7, Figure 8.8), and RhoE siRNA was able to make the elongated PD K l 
depleted cells rounder. However knockdown o f RhoE alone also caused some disruption o f 
rounded cell morphology in M TLn3E cells, which was not expected. It must be concluded 
that although A375 and M TLn3E cells share many mechanisms to regulate cortical F-actin 
and amoeboid cell motility, there are still differences that we do not yet understand.
8.4.3 Double knockdown restores cortical actin organisation and 
MLC phosphorylation
To look at whether the regulation o f cortical acto-myosin network was restored, A375 cells 
transfected with siRNA targeted against P D K l, RhoE or both together were plated onto 3D 
collagen/matrigel matrix and then fixed and stained for ppMLC (Figure 8.9). It was seen that 
rounded cell m orphology was restored when both P D K l and RhoE were knocked down, as 
had been previously seen. In addition to this, level o f  the phosphorylation o f MLC was 
restored and was located throughout the cell cortex, similar to the localisation seen in control 
cells. This indicates that when both P D K l and RhoE are depleted, endogenous ROCK1 is 
able to localise correctly at the plasma membrane, and is able to co-ordinate contraction of 
the acto-myosin cortex through the phosphorylation o f  MLC, similarly to control cells.
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Figure 8.9 Double knockdown of PDK1 and RhoE restores 
cortical acto-myosin contractility. A375 cells were 
transfected with either control, PDK1, RhoE or a combination 
of PDK1 and RhoE siRNA. Cells were then plated on top of 
collagen matrigel matrix. 48 hours later cells were fixed and 
stained with TRITC phalloidin, and ppMLC (T18S19).
8.4.4 ROCK driven blebbing is rescued by double knockdown
The double depletion o f PD K l and RhoE was also able restore the ability o f over-expressed 
myc-ROCKl to cause membrane blebbing (Figure 8.10). In the absence o f P D K l, myc- 
RO CK l was not membrane localised and was only able to induce stress fibres in the 
cytoplasm rather than co-ordinating contractile forces around the complete cell cortex to 
induce blebbing. W hen RhoE is knocked down in addition to P D K l then myc-ROCKl is 
able to localise at the plasma membrane (Figure 8.10 lower panel) presumably through 
interaction with RhoA. This seems to be sufficient for ROCK1 to co-ordinate the 
contraction o f the cell cortex, as the number o f cells expressing myc-ROCKl and exhibiting 
membrane blebbing is similar to that seen in the control (Figure 8.10 upper panel).
8.4.5 Double knockdown restores cell motility in MTLn3E cells
All the experiments in this chapter have so far shown that knockdown o f RhoE in addition 
to depletion o f  P D K l is able to restore the ability o f both over-expressed and endogenous 
ROCK1 to drive contraction and rounded blebbing cell morphology. Early results and 
previously published data had also shown a link between rounded cell morphology and the 
ability o f cell to invade 3D environments in an amoeboid manner. This was the basis for the 
initial siRNA screen, to identify novel regulators o f amoeboid cancer cell invasion using a 
morphology-based read-out, and the assumption that hits that disrupted rounded cell 
morphology could also be required for amoeboid cell motility
To finally test the model that the depletion o f PD K l disrupts cell morphology and reduces 
cell motility by allowing RhoE to bind to and inhibit ROCK1, it was tested whether double 
knockdown o f  both P D K l and RhoE was able to restore cell motility. MTLn3E cells were 
used in this assay as their movement in 3D collagen/matrigel matrix is more persistent and 
easier to measure than the chaotic motility o f A375 cells. Measuring the movement of 
MTLn3E cells on collagen/matrigel gels over 10 hours revealed that this hypothesis held true 
and that double knockdown o f  P D K l and RhoE was able to restore cell motility in this cell 
line and there was no significant difference from the controls (Figure 8.11). Knockdown of 
RhoE alone did not alter cell speed (Figure 8.11).
217
J  Blebbing
J  Increased stre ss  fibers 
qq ™  Normal
I—I R educed s tre ss  fibers
80
Control PDK1#1 RhoE#3 PDK#1 + RhoE#3
■  M em brane diffuse
■  M em brane puncta 
®  Mixed Memb & Cyt
9 0 1 C ytoplasm ic
Control PDK1#1 R hoE#3 PDK#1 + RhoE#3
Figure 8.10 Double Knockdown of PDK1 and RhoE 
restores blebbing phenotype and membrane 
localisation of over-expressed ROCK1. Graphs to show 
phenotypes of over-expressed ROCK1 in A375 cells. A375 
cells plated on 2D substrate were transfected with either 
control, PDK1, RhoE or a combination of PDK1 and RhoE 
siRNA. 24 hours later myc-ROCK1 was transfected. 24 
hours later cells were fixed and stained with 9e10 and 
TRITC phalloidin. Cells expressing myc-ROCK1 were then 
scored into the above categories based on the actin 
phenotype and the localisation of the ROCK construct. ** 



















Figure 8.11 Quantification of the rescue of MTLn3E cell 
motility when both PDK1 and RhoE are depleted.
MTLn3 cells were transfected with either PDK1 or RhoE 
targeting oligos and plated on collagen matrigel. Low 
resolution phase contrast time-lapse sequences were 
analysed to determine the effect of PDK1/RhoE depletion 
on cell motility. ** indicates p<0.001 Mann Whitney U test.
9 Chapter 9 -  Investigating the relationship between 
cancer cell motility and pigment production in vivo.
9.1 Chapter Summary
The previous chapters have uncovered a strong correlation between invasive behaviour o f 
cancer cells and rounded contractile cell morphology. The siRNA screening in chapter 5 was 
carried out based on this hypothesis and it was found that PD K l controlled both 
morphology and cell motility in vivo.
Further to this, I was interested to investigate the motile behaviour o f melanoma in greater 
detail. Differentiated melanocytes residing in the skin have a dendritic phenotype, exhibiting 
multiple protrusions and low contractile forces. Having seen that the A375 cells (human 
melanoma cell line) do not resemble dendritic melanocytes it was possible that the 
acquisition o f  motile invasive behaviour coincided with failure to fully differentiate. To 
investigate this, the mouse melanoma cell line B16F2 was used. B16F2 cells are able to 
produce melanin in vitro and respond to melanocyte-stimulation hormone (MSH) by 
becoming dendritic in morphology. These features made this cell line suitable to determine if 
there was a correlation with cell motility, cell morphology and pigment production. The 
A375 cells used in the previous chapters are not able to produce pigment and so they were 
not suitable for this part o f  the project.
It was found that it was possible to image vesicles containing pigment by both reflectance 
and multi-photon microscopy. The fluorescent vesicles were ablated by inhibition o f PKA, 
and increased in num ber by stimulation o f cells with MSH. Multi-photon imaging o f B16F2 
xenograft tumours in vivo revealed that pigment production throughout the tumour was 
heterogeneous. Time-lapse movies were captured and it was found that motile cells tended to 
contain less pigment than non-motile cells in the same field perhaps indicating that the 
invasive cells were less differentiated.
It was also possible to quantify the pigment content o f B16F2 cells by FACS. B16F2 cells 
stimulated with MSH showed significantly greater emission in the violet range. Based on this, 
B16F2 cells isolated from xenograft tumours were sorted by FACS into two populations 
based on their pigment content. Cells expressing high melanin were compared to those 
expressing low pigment by microarray analysis to identify signalling pathways responsible for 
a switch to a less differentiated, more motile phenotype. From the microarray it was found
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that TGF(32 amongst other genes was up regulated in the cells containing less pigment. This 
was tested in vitro and it was confirmed that both TFG01 and TFG £2 inhibited 
melanogenesis, even in the presence o f MSH. These results add to the body of evidence that 
TG FP can induce invasive pro-metastatic behaviour o f cancer cells in vivo, but in addition, 
that this signal could also potentially perturb or reverse differentiation.
9.2 Melanin containing vesicles can be imaged by multi-photon 
microscopy.
9.2.1 Imaging of melanin in vitro
B16F2 cells plated on glass and stimulated with MSH were imaged on an inverted multi­
photon confocal microscope. The pigment containing vesicles could be seen by transmitted 
light passing through the sample without contrast. Imaged this way the cells looked mostly 
transparent, the only clearly visible feature being the black dots which we assume to be 
melanosomes. Looking at cells in this way showed that even in the presence o f MSH for 48 
hours, not all cells respond and produce more pigment, indicating that this cell line is 
innately heterogeneous in their sensitivity and response to stimuli. The cells that had 
responded to MSH contained many melanosomes throughout the cytoplasm although 
melanosomes were more concentrated at the cell periphery, and in cell protrusions. 
Collecting a reflectance image from the 543 nm single photon laser showed that the cells 
containing m ore black vesicles also had a higher reflectance signal. The pattern o f reflectance 
and melanosomes was similar but what was surprising was that signals were also detected 
following m ultiphoton excitation. The emission following multiphoton excitation was very 
broad and was collected in multiple detection channels (410-450 nm, 500-550 nm, 565-615 
nm) following excitation at 850 nm (Figure 9.1). Cells containing more melanosomes as 
determined by transmitted light, also had a higher signal in the reflectance and fluorescent 
emission channels (Figure 9.1). The broad range o f emission was curious and suggested that 
the signal we were seeing was not the result o f conventional fluorescence. For this reason 
this signal will now be named ‘Near Infra-Red stimulated Visible light Emission’ (NIRVE), a 
term invented solely for the purpose o f describing the data in this chapter.
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Figure 9.1 Pigment containing vesicles can be visualised 
by multiphoton microscopy. B16 F2 cells plated on glass- 
bottomed cell culture dishes were stimulated with a-MSH for 48 
hours. Images were taken using a 63X oil immersion lens 
without contrast. Reflectance was seen using single photon 
laser (543 nm). Emission was also collected at various 
wavelengths following 2-photon excitation at 850 nm. Scale bar 
indicates 50 pm.
Transmitted lightTransmitted light Reflectance
Figure 9.2 Reflectance signal directly co-localises with black 
pigment containing vesicles. The black vesicles seen with 
transmitted light in panel i) were analysed at high resolution to 
determine co-localisation with the reflectance signal panel iii). The 
transmitted light image was inverted (panel ii). Co-localisation was 
determined digitally using LSM510 software (panels iv-vi). Pixels of 
high intensity for both channels are shown in panel vii. Scale bar 
indicates 50 pm.
9.2.2 Co-localisation of black vesicles and reflectance signals
In more detailed analysis, high-resolution images o f pigment-producing B16F2 cells were 
taken and smaller areas analysed. The high magnification images allowed the co-localisation 
o f the vesicles seen in the transmitted and reflectance images to be determined. To do this, 
the transmitted light image was inverted using ImageJ software and overlaid with the 
reflectance image (Figure 9.2). Colocalisation was determined by highlighting pixels o f high 
intensity o f both channels (Figure 9.2 vi vii). The result clearly showed that the black vesicles 
were also the source o f the reflectance signal.
9.2.3 Fluorescence signal is induced by MSH and inhibited by 
inhibition of PKA
To test whether the fluorescent vesicles imaged above were pigment containing 
melanosomes, it was tested whether their presence was increased by stimulation with MSH 
and inhibited by inhibition o f  PKA with the compound H89. The change in pigmentation 
can be clearly seen by trypsinising the treated populations o f cells and centrifuging then into 
a cell pellet. The colour o f these cell pellets is shown in Figure 9.3. The untreated cells appear 
brown, probably an indication that only some o f the population are producing pigment. 
MSH causes the cell pellet to look much darker as a higher proportion o f cells are now 
producing large quantities o f pigment. Treatment o f the cells with the PKA inhibitor H89 
caused the cell pellet to appear white as melanogenesis was now blocked in these cells.
In addition to making cells darker in the cell pellet, MSH also caused cells to contain more 
NIRVE vesicles. In contrast H89 treatm ent caused cells to lose NIRVE vesicles (Figure 9.4). 
The changes in N IRV E signal were imaged using fixed B16F2 cells plated on cover slips, 






Figure 9.3 Pigmentation o f B16F2 melanoma cells can be 
manipulated in vitro. Inhibition of PKA with the compound H89 
(10 pM) inhibits melanogenesis. Stimulation of B16F2 cells with a- 
MSH stimulates melanogenesis. The changes in pigmentation can 
be seen by trypsinising the cells and spinning them into a cell 
pellet. The images above were taken with a digital camera.
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Figure 9.4 Increased pigment production can be measured 
by multiphoton microscopy. B16F2 cells plated on glass- 
bottomed cell culture dishes were treated for 48 hours with either 
10 pM H89 or a-MSH and imaged using both single and 2- 
photon confocal microscopy. Excitation wavelengths were 543 
and 825 nm. Emission wavelengths are as indicated above. 
Scale bar indicates 50 pm.
9.3 Analysis of the spectral properties of the pigment containing 
vesicles.
As this type o f  imaging o f pigment production by melanocytes or melanoma cells had not 
been previously described, it was decided to investigate the spectral properties o f these 
vesicles further. The emission and excitation spectra were determined as well as estimating 
the lifetime o f  the signal.
9.3.1 Analysis of emission spectra
B16F2 cells were plated onto glass-bottomed dishes and stimulated with a-MSH for 48 
hours. Cells were then fixed but not stained. Cells were imaged by excitation with a multi­
photon laser tuned to 800 nm and the emission was collected at wavelengths ranging from 
380-750nm using a M ETA detector that is able to scan trhough a range o f filters to collect a 
range o f emission from the sample (Figure 9.5). The first striking result was that emission 
was detected across a very broad range o f wavelengths (as had been previously seen in Figure 
9.1), the broad range o f emission was actually composed o f 4 different spectra. This 
indicated that there were 4 different types o f pigment-containing vesicles. The different 
‘varieties’ o f  vesicles are colour coded according to their spectra and shown in Figure 9.5 A. 
Some vesicles show only one spectra and some vesicles instead contained a combination o f 2 
or 3 or even all four separate spectra, indicating that each vesicle does not always contain 
only one type o f  NIRV E vesicle. Together the 4 spectra cover wavelengths from 
approximately 400-680 nm (Figure 9.5B). By separating the signal into each o f the 4 distinct 
spectra it was possible to determine the localisation o f each type o f signal (Figure 9.6). It was 
seen that all four types o f  vesicles were found throughout the cytoplasm and also in the cell 
protrusions, and it was not possible to say that the localisation o f each was different from 
any other. How ever analysing larger number o f cells in this way may reveal differences that 
could correlate the spectra to different stages o f  melanosomes maturation, though this is 
only speculation at this point.
9.3.2 Analysis of excitation spectra
Similarly to above the excitation spectra for the pigment-containing vesicles was examined. A 
broad range o f  emission was collected using a KP 650 filter whilst the multiphoton laser 
scanned through excitation wavelengths between 690-1030 nm (Figure 9.7 A). The laser 
power alters with the wavelength, to compensate for these changes an algorithm was written
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by the light microscopy department by Daniel Zicha at the CRUK LRI which ensures that 
the sample is hit with the same laserpower. The KP 650 filter is a special type o f dichroic 
filter used for infra red multiphoton imaging. It allows excitation wavelengths longer than 
650 nm to pass onto the specimen and allows emission in the visible range to pass through 
towards the detectors. The results show that the best excitation o f the pigment occurs 
between 700-850 nm (Figure 9.7 B). It is likely that excitation also occurs at wavelengths 
shorter than 690 nm but it was not technically possible to test this.
9.3.3 Analysis of the lifetime of the signal
It had sometimes been observed that the signal collected from the pigment resulted in a 
‘streaking’ in the direction o f scanning. This was curious and seemed to be dependent on the 
scan speed. Figure 9.8A shows an example o f the same cells imaged at two different scan 
speeds. The green signal shows horizontal streaking whereas the red signal is more discrete. 
The pixel time o f  the two overlaid images is 1.6 ps vs. 106 ps. This result suggested that the 
lifetime o f  the signal was extremely long meaning that depending on the scanning conditions 
the signal was able to ‘leak’ into the neighbouring pixels as the area was scanned. When the 
pixel time was low, streaking occurred, as the emission was still present even after the scan 
had moved to the next position.
To test this theory lifetime imaging was carried out using a FLIM detector that was able to 
count the photons emitted over a 30 second period (Figure 9.8 B). Analysis o f the photons 
as they were emitted showed that following the initial peak there was a sharp decrease as 
would be expected for a normal fluorophores. However this initial drop is followed by an 
area o f the curve with a much shallower gradient, indicating that some component o f the 
emission is very prolonged and could potentially explain the streaking effect we had 
observed. The life time o f  the signal appears to be very long and beyond the capabilities of 
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Figure 9.5 detailed analysis o f emission spectra reveals 4 
d is tinc t spectra. Pigment containing B16 F2 cells were 
plated onto glass bottomed dishes and imaged using a 
multiphoton laser. Emission was detected between 380 -750 
nm using a meta detector attached to a Zeiss510 confocal 
microscope. A) each pixel is pseudocoloured according to the 
emission recorded. Scale bar indicates 10 microns B) Overlay 






















Figure 9.6 localisation of each population of pigment 
contain ing vesicles. Shown above was the location of the 
‘speckles’ that correspond to each of the 4 different emission 
spectra identified.
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Figure 9.7 Analysis of excitation spectra of pigment 
containing vesicles. Pigment containing B16 F2 cells plated 
on glass bottomed dishes were imaged using a multiphoton 
laser. The excitation wavelength of the laser was tuned to 
scan between 760-1030 nm and the emission in the visible 
range was collected. A) gallery view of sequential images 
corresponding to the increasing excitation wavelengths. B) 
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Figure 9.8 Lifetime of emission analysis. A) the image shows 
the overlay of two images of the same cells taken at different scan 
speeds. The red image has a pixel time of 106 ps and the green 
image has a pixel time of 1.6 ps. B) zoomed in image to show 
streaking of green image compared to red, in the direction of 
scanning. C) Life time imaging showing graph of photon count 
against time.
9.4 Visualisation of melanin in xenograft tumours in vivo.
9.4.1 High resolution imaging of living tumours
B16F2 cells stably expressing GFP-CAAX were injected sub-cutaneously into the flank o f 
nude mice. The resulting tumours were imaged when they reached between 4-6 mm in 
diameter. High-resolution imaging using a 63X water immersion lens showed the cell 
membranes labelled with GFP. Cell nuclei and cytoplasm could be seen as black empty 
spaces within the G FP signal. It was found that it was possible to image pigment in 
fluorescent vesicles in the same way as had been carried out in vitro. The emission between 
575-615 nm was collected following excitation at 850 nm to identify the melanin vesicles 
(Figure 9.9 A). 850 nm was chosen although it was not the peak o f the excitation spectra, 
because this allowed the simultaneous imaging o f G FP signal, collagen fibres and NIRVE 
from the pigment. Also the m ultiphoton laser used to the in vivo imaging did not have the 
capability to give sufficient laser power at the lower wavelengths meaning that the best 
excitation was found between 800-850 on this microscope. Due to imaging the GFP signal 
and also the collagen fibres it was not feasible to collect the whole range o f emission and 
575-615 was chosen, as it did not over-lap with other imaging channels (Figure 9.9 B).
The images revealed that the fluorescent vesicles were located at the cell periphery as 
indicated in several examples by arrows (Figure 9.9 A). This was in agreement with the 
location o f vesicles in cells in vitro. It was also clear that the heterogeneity seen in vitro was 
also seen in vivo as not all cells expressed detectable levels o f pigment. Additionally different 
areas o f the tum our showed very different expression levels o f pigment production.
9.4.2 Time lapse multi-photon imaging of melanoma tumours
It was not possible to image the B16F2 tumours at high resolution over the time-lapse period 
as too much photo  bleaching and possibly photo damage and tissue damage from the laser 
would occur. Instead the tumours were imaged using a 20X lens with a lower numerical 
aperture, and with lower laser power and less averaging, to protect against this (Figure 9.10 
A). Images taken at 30 s intervals showed some cells within the tumour moving. Movements 
were either as single cells or in collective chains between other cells (Figure 9.10 B and 
accompanying supplementary movies). Some areas o f tumour showed no motility whilst 
other areas contained many cells moving. Motile cells were generally rounded as had been 
seen in the imaging o f  the A375 tumours suggesting that B16F2 cells might also use
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amoeboid cell motility to invade in vivo. Arrows identify an individual motile cell (Figure 
9.10 B). The image in part B is composed o f 3 time points o f the same area overlaid in red, 
green and blue. The white areas o f the image indicate direcdy overlapping red, green and 
blue signal and therefore show non-motile areas, motile cells are shown in red, green and 
blue, as the 3 time points do not overlay.
9.5 Motile cells in vivo contain less melanin than non motile 
cells
For each time-lapse movie made, motile cells were identified. The level o f pigment contained 
within these cells was measured by signal intensity and compared with the average pigment 
intensity in the whole frame. The data is plotted as a relative frequency distribution. The Y- 
axis shows the proportion o f  each population (motile cells and non-motile cells). The total 
population o f cells, motile and non-motile, shows a skewed distribution ranging from 0 to 7, 
centred on 1. The majority o f cells contain melanin between the ratios o f 0.5 and 1.5. Results 
showed that the ratio o f the melanin content was mostly less than 1 in the motile cells 
(Figure 9.11). The non-motile cells were a more spread population based o f pigment content 
with a few cells containing large amount o f signal, and others containing very little. The 
motile cells in addition to containing less pigment, also move with a rounded morphology, 
and are no longer dendritic as a pigment producing melanocytes would be, which may 
indicate a less differentiated state.
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Figure 9.9 High resolution imaging of B16F2 xenograft 
tumours in vivo. B16F2 GFP CAAX tumours grown 
subcutaneously in nude mice were imaged using multiphoton 
confocal microscopy and a 63X water immersion lens. Imaging 
revealed that the pigment containing vesicles seen in vitro 
could be imaged using similar parameters as in vitro. The 
pigment containing vesicles appeared to be mostly around the 
cell periphery. A) merged image showing GFP CAAX 
expressing tumour cells, collagen fibres in blue (2nd harmonic 
signal), and pigment in pink. B) image of separate channel of 
pigment only. Scale bar indicates 20 pm.
Figure 9.10 Analysis of B16 F2 cell movement in vivo. B16F2 
GFP CAAX tumours grown subcutaneously in nude mice were 
imaged using multiphoton confocal microscopy A) merged image 
showing GFP CAAX expressing tumour cells, collagen fibres in blue 
(2nd harmonic signal), and pigment in pink. Dashed outlines indicate 
single moving cell and group of collectively moving cells. Scale bar 
indicates 20 microns B) 3 consecutive time points are overlaid in the 
image above. The first time point (0) in red, the 2nd (90 sec) in 
green and the 3rd (180 sec) in blue. Cells which are non motile will 
appear white as the 3 colours are overlaid. Motile cells are shown in 
red/green/blue and one example is indicated by the arrows above. 
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Figure 9.11 Motile B16F2 cells contain less melanin than 
non-motile cells in vivo. In vivo time-lapse multi-photon 
movies were analysed using LSM510 software. Average 
intensity of melanin was measured for each area. Cells within 
that area were then analysed and given a score for melanin 
expression relative the average level. The cells were sub­
divided into motile (red) and non-motile (green) categories and 
the frequency distribution of the results is shown above. 155 
motile cells and 316 non-motile cells were analysed from 15 
different imaged areas from 4 xenograft tumours. Relative 
melanin content is categorised into bins of width 0.2.
9.6 Melanin expression can be determined by FACS analysis
As the spectral properties o f melanin expressing cells had been discovered and utilised in the 
microscopy assays, it was next investigated whether optical parameters could also be used to 
examine and sort the B16F2 tumour cells by FACS (Figure 9.12, Figure 9.13) into high and 
low melanin expressers for further analysis.
9.6.1 MSH stimulation causes measurable shifts in violet emission 
measured by FACS
As a negative control B16F2 cells that were not fluorescently labelled were used (Figure 9.12 
A). This sample was used to set the gates for the GFP expression. In part B) B16F2 cells 
stably expressing GFP-CAAX were analysed. A clear shift in emission in 530-30 Blue was 
observed. There was also a small proportion o f the population that were not GFP-positive. 
B16F2 GFP-CAAX cells treated for 48 hours with a-MSH were analysed in C). The level of 
GFP expression was comparable to the untreated cells (Figure 9.12 B C), however there was 
a significant shift in emission in the violet range, (450-40 Violet A). As a final test of this 
change in fluorescent properties, untreated B16F2 GFP-CAAX cells were mixed with the 
MSH treated B16F2 GFP-CAAX cells in equal numbers and these samples were run 
together. In D) the analysis shows that 2 distinct populations were identifiable. E) shows a 
histogram o f  the violet emission o f the mixed sample in D). Separating the two peaks and 
measuring the proportion o f cells in each population showed that there were approximately 
equal num bers in each population as there should have, as the mix was made with equal 
numbers o f  each separate sample. The two populations did still over lap to some degree 
which was not unexpected as looking at the cells in vitro on cover slips had shown that not 
all cells in the population respond to a-MSH stimulation to the same degree.
9.6.2 Sorting of B16F2 tumours by FACS
Having shown that it was possible to measure the pigment content o f cultured B16F2 cells 
by FACS, it was now tested whether the same technique could be applied to tumour cells 
extracted from  the B16F2 GFP-CAAX xenograft tumours. I f  this was feasible then it could 
be possible to separate the less pigmented (containing the more motile cells) population from 
the more highly pigmented (less motile) population.
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Figure 9.12 FACS analysis of melanin production by 
B16F2 in vitro. A)Unlabelled B16F2 B)B16F2 stably 
expressing GFP CAAX C)B16F2 stably expressing GFP 
CAAX stimulated with a-MSH for 48 hours. D)Mixed 
population of untreated B16F2 GFP CAAX and a-MSH 
treated B16F2 GFP CAAX. E) Histogram of violet emission of 
mixed population in D)
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Figure 9.13 FACS sorting of dissected B16F2 GFP 
CAAX tumour cells. B16F2 GFP CAAX or unlabelled 
B16F2 cells were injected subcutaneously into nude mice 
and tumours were allowed to grow to approximately 1 cm in 
diameter. Tumour cells were extracted and sorted by FACS. 
Part B shows the GFP positive population, and part C shows 
the gates used to separate the GFP positive cells into two 
groups based on their melanin content.
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Figure 9.14 RNA profiles of 3 replicates sent for microarray 
analysis. The 3 pairs of RNA samples were run out on Aglient 
pico RNA chips. The profiles are shown above.
RNA extracted from these populations would then be analysed by microarray to try to 
determine signalling pathways altered between the two different populations.
Subcutaneous B16F2 (unlabelled) and B16F2 GFP-CAAX tumours were grown in nude 
mice and dissected out once they reached 0.6-0.8 mm in diameter. The tumours were cut 
into small pieces and incubated in a solution o f collagenase, dispase and trypsin for 90 min at 
37 °C. The cell suspension was then filtered and analysed by FACS (Figure 9.13). Tumour 
cells were identified by their emission for G FP expression, panel B in Figure 9.13 shows the 
distinct G FP positive population. The unlabelled B16F2 tumour sample was used as a 
negative control (Figure 9.13 A). The GFP positive cells were then gated to sort the top and 
bottom  10% o f  the population based on their emission in the violet range. Generally it was 
possible to collect approximately 100,000 cells in each o f the high or low (melanin 
expression) populations from each experiment. The collected cells were then centrifuged and 
RNA was extracted. Figure 9.14 shows the profiles o f the RNA samples collected in 3 
independent replicates run out on RNA pico Chips (Agilent) that were subsequently sent for 
analysis at the microarray facility at the Patterson Institute (CRUK Manchester).
9.7 TGF-p signalling pathways could be responsible for 
hypopigmentation and increased invasiveness.
9.7.1 Results of the microarray
Firstly it was found that the highest degree o f commonality between samples was between 
each pair o f  replicates. This means that the variability between independent experiments was 
higher that the overall differences between the 3 highly pigmented samples and the 3 lower 
pigmented samples. This unfortunately means that the level o f noise in the results was high, 
although this is no t unexpected considering that the RNA was extracted from FACS sorted 
tumour cells extracted from living tumours. Nonetheless, several interesting candidate genes 
were identified which were consistendy up or down regulated between the cell populations 
(Figure 9.15). Am ong the identified genes was TGF-(32, which will be investigated further in 
this chapter.
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Figure 9.15 Results from microarray. The genes that were 
consistently up or down regulated in all three replicates are listed 
above in order of highest to lowest fold change. The top part of the 
table lists genes that were expressed at higher levels in the cells 
containing more pigment. The lower part of the table shows genes 
that were expressed at higher levels in the tumour cells expressing 
less pigment.
Another very interesting result was that phosphatase and tensin homolog (PTEN) was 
expressed at higher levels in the high-pigmented cells. This potentially means that in addition 
to switching o ff melanin production, the lower pigmented cells are also down regulating a 
well-documented tumour suppressor gene. Genes encoding proteins involved in pigment 
production such as M ITF or the enzyme tyrosinase did not appear in this list. However there 
was one melanoma antigen (family H I) that was more highly expressed in the more highly 
pigmented cells. Two other genes potentially playing a role in cell motility that were 
expressed more highly in highly pigmented cells were the chemokine receptor CXCR4 and 
the neural cell adhesion molecule (NCAM), although as this population was found to be less 
motile their high expression is difficult to explain and it was beyond the scope o f this chapter 
to investigate all genes involved in cell motility.
9.7.2 TGF-02 is up-regulated by less-pigmented melanoma cells in 
vivo.
Micro array results showed that TGF-(32 was up regulated in the cell population containing 
less melanin pigment. Although the level o f noise in the results was fairly high due to the 
nature o f  the experiment and the way that the RNA samples were collected, TGF-p2 was 
consistently higher in the lower pigmented samples in all three independent replicates tested. 
The mean fold change was approximately 2.2 (Figure 9.15). As TGFP signalling has been 
known to play a role in cancer and also epithelial to mesenchymal transition (EMT), it was 
decided to investigate this further.
9.8 Investigating the effect of TGFJ3 signalling on B16 cells in 
vitro
To test the results from the microarray a series o f in vitro experiments were conducted to see 
what effect T G FP signalling had on the pigmentation, cell morphology, and motile 
behaviour o f  the B16F2 cells in vitro. The hypothesis from the results o f the o f the 
microarray would be that TG FP may be functionally relevant in one or all o f these processes.
9.8.1 TGFp signalling inhibits pigmentation in B16F2 in vitro
As TGFP2 had been found to be more highly expressed in cells containing less pigment, it 
was tested w hether TG FP2 directly influenced melanogenesis in B16F2 cells in vitro (Figure 
9.16). It was found that both TGFP 1 and TGFP2 reduced the level o f pigmentation in vitro 
within 24 hours o f  treatm ent (Figure 9.16A, B). It was also interesting that even when cells
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were also stimulated with MSH, TGF(3 was able to inhibit the pigmentation production. It 
was also true that the inhibition o f pigment production occurred even at very low doses of 
TG F beta. Although both T G Fpi and TG F02 had similar effects, the inhibition o f 
pigmentation seems slightly more efficient with TG FP than with TGFP2.
9.8.2 TGFp signalling induces stress fibre formation
B16F2 cells were plated on glass bottom ed dishes and stimulated with either a-MSH TG Fpi 
or TGFP2 for 24 hours, then fixed and stained with FITC phalloidin to reveal the actin 
cytoskeleton. Figure 9.17 shows the untreated cells contain some stress fibres and that 
treatment o f cells with a-MSH, even for just 24 hours causes cells to become more spread 
and the num ber o f  stress fibres appears reduced. Stimulation o f cells with either TG Fpi or 
TGFP2 had a different effect and caused cells to induce formation o f more stress fibres 
indicating a higher degree on tension in these cells. It can also be seen that TG Fpi or 
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Figure 9.16 TGFp 1 and TGFp 2 inhibit pigment production in 
B16F2 in vitro. B16F2 cells were plated in 6 well cell culture plates 
and treated with H89, MSH and/or TGF beta 1/TGF beta 2 for 24 
hours. Cells were then trypsinised and centrifuged. The colour of the 
cells pellet was recorded using a digital camera.
Untreated MSH
Figure 9.17 TGFp 1 and TGFp 2 increase stress fibre 
formation in B16 F2 cells in vitro. B16F2 cells were plated 
onto glass bottomed dishes and treated with MSH, TGF beta 1 
or TGF beta 2 for 24 hours. Cells were then fixed and stained 
with FITC phalloidin (green). Pigment was imaged using 
multiphoton excitation at 820 nm (blue). Scale bar indicates 50 
pm.
9.8.3 TGFp signalling inhibits dendritic cell morphology
When plated on deformable collagen/matrigel matrix, B16F2 cells show a mixture o f cell 
morphologies ranging from dendritic to rounded cells. Stimulation with MSH caused cells to 
become more dendritic. It was next tested what effect TGF(3 signalling had on the 
morphology o f B16F2 cells in this in vitro system. B16F2 cells were plated on deformable 
collagen/matrigel matrix, and treated with either MSH, T G F pi or TGF|32 for 4 days (Figure 
9.18). Cells were then fixed and stained with FITC phalloidin and DAPI. The 
collagen/matrigel matrix was imaged using reflectance signals. In this long term treatment 
assay it was found that cells treated with MSH were quite spread with numerous thin 
dendritic protrusions, this was also seen in a sub-population o f the untreated cells. However 
treatment with either T G F p i or TGFP2 inhibited the formation o f these dendritic 
protrusions and cells were fairly rounded instead. Looking at the matrix it was also seen that 
there were more holes in the matrix around cells treated with either TG Fpi or TGFP2. This 
suggested that these cells are more motile or more active, tugging and pushing at the 
deformable matrix and tearing it. Another alternative is that there are changes in the 
proteolytic activity o f  these cells and T G Fpi or TGFP2 increase the ability o f B16 cells to 
degrade the matrix surrounding them.
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Untreated MSH
TGF beta 1 TGF beta 2
Figure 9.18 TGFp 1 and TGFp 2 inhibit dendritic morphology 
of B16 F2 cells in vitro. B16 F2 cells were plated on deformable 
collagen/matrigel and treated with MSH, TGF beta 1 (1 ng/ml) or 
TGF beta 2 (1 ng/ml) for 4 days. Cells were then fixed and 
stained with DAPI (red) and TRITC phalloidin (green). The matrix 
is imaged by reflectance (blue). Scale bar indicates 50 pm.
Untreated MSH
TGF beta 1 TGF beta 2
Figure 9.19 TGF01 and TGF02 inhibit dendritic morphology 
of B16 F2 cells within 24 hours of stimulation. B16 F2 ceils 
were plated on deformable collagen/matrigel and treated with 
MSH, TGF beta 1 (1 ng/ml) or TGF beta 2 (1ng/ml) for 24 
hours. Cells were then fixed and stain with DAPI (red) and 
TRITC phalloidin (green). The matrix is imaged by reflectance 
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Figure 9.20 TGFp causes increased cell motility in B16F2 
cells plated on deformable collagen/matrigel matrix. A)
Graphs showing tracks of each treatment group all centred at 
zero. B) box plots showing range of cells speeds of each 
treatment group. * indicated p<0.01 Anova test.
It was next tested at what time point the cell rounding induced by TGF(3 signalling occurred. 
The same experiment as above was carried out but cells were fixed after only 24 hours. This 
time was chosen because the inhibition o f pigmentation occurred in this time frame. Figure 
9.19 shows that at 24 hours cells treated with T G Fpi or TGFP2 were rounded and did not 
exhibit dendritic protrusions like the untreated cells or the MSH treated cells.
9.8.4 TGFp signalling increases cell motility
In addition to causing retraction o f dendrites and causing cells to become more rounded, 
TG FP signalling also increased cell motility. This was measured by plated B16F2 cells on 
deformable collagen/matrigel matrix and performing phase contract time lapse imaging. 
Untreated cells and cells treated with aM SH appeared dendritic with multiple long 
protrusions. The cells treated with either T G F pi or TGFP2 became less dendritic as would 
be predicted from previous data, but they also became more motile, moving grater distances 
(Figure 9.20). Movement o f the non-treated cells tended to be the extension and retraction of 
cell protrusions but for this analysis only translocation o f the nucleus was tracked (see 
supplementary movies for examples o f cell motility used for this quantification). N ot all the 
cells responded to TG FP and moved faster, this seemed to occur in a sub population o f cells 
only, and can be seen by the large spread o f cell speeds in the box plot.
Although it is unlikely that TG FP signalling is solely responsible for the differences in 
pigmentation and motile behaviour that we see in vivo, initial results suggest that TGFP is 
capable o f causing both hypopigmentation and increased cell motility. TGFP signalling might 
be a good potential target in treating melanoma as it would be predicted that this would 
target the highly motile and potentially more metastatic sub-population o f tumour cells.
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10 Discussion
The experiments within this thesis have covered 3 main areas: firsdy the search for regulatory 
phosphorylation sites within ROCK1, secondly the discovery that PDK1 is able to regulate 
amoeboid cell motility in vivo through interacting with ROCK1, and finally, the investigation 
into the heterogeneity o f melanoma cells in vivo and the finding that TG F0 signalling may be 
responsible for inhibiting pigmentation and stimulating motile behaviour. Although each 
different starting point was designed to learn more about cancer cell motility, each line of 
investigation has generated further questions. The results and the further implications are 
discussed in detail in this chapter.
10.1 Investigating the regulation and function of ROCK1
The first results in chapter 3 showed that ROCK1 was regulated by more inputs than just 
binding to RhoGTP. Binding o f ROCK1 to RhoA was required for the membrane 
localisation o f ROCK1 but not the kinase activity o f ROCK1 (Figures 3.1, 3.2). The 
localisation o f  ROCK1 affected ROCK1 function, i.e. cytoplasmic distribution led to the 
generation o f stellate stress fibres, and membrane localisation led to cell blebbing; it is 
possible that ROCK1 is able to carry out different functions in different cellular locations. 
Different substrates available in the cytoplasm and membrane compartments could account 
for these differences in phenotypes. Defining whether ROCK1 preferentially phosphorylates 
different substrates in different locations could be an interesting avenue to explore. The 
activation o f  RhoA in specific areas o f the cell could be one way in which ROCK activity is 
permitted in specific locations, for example to the cleavage furrow during cytokinesis 92,175. 
Localised activation o f  Rho and therefore localised membrane accumulation o f ROCK could 
also model how RO CK  activity could be polarised to the rear o f blebbing cells as seen in 
chapter 7 (Figure 7.8). Although data in this thesis confirm the importance o f Rho binding to 
regulate RO CK , it was found that Rho function was more important in the localisation of 
ROCK and had less input into regulating ROCK kinase activity. The next step was to 
investigate other mechanisms o f regulation such as phosphorylation.
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The investigations into potential phosphorylation sites in ROCK1 revealed that ROCK1 
does not require phosphorylation at T233 in the activation loop for its activity. This result 
means that ROCK1 functions differently to other members o f the AGC family kinases 
despite its significant sequence homology with other family members. This finding has been 
confirmed by structural analysis o f the ROCK1 kinase domain and it has been shown that 
the activation loop o f ROCK1, even in the absence o f phosphorylation resembles an active 
conformation 234, 235. Furthermore, the basic residues in the kinase domain that would 
normally interact with phosphate o f the phosphorylated activation loop residue (Thr233) are 
not conserved in ROCK1. Instead these residues are hydrophobic (Phel20, Met221, Cys231) 
234. With hindsight it was not unexpected that mutation o f T233 and D232 did not 
significantly alter kinase activity o f ROCK 1.
Mutation o f  the hydrophobic m otif was also carried out. Mutation o f T398 inhibited kinase 
activity o f  ROCK1 and caused ROCK1 to become mislocalised, which initially led us to 
believe that it was a regulatory site. However substitution o f an acidic residue at T398 failed 
to restore a phenotype similar to W T ROCK1. Since the structure o f ROCK1 kinase domain 
is now available, it looks unlikely that T398 is a phosphorylation site in ROCK1. T398 is 
buried within the structure o f the kinase domain and would be unlikely to become accessible 
to be phosphorylated 235. The most plausible explanation for the results obtained in chapter 3 
is that mutation o f T398 causes a mis-folding o f the kinase domain, which would explain the 
loss o f  kinase activity and mis-localisation.
The investigations into the role o f  T380 were more revealing. T380 is situated on the outer 
surface o f  the kinase structure so is therefore a possible phospho-acceptor site 235. Results in 
chapter 3 showed that mutation o f T380 caused the kinase to be mislocalised but did not 
inhibit kinase activity. This could be explained by the result that T380A binds more strongly 
to the negative regulator RhoE. This would mean that T380A ROCK1 was interacting with 
endogenous RhoE and inhibited from interacting with its substrates, therefore unable to co­
ordinate contraction for cell blebbing. Inhibition o f PI3K signalling with the inhibitor 
LY294002 caused WT-ROCK1 to behave similarly to T380A ROCK1, as it caused the 
kinase to be mislocalised, but did not inhibit kinase activity. Initially it was hypothesised that 
T380 could be phosphorylated downstream o f PI3K signalling, which may still be the case. 
However, subsequent work in chapter 7 can explain that this could also be due to the
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reduced levels o f  phospholipids in the plasma membrane and following this, reduced levels 
o f PDK1 at the membrane to bind ROCK1 (see Figure 1.6). Therefore treatment o f cells 
with LY294002 causes the balance o f PDK1 and RhoE to be swayed such that there is more 
RhoE available to bind to ROCK1. This would mimic the phenotype o f T380A that binds 
more strongly to RhoE than the WT ROCK1. The outstanding questions surrounding the 
role o f  T380 arise from the behaviour o f T380D and T380E mutants. The acidic substitution 
o f T380 was firsdy found the render ROCK1 resistant to the mislocalisation and reduced 
blebbing cause by treatm ent o f  cells with LY294002 (Figure 3.10). This would suggest that 
T380E is less dependent on the availability o f phospho-lipids and PDK1 at the plasma 
membrane to induce cell blebbing. Consistent with this is the failure o f T380E ROCK1 to be 
effectively inhibited by RhoE over-expression (Figure 3.15). However it was also found that 
T380E ROCK1 bound m ore strongly to RhoE than WT-ROCK1, which is contradictory to 
the in vivo result. Results in chapter 8 showed that T380 is contained within the region of 
ROCK1 required for binding to both PDK1 and RhoE and it could perhaps be hypothesised 
that mutation o f  T380 changes the binding affinity o f ROCK1 to both PDK1 and RhoE, so 
that in some assays T380E ROCK1 appears more active than WT-ROCK1 (due to stronger 
binding to PDK1), but in other assays it appears that it was more inhibited than WT- 
ROCK1 (due to stronger binding to RhoE). Therefore T380E may be a version o f ROCK1 
that is m ore highly sensitive to the balance between PDK1 and RhoE. Mutation o f T380 to 
alanine did not affect the binding o f ROCK1 to PDK1 but the binding o f T380D or T380E 
to PDK1 remains to be tested (Figure 7.17). Despite the binding data suggesting that T380E 
binds more strongly to RhoE, functional data did not support this as co-expression o f GFP- 
RhoE with T380E only had a small inhibitory effect o f the induction o f cell blebbing.
It is possible that T380 in the hydrophobic m otif o f ROCK1 is modified to regulate the 
function o f  ROCK1. Unfortunately it has not been possible to identify the presence of 
phosphate on this residue despite attempting to generate phospho-antibodies and also 
carrying out analysis by analysis by mass spectrometry. The antibodies we generated were not 
very specific and a better purification method may result in a better antibody to use as a tool 
to investigate this further. The mass spectrometry analysis was carried out using ROCK1 
protein that was autophosphorylated. We now know that T380 is not an 
autophosphorylation site in ROCK1 as this peptide was seen in the analysis but never 
appeared to be phosphorylated. However, testing a range o f kinases against peptides
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containing T380 may reveal that T380 is indeed a substrate for an as yet unidentified kinase. 
Also the purchased recombinant ROCK1 protein used for the mass spectrometry analysis 
was isolated from  a baculovirus culture and not mammalian cells. So although no constitutive 
phosphorylation occurs in insect cells it does not rule out regulation o f T380 in mammalian 
cells.
Results in chapter 4 have revealed that ROCK1 will also autophosphorylate itself in at least 2 
positions: S479, and T518. A relevant function o f these phosphorylation sites is yet to be 
confirmed. N either o f  these sites is contained within regions that have been reported to be 
required for dimerisation o f ROCK1, and neither site is in the hydrophobic m otif or the 
activation loop, which were investigated by mutagenesis in chapter 3. The function o f T518 
was investigated further in chapter 4 and it was found that although T518A ROCK1 was able 
to localise to  the plasma membrane and had kinase activity similar to WT ROCK1 in vitro, 
the ability o f  T518A ROCK1 to cause cell contraction and induce membrane blebbing was 
reduced com pared to WT-ROCK1. This was similar to the phenotype seen when truncated 
ROCK1 was tagged to the plasma membrane by cloning the CAAX sequence o f K-Ras or 
RhoA onto th e  C-terminus.
T518 occurs in a region o f ROCK1 that has been reported to be part o f a Rho-interacting 
domain w ith homology to the HR1 domain in PKN m ' 236. Some initial attempts to test 
whether m utation  o f  T518 results in altered binding to RhoA has not revealed any obvious 
differences b u t this might still be an interesting avenue to explore more thoroughly. Acidic 
substitution o f  T518 would also be important to investigate to complete this line of 
investigation. The role o f S479 has not been investigated at this point.
It seems th a t to effectively drive cortical F-actin contraction and blebbing, ROCK1 requires 
kinase activity, localisation to the plasma membrane, and also another signal, because tagging 
truncated RO CK 1 to the plasma membrane was not sufficient to induce contraction and 
rounding o f  cells to mimic WT ROCK1. Perhaps auto-phosphorylation o f T518 or S479 or 
at other sites such as T380, or perhaps undiscovered sites in the C-terminus, are the 
remaining inpu ts  required. Truncated-ROCKl (1-727), which remains cytoplasmic and 
induces star-like stress fibres, includes the region containing T518. It will be interesting to 
determine w hether T518 is phosphorylated in truncated ROCK1. More investigation will be 
required to determ ine if  these sites really regulate ROCK1 function, and where and when
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these phosphorylations occur. Although these sites are present in truncated ROCK1 (1-727) 
tagging this construct to the membrane did not induce rounding o f the cells. Perhaps the C- 
terminus is required either for these phosphorylations to take place or for a conformational 
change to occur downstream o f the phosphorylation.
10.2 The identification of PDK1 as a regulator of amoeboid cell 
motility.
The next approach undertaken to determine novel regulators o f rounded/blebbing 
morphology and amoeboid cell motility was an siRNA screen. Knowing that amoeboid cell 
motility required signalling through ROCK 153, it was also possible that we would have 
uncovered pathways feeding directly into the phosphorylation o f ROCK that had been the 
focus o f  chapters 3 and 4. As it turned out we did not find a signalling pathway that 
controlled the phosphorylation o f ROCK but did discover that PDK1 directly bound to 
ROCK and regulated its localisation by acting as a scaffold at the plasma membrane.
10.2.1 siRNA screen identifying candidate signalling pathways 
required for amoeboid cell motility
The siRNA screen was a useful way to identify novel regulators o f rounded cell morphology 
and in the case o f  PD K 1, disruption o f rounded cell morphology also led to inhibition of 
amoeboid cell motility. Plating cells onto thick layers o f collagen/matrigel more accurately 
mimics the range o f  morphologies seen in vivo, than rigid 2D cell culture. This is due to the 
deformable nature o f  the gel, allowing the contractile forces exerted by the cell to remodel 
the matrix and determine the cell morphology. O n rigid substrates, the cells stretch flat and 
the underlying changes in contractility that alter cell morphology are sometimes masked. This 
was clearly seen in the case o f depleting PDK1 as no discernable change in morphology was 
seen in 2D culture, but in deformable collagen the disruption o f rounded cell morphology 
was significant.
Contractility in A375 cells has been previously reported to be largely dependent o f signalling 
through Rho and R O C K  17°. This has been validated further by the siRNA screen, as the 
strongest elongated phenotypes were seen when Rho-ROCK signalling was disrupted: RhoA 
siRNA, ROCK1 or ROCK 2 siRNA, TAT-C3, Y27632, HA1077, H I 152. The other positive 
control was the treatm ent o f  cell with blebbistatin, which directly inhibits contraction of
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myosin filaments. Depletion o f another Rho effector, Citron kinase, which is also able to 
regulate the phosphorylation o f MLC did not disrupt rounded cell morphology. Interestingly 
depletion o f  the Cdc42 effectors, M R C K a/P , which can also regulate phosphorylated 
myosin, also did not affect the contractility o f A375 cells, indicating that the effector that is 
required for contractility is ROCK 1 and 2 in A375 cells, confirming the previously published 
data 17°.
Another interesting result was that depletion o f either D ial or Dia2, 2 other Rho effectors, 
also caused A375 to become more flattened and less rounded. Dial and Dia2 have been 
thought to regulate contractility during cytokinesis, but recent research has shown that Dial 
is able to activate Rho signalling by interacting with the Rho-GEF, LARG 232. In this way 
Dial could function upstream o f RhoA and be necessary for contractility effected through 
ROCK. We found that depletion o f Dia2 has similar effects to depletion o f Dial in our 
screen so may also function upstream to modify signalling through Rho and ROCK.
It has previously been reported that amoeboid cell motility does not require integrin 
mediated adhesions 220’ 221. The results from the siRNA screen are consistent with this 
finding, as knockdown o f a range o f integrin isoforms did not disrupt rounded cell 
morphology, indicating that signalling through these integrins was not required to regulate 
contractility in A375 cells. However it has not been tested whether cell motility is dependent 
on integrins in this model system. It might also be necessary to deplete multiple integrin 
molecules simultaneously to investigate this fully. It is thought that amoeboid cell motility 
uses much more transient contacts with the ECM  and may use different adhesion molecules 
to achieve this, though as yet the alternative adhesion molecules have not been identified. A 
recent paper showed that leukocytes moving in an amoeboid manner also do not require 
integrins 164. It may be true that cancer cells moving in an amoeboid manner use similar 
mechanisms to move as leukocytes and we may find more commonality as these areas o f 
research are investigated further.
Although integrins are not required for rounded cell morphology, depletion o f paxillin or 
vinculin caused cells to become elongated. Both o f  these molecules are commonly known as 
components o f  focal adhesions, an adhesion complex that we do not observe in A375 cell 
plated in deformable collagen/matrigel matrix. As A375 cells do not utilise conventional
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focal adhesions in 3D culture or in vivo, then why then are paxillin and vinculin required for 
their contractile phenotype? One possibility is that vinculin and paxillin are required to link 
the actin cytoskeleton to the plasma membrane. Membrane blebbing can only occur if the 
actin cortex is attached to the plasma membrane, so that the membrane is pulled and 
squeezed in concert with contraction o f the actin filaments. It will be interesting to 
investigate this idea further and look in detail how the actin cytoskeleton in organised in cells 
lacking vinculin or paxillin. A test o f this hypothesis will be whether over-expression of 
ROCK1 is able to cause blebbing in cells lacking vinculin and paxillin. Paxillin and vinculin 
might function independently o f binding to integrins in the cell membrane, as knockdown of 
integrins did not have the same effect as the depletion o f paxillin and vinculin. Vinculin can 
be recruited to adherens junctions so some o f its functions are certainly integrin-independent 
237. It is also possible that there is significant redundancy between integrins meaning that the 
single knockdowns tested in the screen are not sufficient to disrupt the localisation and 
function o f paxillin and vinculin.
10.2.2 Differences between 2D and 3D cell motility
It was interesting that PDK1 had not previously been identified as a regulator o f cell motility. 
This is probably because m ost analysis o f cell morphology and cell motility has been carried 
out on rigid 2D substrates. It is clear in chapter 5 that the effect o f PDK1 depletion only 
becomes apparent w hen cells are plated on a deformable 3D matrix. It seems that the same 
population o f  cells are able to adopt different modes o f cell motility based on the 
environment or substrate they are presented with. O n glass these cells are able to spread, 
form large complex focal adhesions and use actin polymerisation to push lamellipodia 
forward. The contractile machinery in 2D is manifested as actin stress fibres. When faced 
with a deformable matrix such as they might encounter in vivo, A375 cells adopt a different 
mechanism o f  cell motility in which actin is organised around the cell periphery in thick 
cortical bundles/m eshw ork, and contractile forces are generated to increase hydrostatic 
pressure pushing m em brane blebs forwards as protrusions.
ROCK activity is required for retraction o f the ‘tail’ o f  cells moving on 2D substrates but is 
dispensable for the formation o f lamellipodia and for actin polymerisation 63. In 3D 
environments, R O C K  is absolutely required for amoeboid cell motility and A375 and 
M TLn3E cells are less able to invade if ROCK is inhibited (see Figure 5.8)153’154. Conversely 
inhibiting R O C K  in 2D  systems is able to increase cell speed 238. This has been shown by
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several groups using ROCK inhibitors, and also indirecdy by the expression of RhoE 239. On 
rigid substrates where cells can form strong attachments, it seem that high levels of 
contractile forces are not required and slow the cell down, but in 3D deformable matrices 
higher levels o f  contractile forces may be required for movement. It is now also clear that 
PDK1 is also required for co-ordination o f acto-myosin contraction in deformable 3D 
matrices.
Another clear difference is that on 2D substrates, almost all the A375 cells in the population 
are able to migrate some distance, meaning that this mechanism of cell motility is something 
that the whole population o f cells is capable of. However in vivo, the subcutaneous tumours 
imaged reveal that in any one imaging period, only around 1 % o f cells are motile (Sahai lab — 
unpublished data, and estimate from in vivo data in chapter 6), and in many areas no cell 
motility is observed (Figure 6.1). This would suggest that amoeboid cell motility is a 
mechanism that only a sub-population o f the cancer cells is capable of. This could be due to 
genetic heterogeneity within the population; this could also be due to differences in the 
tumour microenvironment, providing signals allowing cell motility in specific tumour areas.
One significant difference between the cell motility observed in vivo and cell motility on 
deformable substrates is the directionality. Although we can monitor blebbing in vitro that 
causes rapid changes in cell shape and rapid changes in the position o f the cell centroid, we 
are unable to model the directional amoeboid movement we see in living tumours. In 
tumours we do occasionally see cells blebbing chaotically, changing shape but not changing 
their position in the tum our significantly, and we also see cells switching from directed 
amoeboid m ovem ent to pausing and moving more chaotically in one position. This would 
suggest that in vivo, cells are responding to a cue from the microenvironment to indicate the 
direction they should follow. To date we are unable to reproduce this effect in vitro.
The directional migration in vivo could be chemotaxis/haptotaxis, or it might also be a more 
passive process, with cells that have escaped the primary tumour moving in the direction of 
interstitial flow within the tissue, for example towards draining lymph nodes. However this 
second possibility seems unlikely as it would mean all motile cells were moving in the same 
direction, but it has also been observed that host cells within the tumour often migrate in 
opposite directions to tum our cells 198(Pinner & Sahai, unpublished data). If  chemotaxis is 
involved, more investigation is required to determine which signals are responsible.
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The ECM also dictates the direction chosen by tumour cells. Imaging matrix components by 
reflectance imaging has revealed ‘tracks’ o f less dense matrix through which motile tumour 
cells will migrate in trails, with multiple cells following the predetermined path 198,240. It has 
been shown previously that A375 cells and other cells moving in an amoeboid manner do 
not require proteases to invade, but having seen tracks in the matrix which amoeboid cells 
follow, it might also be true that they do not require proteases only because another cell has 
already carried out that job on their behalf. We have seen that A375 tumours contain cells 
with both rounded cell morphology and also elongated morphology. Although the majority 
o f cell motility we observe is amoeboid (rounded morphology), elongated motility is also 
occurring and protease activity by these cells could potentially explain the presence o f less 
dense ‘tracks’ in the tumour matrix. Alternatively protease activity and remodelling o f the 
matrix could be done by carcinoma-associated fibroblasts 79. The directional migration o f 
tumour cells in vivo is a complex issue and invasion may occur through the synergistic 
actions o f host and tum our cells, as well as the heterogeneous populations o f tumour cells 
utilising different forms o f cell motility 153’213’222.
The first in vivo experiment was to test the requirement o f ROCK1 and ROCK2 for cancer 
cell motility in tumours. Treatment o f tumours with the inhibitor Y27632 caused a significant 
reduction in amoeboid cell motility (Figure 6.1). This confirmed previous analysis showing 
that RO CK activity was required for rounded cell morphology and amoeboid invasion in 
vitro 153. Interestingly there was also a slight increase in the numbers o f cells invading in an 
elongated mode (Figure 6.3). This could potentially be because low ROCK activity allows 
other mechanisms o f  cell motility to function instead, such as the activation o f Rac (Marshall 
lab unpublished data).
Despite the limitations o f  the 3D cell culture performed on deformable collagen/matrigel 
gels described above, the fact that depletion o f PDK1 caused the same changes in cell 
morphology and reduction in cell motility in vivo highlights the similarities between the 
behaviour o f  cell in vivo and in the deformable collagen/matrigel gels used to observe cells 
in vitro. This m ethod o f  cell culture is certainly a closer approximation to amoeboid cell 
motility than 2D  culture. Intravital imaging o f tumours has only been utilised relatively 
recently and there are many unanswered questions in this area o f research. Now that we can 
collect dynamic inform ation about tumour cell behaviour in vivo we can start to address how 
the knowledge o f  cell motility gathered from 2D studies applies to the in vivo situation.
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10.2.3 PDK1 is required for amoeboid cell motility
The depletion o f PDK1 disrupted rounded cell morphology o f A375 cells on 
collagen/matrigel gels almost to the same degree as treating cells with ROCK inhibitor, 
Y27632. In M TLn3E cells, depletion o f PDK1 also disrupted rounded cell morphology but 
instead o f  becoming elongated and protrusive, cells generally appeared flatter. This difference 
is apparent when the ratios between Figure 5.4 (A375) and Figure 5.6 (MTLn3E) are 
compared. The ratio o f the perimeter and area used for the analysis o f morphology can be 
more useful than just measuring the ratio between the longest and shortest axis o f  the cell 
because the perimeter measurement can supply information about either the length o f the 
cell and /o r the num ber o f  protrusions. Nonetheless, both o f these factors are important 
when measuring the disruption o f rounded morphology.
In vivo, depletion o f PDK1 caused a significant reduction in the number o f cells able to 
move and invade the surrounding extra-cellular matrix. The loss o f PDK1 reduced the 
numbers o f cells moving both in an amoeboid manner and also in an elongated manner. 
There was a higher proportional reduction in the amoeboid category, further evidence that 
PDK1 is required for amoeboid cell motility. A375 cells have previously been shown to be 
able to switch between amoeboid and elongated cell morphology 153, however in the case o f 
PDK1 depletion this switch does not seem to occur and the number o f cells moving in an 
elongated manner is also reduced. This could be because PDK1 is also required to regulate 
mesenchymal motility by another mechanism, possibly signalling through other members o f 
the GTPase family such as Rac or Cdc42. For example, PDK1 has been shown to be 
required for motility o f endothelial cells through a mechanism involving signalling through 
A kt/PK B.
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10.2.4 The role of PDK1 in other stages of the metastatic
process.
It is intriguing that depletion o f PDK1 also reduces the ability o f tumour cells to colonise the 
lungs. Although the experimental set up used is not a real mimic o f the metastatic process, 
the lung colonisation assay can give some insights into how cells survive transit in the blood 
stream, and whether they can lodge, extravasate and survive and proliferate in the lung 
environment. O f  the three different ways this experiment was carried out, the short term 
assay using M TLn3E cells is the most convincing. The A375 cells are apparendy cleared 
from the lungs much faster than the MTLn3E cells. Both cell lines can be used to grow 
subcutaneous tumours in nude mice to the same degree o f efficiency and grow at similar 
rates, however in the lung, the MTLn3E cells are more effective at forming tumours in the 
lungs following i.v. injection. This could be due to the MTLn3E responding better to growth 
factors availably in the lung tissue, it could also be due to the A375 cells becoming damaged 
in transit in the blood stream. The differences in the fate o f  different cell lines in this assay 
would be interesting to investigate further but is beyond the scope o f the experiments 
presented here.
Despite the differences between the two cell lines, the lung colonisation experiments showed 
that depleting PDK1 meant that cells were less able to colonise the lungs. Previous studies 
have suggested that having strong contractile cortical F-actin organisation can help cell to 
survive transit in the blood stream and reduce physical damage to the cells 198. Loss o f PDK1 
certainly disrupted the actin organisation o f both A375 and MTLn3E cells, so one 
explanation for the differences we see in the lung colonisation assays is that PDK1 depleted 
cells become damaged in transit and soon after they arrive, they die (between 2 and 24 hours 
post injection). An alternative explanation could be that to survive and proliferate in the lung, 
arriving cells m ust extravasate and that amoeboid cell morphology/motility is better suited to 
this. At 2 hours post-i.v. injection, cells appear to be collected in small vessels between 
alveoli, but at 24 hours, this appearance is changed and cells appear to be located in small 
clusters throughout the lung tissue. To judge this definitively, the blood vessels would need 
to be labelled fluorescentiy. I f  PDK1 depleted cells failed to colonise the lungs because they 
were less able to extravasate then this would also implicate PDK1 in another type o f cell 
motility/invasion, through endothelium. It could also mean that tumour cells traverse
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endothelial barriers in an amoeboid manner similar to cells such as neutrophils without the 
need for pro teases and degradation o f the basement membrane 201.
10.2.5 ROCK1 is regulated by PDK1 to drive amoeboid cell 
motility
The first insight into the mechanism behind how PDK1 regulated amoeboid cell motility is 
seen in Figure 5.8. The intermediate knockdown o f PDK1 in MTLn3E cells due to one mis­
matched base in the siRNA oligo sequence resulted in an intermediate inhibition o f cell 
motility. The apparent dose-dependent effect o f PDK1 availability on cell motility was 
interesting as it meant that the total amount o f PDK1 was probably the most important 
factor determining cell motility. It is later shown that kinase activity of PDK1 was not 
required for PDK1 to regulate ROCK1 (Figure 7.13).
One explanation for how PDK1 was able to regulate amoeboid cell motility was through 
affecting the activation o f  RhoA. However it was shown that when PDK1 was depleted, 
RhoA was activated in response to serum, and that this activation was actually at a slightly 
higher level than in control cells. So depletion o f PDK1 did not inhibit the activation of 
RhoA but signalling downstream o f GTP-bound RhoA was inhibited. The reason why GTP- 
bound RhoA should be higher in response to serum when PDK1 is depleted is unclear. 
Perhaps RhoA cycles between G TP and G D P bound states is altered in cells lacking PDK1, 
so the level o f  RhoA-GTP appears higher overall, although this is only speculation at this 
point. It was also found that the steady state levels o f RhoA-GTP were unchanged when 
PDK1 was depleted233.
One other observation from this experiment was that PDK1 ran at a slightly higher position 
on the SDS-PAGE gel when the cells had been serum starved. This mobility shift might 
indicate phosphorylation o f PDK1. it would be interesting to find out whether 
phosphorylation o f  PDK1 is occurring in serum starved conditions and which sites in PDK1 
are affected.
It was found that PDK1 regulated amoeboid cell motility by directly affecting ROCK1 and 
not Rho activation. The depletion o f PDK1 dramatically inhibited the ability o f over­
expressed ROCK1 to cause membrane blebbing. This inhibition o f blebbing was even more
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striking when A375 cells over-expressing ROCK1 were plated on deformable 
collagen/matrigel gels. In this environment the contraction required to cause cell rounding 
and blebbing is presumably less than is required to overcome focal adhesions in the 
equivalent 2D assay as the matrix is deformable and able to be pulled and pushed by the 
cells. This means that the blebbing seen in the control cells expressing ROCK1 is very 
dramatic but it also highlights the complete lack o f contractile forces when PDK1 is depleted 
as over-expressed ROCK1 cannot even contract the cell enough to pull the deformable 
matrix they are attached to.
Looking at the localisation o f endogenous ROCK1 was technically challenging, as the 
antibodies available were not very suitable for use in immunofluorescence as the signal was 
not completely specific or very strong. However it was possible to see localisation o f 
endogenous ROCK1 at the cell periphery o f A375 cells on 2D substrates. This localisation 
was lost when PDK1 was depleted. Even though this is not an ideal way to show the 
membrane localisation o f  endogenous ROCK1, the fact that the signal at the cell periphery is 
reduced when PDK1 is depleted suggests that there is less ROCK1 at the plasma membrane 
when PDK1 is depleted. Better imaging o f endogenous ROCK1 in cells on deformable gels 
has since been carried out by Erik Sahai and this has confirmed that PDK1 does regulate the 
localisation o f endogenous ROCK1 233.
Dynamic analysis o f  the localisation o f  GFP-ROCK1 was able to give better insight into the 
mechanism behind the contraction co-ordinated by Rho-ROCK signalling. In blebbing 
control cells, GFP-ROCK1 was located at the cell periphery, and when a cell was not making 
significant m ovem ent in any one direction, GFP-ROCK1 was spread more or less uniformly 
around the whole cell circumference. However, in cells making significant translocation o f 
the cell body, GFP-ROCK1 was asymmetrically localised at the rear o f the cell perhaps 
acting to cause squeezing and shortening on the actin cortex at the back causing the 
cytoplasm and nucleus o f the cell to be pushed forwards, though this is only speculation at 
this point. W atching the time-lapse movies the impression is that ROCK1 remains at the 
plasma membrane but is able to move within the membrane to accumulate in one part on 
the cell. To test this it would be interesting to use a photo-activatable GFP tagged to 
ROCK1 to m onitor whether membrane localisation was maintained during blebbing.
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The localisation o f ROCK activity during amoeboid cell motility could provide the 
polarisation required for directed cell movement. It has been seen in vivo that cells moving 
in an amoeboid manner are able to change direction rapidly, and from the in vitro time-lapse 
movies, it can be seen that the localisation o f ROCK1 is also able to change rapidly. 
Asymmetric ROCK1 activation could then drive amoeboid cell motility. ROCK1 localisation 
requires binding to RhoA or RhoC, so the localised activation and membrane localisation of 
RhoA could determine the localisation o f ROCK1 in the membrane. As the membrane 
localisation o f PDK1 is determined by the interaction o f its PH domain with phospholipids, 
asymmetric PI3K  signalling could determine the localisation o f PDK1 which would in turn 
result in prolonged ROCK1 activity in specific parts o f the cell membrane. As we have seen 
that PDK1 co-localises with ROCK1 at the plasma membrane it could actually be 
asymmetric localisation o f PDK1 that regulates the asymmetric localisation o f ROCK1. 
ROCK1 had been observed at the back o f blebbing cells in vitro, suggesting that PI(3,4,5)P3 
could be at higher concentrations at the back o f amoeboid moving cells. This would be 
controversial as PI(3,4,5)P3 has been reported to be located at the leading edge o f cells 182,186, 
but these data have resulted from analysis o f cells in rigid 2D environments, and as discussed 
earlier, cell motility in vivo can be co-ordinated differently. It has been shown that A375 cells 
with a rounded phenotype on deformable matrices have a uniform distribution o f PI(3,4,5)P3 
153, suggesting that PI3K  signalling is not spatially separated from front to back under these 
conditions.
I f  the distribution o f PI(3,4,5)P3 is uniform in amoeboid cells then the hypothesis would be 
that RhoA controls the localisation o f  ROCK1 activity, but that P D K l/R hoE  control the 
duration and magnitude o f  RO CK activity at the membrane.
10.2.6 PDK1 binds directly to ROCK1 at the plasma membrane
R O C K l also required PDK1 for plasma membrane localisation. Interestingly PDK1 was 
only required for the membrane localisation o f RO CK l and not ROCK2. Over-expression 
o f  ROCK2 did cause membrane blebbing but was also able to cause membrane blebbing in 
the absence o f  P D K 1. It was also found that PDK1 bound direcdy to ROCKl but did not 
interact with ROCK2 (Figure 7.16). To fit with this, ROCK2 is also not inhibited by binding 
to RhoE 85. It seems that the competitive mechanism between PDK1 and RhoE discovered 
here in the regulation o f amoeboid cell motility only involves RO CK l and that ROCK2 is
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regulated in a separate manner. It has been reported that Raf-1 is able to regulate the 
localisation o f  ROCK2 by physical interaction that is required to maintain ROCK2 in its 
correct location. In this work it was also found that kinase activity o f Raf-1 was not required, 
and that the interaction was specific to ROCK2 and not RO CK l 118. It can be concluded that 
amoeboid cell motility is driven by Rho signalling through RO C K l, if there was any 
compensation between R O C K l and ROCK2 we would not see such dramatic changes in 
morphology and inhibition o f cell motility when PDK1 was depleted. However we do seen a 
strong disruption o f rounded cell morphology when ROCK2 is depleted so perhaps ROCK2 
also has a role in amoeboid cell motility but a role that is distinct from ROCKl and does not 
require PD K 1. Over-expression o f ROCK2 is able to drive contractility, but is apparently 
not sufficient to drive amoeboid cell motility when ROCK l is inhibited. ROCKl and 
ROCK2 have been shown to have independent functions in a variety o f contexts as 
discussed in the introduction. Amoeboid cell motility is now another cell behaviour in which 
R O CK l and ROCK2 probably have independent functions.
Much effort was put into the investigation as to whether ROCK l was a substrate o f PDK1. 
Chapter 3 describes in detail the investigation into potential phosphorylation sites in 
R O C K l, and the hydrophobic m otif surrounding T398 was first identified as a potential 
PDK1 binding site by Scansite analysis. However despite these efforts, no evidence was 
found to suggest that R O C K l is phosphorylated by PDK1. Addition o f PDK1 did not 
increase R O C K l kinase activity, and furthermore no phosphorylation at T398 was ever 
detected by mass spectrometry. The final evidence that ROCK l was very unlikely to be a 
PDK1 substrate was that a kinase dead mutant o f PDK1 could rescue the morphological 
changes caused by PDK1 depletion.
The finding that the PH  domain o f PDK1 that is required for the membrane localisation o f 
PDK1, was also required to regulate RO CK l reinforced the result that ROCKl regulated 
amoeboid cell motility by localising to the cell periphery. It was therefore logical that PDK1, 
which was by this point known to regulate the membrane localisation o f R O C K l, would also 
require m em brane localisation to carry out this function. This led to testing whether PDK1 
could bind to R O C K l directly. W hen it was found that PDK1 bound directly to ROCKl 
using a sequence o f the R O C K l hydrophobic motif it was tested one final time whether 
T398 (the site indicated by Scansite) was implicated in the binding between PDK1 and 
R O C K l. Figure 7.17 shows that neither mutation o f T380 nor T398 to alanine influences the
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interaction between ROCK and PDK1. As discussed earlier it would be interesting to 
investigate whether this is also true for T380D or T380E RO CK l.
10.2.7 The regulation of ROCK1 through the competition 
between PDK1 and RhoE
Chapter 8 describes experiments leading to the model that the competitive binding o f RhoE 
or PDK1 to R O C K l at the plasma membrane regulates R O C K l. It was possible to show in 
vitro that both PDK1 and RhoE interact with ROCKl directly using a similar, overlapping 
sequence in the hydrophobic m otif in order to do this. It was also possible to manipulate the 
cell system in order to force RO CK l into interacting more with one or other binding partner 
by changing the balance between RhoE and PDK1. As discussed earlier, T380A ROCKl 
m utant binds better to RhoE than W T RO CK l, however it is shown that mutation of 
T380A does not affect binding to PD K 1. So even though RhoE and PDK1 utilise the same 
40 amino acid sequence (375-415) in the hydrophobic m otif to bind to RO CK l, they must 
still bind to RO CK l slightly differently. RhoE binding is influenced by the amino acid in 
position 380, but PDK1 binding is apparently unaffected by mutation to alanine (Figure 
7.17).
W hat this chapter fails to show is that endogenous ROCK l and PDK1 interact in a cell at 
the plasma membrane. Numerous attempts to co-immunoprecipitate these binding partners 
from cells were carried out but all failed. Cross-linking experiments were also carried out to 
determine what complexes R O C K l might be involved in. However the cross linking 
experiments only revealed that RO CK l was isolated as a single complex o f high molecular 
weight which may be a dimer o f R O C K l, or a heterodimer o f RO CK l and ROCK2 (data 
not shown). The dimerisation o f  RO CK l has been previously reported and the regulation of 
dimerisation is actively being investigated by other laboratories m . ROCK l is known to have 
many substrates and interacting proteins so it is curious that the only complex o f ROCKl 
that was isolated is the kinase dimer. There may be something innately interesting about this 
result, perhaps meaning that interactions o f most proteins with ROCK l are extremely 
transient. However PDK1 seemed not to associate with any binding partners in this cross- 
linking experiment suggesting that the approach might be flawed. Another potential reason 
that it has not been possible to co-immune precipitate RO CK l with PDK1 is that the lipids 
o f the plasma membrane could play a crucial role in regulating the conformation o f the
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proteins, or be included in the complex in some way. Therefore to lyse a cell would mean the 
breakdown o f  the plasma membrane and also the destruction o f the RO CK l/PD K 1 
complex. Despite this short-coming, it was possible to co-immune precipitate endogenous 
RO CK l with endogenous RhoE, and the isolation o f that complex was dependent on the 
level o f  PDK1 in the cell. Perhaps it was possible to isolate ROCK l with RhoE because that 
complex is more stable in the absence o f PDK1, and also seems not to require interaction 
with the plasma membrane. Figure 8.4 shows that ROCKl and RhoE co-localise in some 
kind o f  vesicle when RhoE is over-expressed. Other members o f the Sahai lab have tried to 
identify the nature o f these vesicles but no co-localisation with markers for known endocytic 
or other transport pathways has been identified.
Previous results had given some clue towards building this model o f ROCKl regulation. 
There was perhaps a slight decrease in the ability o f endogenous ROCKl to phosphorylate 
MLC in vitro when PDK1 had been depleted from the cells, however this decrease was 
never very dramatic (Figure 7.11). I f  this decrease is real, a potential explanation was found 
in chapter 8 when it was found that in the absence o f PDK1, endogenous ROCKl was 
found in a complex with RhoE. The R O C K /R hoE complex might be less efficient at 
phosphorylating MLC, or RhoE co-immune precipitated with the ROCKl could compete 
with MLC in the kinase reaction. Figure 7.11 also gives a slight clue to the eventually derived 
mechanism o f  competition between PDK1 and RhoE for interaction with ROCKl. 
Although not hugely obvious, it can be seen that the phosphorylation o f RhoE by ROCKl is 
slightly decreased when PDK1 is added to the reaction (compare lanes 5 and 7 in Figure 
7.11). This is potentially because PDK1 is binding to ROCK l and preventing ROCKl from 
phosphorylating RhoE. This decrease is not observed when ROCKl is used to 
phosphorylate MLC (Figure 7.10). Perhaps the interaction o f PDK1 with ROCKl affects the 
substrates that R O C K l is able to interact with. Phosphorylation o f RhoE by ROCKl 
stabilises the R O C K /R hoE  interaction so perhaps it is not unreasonable to speculate that 
interaction with PDK1 favours ROCK activity on substrates such as MLC instead.
A nother interesting result is shown in Figure 8.5. Although this western blot was carried out 
simply to ensure that the proteins had been knocked down efficiently, it could perhaps give 
some further insight into the mechanism o f the competition between PDK1 and RhoE. It 
was seen that when PDK1 was depleted alone, the levels o f RhoE are slightly increased 
(compare lanes 1 and 2 with lanes 3 and 4). This could mean that the interaction o f ROCK
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with RhoE when PDK1 is absent might also act to prevent the degradation o f RhoE 
explaining the slight increase in RhoE protein. This slight increase in RhoE protein levels is 
also seen in the cell lines stable depleted o f PDK1, however this small change in protein 
levels can not explain the gready increased interaction between ROCK l and RhoE (Figure 
8.3). I would continue to argue that the competition between PDK1 and RhoE for binding 
to R O C K l seems the best model for the data. See Figure 10.1 for model o f the interplay 
between PDK1 and RhoE and resulting ROCK activity.
10.2.8 Double knockdown of PDK1 and RhoE rescues cell 
motility
The final part o f  chapter 8 describes the testing o f the competition model by knocking down 
both PDK1 and RhoE simultaneously. Results showed that in both A375 cells and MTLn3E 
cells rounded cell morphology was mostly rescued by the combined knock down of PDK1 
and RhoE. In MTLn3E cells knockdown o f RhoE alone cause cells to become more 
elongated/protrusive than in control cells (Figure 8.7). This was strange and unexpected. 
Although both M TLn3E cells and A375 cells are grouped together as ‘amoeboid’ by our 
classification, based on their behaviour in vivo, it is clear that the signalling controlling their 
morphology is slightly different with respect to the role o f RhoE. It is also possible that there 
might be some off-target effects o f the RhoE siRNA sequences when used in the MTLn3E 
(rat) cells that are not seen in the A375 (human) cells, as they are from different species. 
Nonetheless, when both PDK1 and RhoE where knocked down, the speed o f cell migration 
o f M TLn3E cells on deformable collagen gels was restored to levels similar to the control 
cells.
I f  R O C K l is able to co-ordinate cell motility in the absence o f both PDK1 and RhoE then 
why should this mechanism o f regulation exist? ROCK l requires binding to RhoA for 
membrane localisation, and in the absence o f both PDK1 and RhoE this seems to be 
sufficient for blebbing cell motility in vitro. It remains to be tested whether amoeboid cells 
are able to move in vivo without regulation o f ROCKl by PDK1 and RhoE. RhoE could 
function to limit RO CK  activity at the front o f the cell. PDK1 could have the opposite 
function, increasing R O C K l activity at the rear o f blebbing cells. It could be possible that 
the regulation o f  R O C K l by PDK1 and RhoE is not a mechanism that controls total 
amounts o f  R O C K l activity but a mechanism that spatially controls where ROCKl is
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activating F-actin contraction. It might also be that PDK1 and RhoE act to fine tune ROCK 
activity and provide cells with a ‘gain’ control mechanism, controlling the magnitude o f the 
response after RhoA has determined the localisation. Therefore the significance o f both 
PDK1 and RhoE depletion might only be apparent in vivo in directed amoeboid movement.
The online database, Oncomine (http://w w w .oncom ine.org/) reveals several cases of 
metastatic tumours showing altered levels o f PDK1 or RhoE. For example some pancreatic 
cancers have shown to have reduced levels o f RhoE, which could potentially mean that these 
cells have higher levels o f RO CK activity and perhaps increased potential for amoeboid cell 
invasion. RhoE has been reported to be a transcriptional target o f p53, an extremely 
comm on m utation in a wide range o f cancers, meaning that levels o f RhoE are likely to mis- 
regulated in a wide range o f tumours 87’89. RhoE can also be transcriptionally up regulated by 
signalling through the M APK pathway 241, and as discussed in the introduction this pathway 
is also often over-activated in cancers such as melanomas. Although the work in chapters 
suggested that low RhoE levels would correlate with increased invasive behaviour, this might 
only be true for amoeboid invasion, and in elongated/ROCK-independent forms o f tumour 
invasion, high RhoE might be preferable to keep ROCK activity low.
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Figure 10.1 Model of the competition between PDK1 and RhoE at 
the plasma membrane. RhoA binding to ROCK1 is required for 
translocation of ROCK1 to the plasma membrane. If PDK1 is present, 
ROCK1 and PDK1 interact allowing sustained ROCK1 activity at the cell 
periphery. The binding of PDK1 inhibits RhoE from binding to ROCK1. If 
PDK1 is absent, RhoE binds to and inhibits ROCK1 meaning that 
contraction is not maintained after RhoA brings ROCK1 to the plasma 
membrane
ROCK1
Since carrying these experiments, other published work has confirmed that PDK1 is 
im portant during other forms o f cell motility. It has been found that PDK1 is essential for 
endothelial cell migration in response to V E G F120, although the mechanism that is proposed 
for this involved signalling through Akt, which is different to the findings in this thesis. The 
siRNA screening showed that knockdown o f Akt isoforms did not mimic the phenotype 
seen when PDK1 was depleted. It has also been shown that signalling through the PI3K 
isoform p i 10a is able to regulate angiogenesis by control endothelial cell migration242, 
perhaps PDK1 is also involved downstream o f p i 10a. The regulation o f ROCKl by PDK1 
is also starting to be shown in other systems. Another recent paper has shown that PDK1 is 
required for Toll-like receptor signalling (innate immune system) and actin dynamics in 
dendritic cells243. It is interesting to put these results together with previously published work 
by the group o f Alan Hall, who were able to show that there were two distinct mechanisms 
o f  phagocytosis and that the type o f  phagocytosis used by the complement receptor (also 
innate immune system) was mediated by Rho244. These two sets o f data potentially implicate 
PDK1 and RO CK  in the actin re-organisation required for phagocytosis during activation o f 
the innate immune system.
10.3 The relationship between pigmentation and cell motility in 
vivo
Chapter 9 describes a novel imaging m ethod to determine the degree o f pigmentation in 
melanoma cells. To my knowledge this type o f imaging has not been previously reported. 
Although not all differentiated melanocytes will produce pigment, pigment production was a 
useful indicator along side dendritic cell morphology, to judge how far removed the 
melanoma cell was from a differentiated melanocyte. Using this imaging technique, it was 
found that invasive behaviour o f  melanoma cells in vivo correlated with reduced pigment 
production. Microarray data from the dissected tumour cells was able to give us some insight 
into which genes might be differentially regulated and be responsible for reduced pigment 
production and increased cell motility.
10.3.1 Imaging pigment containing melanosomes
Melanosomes, being full o f  concentrated dark pigment, were easily identified using 
transmitted light. It was not initially surprising that these vesicles were also reflective as many
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cell and matrix components have some reflective properties. What was unexpected was that 
the melanosomes would also be seen following multiphoton excitation.
Melanin is thought to have an absorption spectra across a range o f UV-visible wavelengths 
and converts these potentially damaging wavelengths to infrared to protect against DNA 
damage 7. This property o f the melanin spectra was used in the FACS analysis, and changes 
emission following excitation with a violet range laser allowed us to distinguish populations 
o f cells based on their pigment production. The spectral properties used for the imaging of 
cells in vitro and in vivo seem to be the opposite to the above, as the vesicles could be seen 
when excited with wavelengths in the infrared range and emission was collected in the visible 
range (Figure 9.1). This has not been previously reported.
The strongest evidence that the spectrum we observed actually corresponded to melanin 
production was that the signal correlated completely with increases and decreases in pigment 
production stimulated by a-M SH  or inhibition o f PKA. The changes in pigment could be 
seen in the changing colour o f the cell pellets, the number o f black vesicles seen by 
transmitted light, and also the m ultiphoton imaging (Figure 9.3 9.4).
Initially the broad spectrum o f emission was also puzzling, as this large range is not normally 
seen with conventional fluorophores. More detailed analysis showed that there were actually 
4 distinct spectra which could explain the large spread, but this then posed the question as to 
what molecules were responsible for each o f the distinct spectra. As melanosomes develop 
they go through 4 stages o f  maturation, which can be distinguished by their different 
appearance by electron microscopy 24S. It could be possible that each stage o f maturation 
causes the vesicles to have different spectra properties. However, during the first 2 stages 
for maturation melanosomes do not contain any pigment. Pigment production begins in 
stage III vesicles and only the stage IV vesicles have the black appearance meaning that we 
can detect them  under the microscope by transmitted light 246. So if  the 4 different spectra 
correspond to the stages o f melanosome maturation then it is not the pigment we are seeing 
but perhaps some other com ponent o f  developing melanosomes such as the coating o f the 
vesicles or the fibrils inside. W ithout detailed analysis by electron microscopy alongside the 
m ultiphoton imaging we will be unable to answer these questions. Figure 9.6 makes a start 
into investigating the different nature o f the different emission spectra by looking at the 
cellular localisation o f  each type o f  vesicle but the results are not conclusive. I f  more analysis 
revealed that one type o f  vesicle was always closer to the cell periphery than others then this
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might indicate that that spectra belonged to the fully mature stage IV melanosome that had 
been transported to the cell periphery for export out o f the cell.
In vivo it was also possible to image the pigment-containing vesicles. It was important to 
show that the vesicles imaged were actually inside cells and not just pieces o f cell debris with 
strange spectral properties. It was also important to show that the vesicles were contained 
within tum our cells and were not pieces o f phagocytosed cell debris taken up by host cells 
such as macrophages. To try to show this the B16F2 cells were stably transfected with GFP 
CAAX to fluorescendy label the cell membranes. The high resolution imaging o f tumours in 
Figure 9.9 shows that the pattern o f  vesicles is not random and is found in shapes following 
the G FP signal, suggesting that the vesicles are contained within the tumour cells but are 
located at the cell periphery. Some o f the vesicles are not clearly located within the 
boundaries o f  G FP signal but they could be vesicles at the end o f dendrites. However, due to 
the close packed nature o f the tumour cells in vivo it is not easy to see dendritic protrusions 
to verify this.
Analysis o f  the time lapse in vivo movies showed clearly that cells containing pigment tended 
to be non motile, whilst the motile cells tended to contain very little detectable pigment. The 
motile cells are also rounded in morphology. Both o f these observations suggest that the 
motile cells are less well differentiated than other cells in the same tumour area. More 
markers o f  differentiation would be required to verify this statement, perhaps in vivo imaging 
o f  cells expressing a fluorescent reporter construct sensitive to MITF transcriptional activity 
would be one way to do this, but this was not possible in the time remaining o f my PhD.
Assuming that our assumptions are correct and that the motile population o f B16 cells is less 
well differentiated than other non-invasive cells then this could be due to one o f two 
possibilities. Firstly, perhaps the cells were at one stage better ‘differentiated’ and more 
similar to melanocytes and producing pigment, but they have received a signal either from 
surrounding tum our cells, host cells or the local microenvironment causing them to 
dedifferentiate. Secondly the less ‘differentiated’ cells could have always been less well 
‘differentiated’, and they might make up, or over-lap with a population o f recently termed 
‘cancer stem cells’247,248. These cells are hypothesised to initiate tumour growth, their progeny 
being m ore differentiated and closer to melanocytes. There are theories suggesting that 
cancer stem cells might also be the cells that are resistant to chemotherapy, causing the 
tum our to re-grow after seemingly successful treatment 248. Several markers have been
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published that the authors claim can be used to isolate stem cells, one recent marker in 
melanoma is ABCB5 26. Populations o f cells expressing ABCB5 are more tumourigenic but 
whether they are stem cells is still questionable, it is more likely that this marker only isolates 
a cell population enriched in tumour initiating cells. O ther markers are CD133 in pancreatic 
cancer 249,25<), and nestin in the case o f melanoma 251'253.
Although all these data support the theory o f a sub population o f tumour cells that are more 
highly tumorigenic than others, it has not yet definitively proven the theory o f cancer stem 
cells. In  reference to the data in chapter 9, it is unlikely that all o f the motile, poorly 
pigmented tum our cells are cancer stem cells, as there are so many o f them. It is more likely 
that there is a degree o f  genetic heterogeneity amongst the cell population and that in 
addition differences in the local microenvironment cause cells to behave differently from 
their neighbours.
To find out what changes could be responsible for the differences in pigment production 
and motile behaviour microarrays comparing the high and low pigmented cells from the 
tumour was undertaken. The most interesting candidate that came out o f this analysis in my 
opinion was TGFP2. TG FP signalling has been extensively studied and has previously been 
reported to play a role in cell motility in other systems (as discussed in the introduction). It 
was found that TG FP signalling inhibited pigmentation o f B16 cells (Figure 9.16). This has 
been previously reported but not much has been done to elucidate the mechanism behind 
this effect 254. It has been shown that TG FP stimulation o f cells increases the number of 
melanosomes in stage III o f maturation and prevents their maturation to stage IV. It is 
thought that T G FP inhibits tyrosine hydroxylation and prevents melanin synthesis 254. 
Results in chapter 9 are consistent with these data but we are not any closer to being able to 
explain which signalling pathways downstream o f TG FP are responsible for the 
hypopigmentation.
Additionally it was found that TG FP signalling inhibited dendritic cell morphology and 
increased cell motility on deformable matrix in vitro. These results are consistent with the 
hypothesis that it is TG FP signalling in vivo that is responsible for the invasive behaviour of 
the subset o f  tum our cells we see moving with a rounded morphology and low pigmentation.
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10.4 Concluding remarks
This thesis has covered the investigation o f cancer cell motility in vivo, covering a range of 
approaches. The molecular mechanisms regulating the localisation and activity o f the kinase 
ROCK1 were investigated and it was found that unlike other members o f the AGC family 
kinases ROCK1 was not phosphorylated in the activation loop, but that T380 in the 
hydrophobic extension o f the kinase domain is a potential regulatory site, and that other 
autophosphorylation sites existed that require further investigation. It was also found that 
ROCK1 is regulated by PDK1 but that this regulation is through a binding interaction and 
not through phosphorylation. The binding o f ROCK1 to PDK1 is hypothesised to allow 
prolonged R O C K  activity at the plasma membrane and prevents ROCK1 from binding to 
the inhibitory partner RhoE. These findings have been tested in vivo and in 3D in vitro 
assays. In addition to this it was found that motile melanoma cells had a rounded 
morphology and did not contain pigment. The mechanism behind this hypopigmentation 
and increased cell motility in a subset o f tumour cells was investigated by microarray analysis 
and TG FP signalling was identified as a strong candidate signalling pathway responsible for 
these changes in cell behaviour.
Although these findings are only small steps towards understanding the larger problem of 
cancer cell motility in vivo, they have been investigated in detail in order to identify as much 
mechanistic insight as possible. More work is required to continue to uncover how and why 
cancer cells become motile in tumours, and this information will be useful in the broader 
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Screen of cvtoskeletal regulators
A375 cells were transfected using smart pools of 4 oligos targeted against each 
gene (Dharmacon, catalogue numbers are listed below) 56 hours prior to assay 
end point. CTTN M-010508-00, WASL M-006444-01, ZYX M-016734-00, PXN M- 
005163-00, VCL M-009288-00, TLN1 M-012949-00, GRB2 M-019220-00, NCK1 
M-006354-01, RAC2 M-007741-00, RAC3 M-008836-01, CDC42 M-005057-00, 
RHOA M-003860-00, RHOB M-008395-01, RHOC M-008555-00, RHOD M- 
008940-00, ARHE M-007794-01, RND1 M-008929-00, ARHN M-009727-00, 
RHOF M-008316-00, RHOG M-008995-00, RHOH M-008804-00, RHOJ M- 
010367-00, RHOQ M-009943-00, RHOU M-009882-00, RHOV M-006374-00, 
RHOBTB1 M-009389-00, RHOBTB2 M-009252-00, RHOBTB3 M-020480-01, 
RHOT1 M-010365-00, RHOT2 M-008340-00, DIAPH1 M-010347-01, DIAPH2 M- 
012029-00, DIAPH3 M-018997-00, WASF1 M-011557-00, WASF2 M-012141-00, 
CFL1 M-012707-00, PTK2B M-003165-03, PTK2 M-003164-02, LIMK1 M- 
007730-01, FMNL1 M-019176-00, FMNL3 M-019007-00, PAK1 M-003521-03, 
PAK2 M-003597-02, FMNL2 M-031993-00, RAC1 M-003560-02, ITGA1 M- 
008516-00, ITGA2 M-004566-01, ITGA3 M-004571-01, ITGAV M-004565-03, 
ITGA5 M-00803-01, ITGA6 M-007214-00, ITGB1 M-004506-00, ITGB3, M- 
004124-02, ITGB4 M-008011-01, CIT M-004613-01, AKT1 M-003000-02, AKT2 
M-003001-01, AKT3 M-003002-02.
For ROCK1, ROCK2, MRCKa MRCKp specific sequences were used as 
previously published 25. Approximately 32 hours after transfection cells were 
trypsinized and plated on top of Collagen/matrigel matrix 24 hours prior to fixation 
with 4 % PFA and permabilisation with 0.3 % Triton X100. Cells were then 
stained using TRITC phalloidin, propidium iodide, and DAPI and imaged using a 
Zeiss LSM 510 confocal microscope. A375 cells were plated onto 
collagen/matrigel matrix for 18 hours then treated with inhibitors for 6 hours 
before fixation and staining as above. Concentrations and major targets are as 
follows: DMSO 0.05 %, Blebbistatin 5pM (non-muscle myosin), TAT-C3 500nM1 
(Rho), Y2763210 *iM (ROCK), HA1077 10m.M(ROCK,PKA), H1152 5*iM(ROCK), 
U0126 10pM(MEK1/2), SB203580 10jxM(p38 MAPK’s), SP600125 10^M(JNK’s), 
AG1478 10pM (EGFR’s), SB431542 10 p,M(TGFbetaRII), LY294002 20jiM(PI- 
3K’s), BIM 0.5p,M(PKC’s), ML-7 25p,M(MLCK), PP2 10p,M(src family kinases), 
Go6983 10 pM(PKC’s).
RhoGTP pulldown assays
A375 cells transfected with either control siRNA duplexes or duplexes targeted 
against PDK1. 24 hours after transfection cells were plated on collagen/matrigel 
gels. A further 24-30 hours later GTP-RhoA was pulled down using the Rho- 
binding domain of Rhotekin, as previously described2. Levels of RhoA were 
visualised by western blot using RhoA (sc-418 Santa Cruz)
O 2008 Nature Publishing Group
Adhesion assays
Cells were non-ezymatically removed (using Gibco-BRL #13150-016) before 
replating in 12 well plates that were coated with 1.8mg/ml matrigel, 3.2 mg/ml 
Collagen type 1 in DMEM + 1% FCS. After 30 minutes non-adherent cells were 
removed by tipping the media out and washing twice with PBS. Adherent cells 
were then fixed using 4% PFA and the number of cells in three 20x fields was 
counted.
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